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Abstract 
Preterm infants are those born before 37 completed weeks of gestation. Worldwide, about 
one million children die each year due to complications of prematurity and survivors may 
face lifelong disabilities. Approximately 50% of neonatal deaths and 17% of deaths among 
children under five are affected by prematurity. Colostrum is the first milk produced by the 
mother within the early few days after birth. Colostrum is very rich in immunological and 
growth factors that indicates its primary functions are protective and trophic. 
Oropharyngeal administration of colostrum (OPC) is a novel route that involves coating 
the infant’s oropharynx with a small amount of colostrum (0.1 to 0.5 ml) during the early 
neonatal period. Immune and growth factors in colostrum might interact with the 
oropharyngeal mucosal-associated lymphoid tissues to modulate the infant’s immune 
system and promote intestinal growth, potentially reducing infection and necrotising 
enterocolitis (NEC), improving survival and health outcomes. Ultimately OPC could 
provide a potential target to prevent mortality and morbidities of preterm and sick infants. 
This thesis aimed to investigate whether OPC administration during the early neonatal 
period prevents deaths, improves health outcomes and promotes the growth of preterm 
infants.  
To achieve the aim of this thesis; initially, an online survey targeted neonatal professionals 
was performed to evaluate the current practice and perception of OPC administration in 
the UK neonatal units. Oropharyngeal colostrum has been introduced into UK neonatal 
practice despite a lack of high-quality evidence regarding its efficacy and safety. OPC 
practice was variable, frequently without written guidelines. 
A Cochrane systematic review was conducted to synthesis and appraise the currently 
available randomised controlled trials (RCTs), which evaluated if early OPC given within 
the first 48 hours has a positive impact in preterm infants (< 37 weeks gestation) 
compared with control. Six RCTs were eligible for inclusion in this systematic review. 
Meta-analysis showed that early OPC could shorten the time to reach full enteral feeds 
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but did not reduce the incidence of late-onset infection (LOI), NEC and death nor the 
length of hospital stay. Available evidence is insufficient due to lack of participants and 
very low quality to demonstrate the benefits effects of OPC for preterm infants.  
The third study, a matched case-control study evaluated the effects of OPC administration 
on the short-term health outcomes in preterm (≤ 32 weeks) infants. Eligible infants who 
were admitted to the Nottingham neonatal units after the implementation of OPC in the 
care of preterm infants, and received OPC, compared with those who were admitted 
before the use of OPC in the units. Preterm infants who received OPC within the first 96 
hours of life achieved full enteral feeding (150 ml/Kg/day for consecutive 72 hours) earlier 
than those infants who did not receive OPC. A higher rate of receiving breast milk at 
discharge to home was also observed. However, the two groups had a similar length of 
hospital stay, weight Z-score at hospital discharge, and incidences of NEC, LOI and 
deaths.     
Finally, a non-randomised observational study evaluated the response of gut hormones to 
OPC administration in preterm (< 37 weeks of gestation) and ill infants requiring neonatal 
intensive care (NIC). Preliminary results demonstrated a rising trend in plasma gut 
hormone concentrations in response to OPC administration in the participant preterm and 
full-term infants. This study is ongoing, and more infants are required before final 
conclusions can be elicited.  
In conclusion, OPC administration is a potentially feasible intervention that shortens time 
to attain full enteral feeds in preterm infants. Given the high risk for preterm infants and 
the benefits of maternal colostrum, OPC may have preventive implications for improving 
the health outcomes of this vulnerable population. This work expands the current 
knowledge about the use of OPC in the care of preterm and sick newborn infants and 
could benefit efforts to improve preterm birth outcomes by informing guidelines, clinical 
decision and future research.  Larger, well-designed, high-quality research with sufficient 
power are needed to assess the efficacy and safety of this intervention.  
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Chapter 1. Introduction 
A newborn baby is a challenge but can be more challenging to families, health care 
system and societies if the baby born prematurely. Whilst being a newborn is not an 
illness or a disease, the neonatal period (first 28 days of life) is a critical stage of life. In 
2016, the World Health Organization (WHO) reported that approximately 2.6 million 
babies died during the first month of life (1), which account for about 46% of deaths in 
children under five years of age (2).  
1.1 Definitions of Preterm Infants 
Preterm birth is delivery of an infant before completed 37 weeks (259 days) of pregnancy, 
and according to the WHO, preterm infants are defined as infants born < 37 weeks of 
gestation (3). Based on the degree of immaturity preterm infants are classified into (3, 4) : 
- Extremely preterm infant (EXP), born before 28+0 weeks of gestation. 
- Very preterm infant (VP), born between 28+0 to < 32 weeks of gestation.  
- Moderate-late preterm infant (MLP), born between 32+0 to <37 weeks of gestation. 
 As the growth and development of many of the body organs occur during the last 
trimester of pregnancy (5), preterm infants usually have low birth weight (LBW, birth 
weight <2500g) and immature functions of the major organs and systems. While 
prematurity is the most common cause for a baby being born with low birth weight, very 
low birth weight (VLBW, birth weight <1500g) or extremely low birth weight (ELBW, birth 
weight <1000g), preterm and LBW terms are not interchangeable (6). Some full-term 
babies have LBW or VLBW which are referred to as small-for-gestational-age (SGA) 
infants. SGA is defined as a baby born with a birth weight less than the 10th centile of his 
gestational age (GA) (7).  
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1.2 Preterm infants: a global challenge 
Preterm birth is one of the most significant issues of perinatal and neonatal medicine 
creating a substantial global burden on diseases due to high mortality and morbidities in 
preterm population (8, 9). In 2015, the WHO reported that one in 10 babies are born 
preterm every year, and there were approximately 15 million preterm births across the 
world. Over one million children die each year due to complications of prematurity, and 
those who survive may face lifelong disabilities (8). The incidence of preterm birth varies 
between countries ranges from 5% to 18%. It was approximately, 7%  in the UK, (10), 
10% in the USA (11) and 5-9% in other developed countries (12) and it reached 18% n 
some African countries, that could be attributed to higher infection rates, maternal 
malnutrition, and inadequate antenatal care in these countries (13, 14). Approximately 
60% of preterm births occur in developing countries, in Southern Asia and Sub-Saharan 
Africa (12) where the highest neonatal mortality also occurs representing 38 % and 39 % 
of neonatal deaths respectively (15).  
With advances in reproductive technology and obstetric care, the rate of preterm birth has 
risen over the last 20 years in many countries (16, 17). Worldwide the WHO estimated a 
rise in preterm birth from 9.6% of live births in 2005 (18) to 11.1% in 2015 (8). The 
National Center for Health Statistics in the USA also reported a 4% increase in preterm 
births between 2014 and 2017 (19). This continuous rise in preterm births is an increasing 
burden on diseases.  
Preterm infants have a high mortality rate; in the UK, in 2012, the preterm infants mortality 
rate was 23.6 deaths per 1,000 live births compared to 1.4 per 1,000 live births in full-term 
infants (20). Neonatal deaths contributed to approximately 50% of under-five deaths (2). 
Prematurity is the primary cause of neonatal death and the second leading cause of death 
in children under five years of age (8); accounts for approximately 35% and 16% 
respectively, Figure 1.1 (21).  
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Figure 1.1  Leading causes of deaths among children under five years of age, 2016 
Causes of death in children under five years of age. Each part is proportional to the 
percentage of total deaths in under five years.      
Source: World Health Organisation, Global Health Observatory Data, Child Mortality and 
causes of death 2016 (21). 
 
Advanced technology and collaborative work in perinatal and neonatal medicine, have led 
to an improvement in the survival rates of preterm infants, especially in developed 
countries. This is evident in the UK where the preterm infant mortality rate declined by 
approximately 15% from 2008 to 2012 (20). Improvement of survival rates was also 
reported in the USA where about 50% of infants born between 22 to 24 weeks survive and 
80% to 100% in those born after 28 weeks gestation (22).  Whilst, in developing countries, 
preterm infants have less chance to survive; and more than half of babies born between 
28 and 32 weeks die. In 2014, in Nigeria, Iyoke et al. found a 16.9% prevalence rate and a 
preterm mortality rate of 46.1% for a population of babies with a mean GA of 32.6 ± 3.2 
weeks (23).   
Although early survival has improved, life-long morbidities showed a slight change that 
increases the burden on the health services, parents, societies and national economy. In 
the Global Burden of Disease Study 2010 (24), neonatal diseases contribute to 8.1% of 
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the Disability Adjusted Life Years (DALYs), and prematurity-related complications account 
for 3.1% of the DALYs (25). DALYs are measured by the sum of numbers of years lost 
due to early deaths and the years lived with impairments and disabilities (25). Therefore, 
prematurity was considered a significant cause of DALYs and continued a growing public 
health concern worldwide.  
1.3 Preterm infants: a personal burden  
The continuous surge in preterm births mean many people may experience the tragedy of 
being a parent of a critically ill baby or as family members or friends, thus may create 
substantial burdens on the life of the infants and their families (26-28).  
1.3.1 Burdens on the infants 
Preterm infants particularly those born before 32 weeks of gestation or LBW are at a 
higher risk for complications during the neonatal period and may require a prolonged 
hospital stay (29). Furthermore, the survivors may have long-term poor neurodevelopment 
and other chronic conditions (30, 31) that might be associated with functional deficiencies. 
It was reported that children who born preterm have a lower health-related quality of life 
which, is sufficient to influence their daily life compared to those born at term (32). For 
example, chronic lung diseases may increase the susceptibility to respiratory infections 
and reduce the functional capacity of the lung leading to exercise intolerance (33). 
Although the major neurodevelopmental disabilities such as cerebral palsy are diagnosed 
early, sometimes it is difficult to diagnose mild neurological impairments such as learning 
difficulty, behavioural and emotional problems, particularly in those infants born >32 to 36 
weeks of gestation who are also facing an increased risk of long-term sequels such as 
unfavourable growth, neurological, behavioural and educational outcomes (34, 35). 
Additionally, children who are born premature may need frequent rehospitalisation due to 
their ongoing chronic conditions (36, 37).  
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1.3.2 Burdens on the parents  
1.3.2.1 During hospital stay  
Preterm birth and the hospitalisation of the infants are very stressful experiences to 
parents. Preterm birth is often unexpected, therefore could be considered as traumatic 
events, which affect the daily lives of the parents (38) and increase the risk of post-
traumatic symptoms and preventing the development of normal parenthood (39). Parents 
of preterm infants are susceptible to emotional problems compared to parents of term 
infants (40). When the baby is born, parents are shocked by the event and the clinical 
condition of their baby that may prevent the parents from caring for their baby (41), this 
may make them feel powerless and helpless (42).   
In the Neonatal Intensive Care Unit (NICU), the initial reaction of the parents to their 
preterm infant is often that of a guest or foreigner and a feeling of uncertainty about 
parenthood (43) especially the mothers who experience more anxiety and poor adaptation 
(44). Parental stress is due to physical and emotional separation from their infant, their 
infant’s health, the uncertainty of survivals and the future of their infants. Some parents 
are also affected by the appearance of the infants especially EXP infants that may further 
worsen the first relationships between parents and their babies (45). The infant clinical 
status and environment of the NICU may also prevent skin-to-skin contacts that may 
adversely affect the mother’s bonding to her baby (43), which might has a potential impact 
on the infant’s long-term outcome (46). Since preterm infants might require a prolonged 
hospital stay (47), parents may have to suspend their normal life and spend extended time 
in the NICU; these may have great stressful effects on the families (48, 49).   
1.3.2.2 Beyond the hospital  
Parental stress may continue after hospital discharge and during the first few years, as 
they need to adapt to the independent role and safeguard high-risk fragile infant. 
Additionally, parents’ uncertainties about the future growth and development of their 
infants may continue after discharge to home particularly with the mothers who are more 
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prone to depression and anxiety (50). Due to the ongoing problems of preterm infants 
especially EXP infants, parents have to manage, further medical and developmental 
necessities. The daily care of preterm infants needs more efforts from the parents and 
possibly more time consuming than the need for full-term infants. Such as, preterm infants 
are more likely to experience feeding difficulties (51); approximately 31 to 45% of preterm 
infants suffer from feeding complications during the first two years of life (52).  
Moreover, long-term complications, particularly those associated with poor 
neurodevelopment (30), may lead to persistent increased stress and burden on the 
families (26, 53), through functional impairments and disabilities of the diseases such as 
cerebral palsy. Securing medical care and rehabilitation programmes for the child are also 
time-consuming as well as requiring extra expenses. Preterm infants are likely to be re-
hospitalised and require frequent outpatient visits (37) that may overburden the parents 
(27, 54). Furthermore, financial concerns are other factors that might exaggerate parental 
stress. The unpaid leave from work, reducing hours of work and out-of-pocket budgets 
contribute to the financial burden on the parents and their quality of life (55). Given the 
negative impacts of a disabled child on the families , improving health outcomes of 
preterm infants might minimise the adverse effects of having preterm infants on the 
parents (27).  
1.4 Prematurity is a research priority 
Healthy births and reduction of LBW and VLBW are one of the National Leading Health 
Indicators (NLHIs) recommended by the American Institute of Medicine (56).  Reducing 
child mortality is one of the United Nations Millennium Development Goals (MDGs) (57). 
Though there was a global reduction in child mortality, there was a slighter decline in 
neonatal mortality (8). Prematurity contributes to about 35% of neonatal deaths and 
represents a significant share of deaths in children under five years of age (2). The Office 
of National Statistics 2016 data for England and Wales also showed an increase in the 
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neonatal mortality rate between 2015- 2016 and complications of prematurity were the 
leading cause of neonatal and infant deaths, Figure 1.2 (58).  
 
Figure 1.2  Causes of neonatal, post-neonatal and infant deaths in England and 
Wales, 2016  
Columns represent percentages of the causes of infants’ deaths. Neonatal: < 28 days of 
life; Postneonatal: 28 days-one year; Infants: under one year.  Light blue column: 
Congenital anomalies; Orange column: prematurity complications; Grey column: Sudden 
infant deaths. Source: data downloaded from the website of the Office for National 
Statistics, UK (58). 
 
The continuous increase in preterm births creates more burden on diseases (12). In the 
UK, the EPICure study, population-based studies of EXP infants (22 to 26+6 weeks) 
demonstrated that there was a rise in the rate of infants born at or less than 26 weeks by 
44% between 1995 and 2006 and survivors are also increased, however, morbidities were 
unchanged among the survivors (59).  
Although MLP infants have better outcomes compared to VP and EXP infants, however, 
compared to full-term infants, they may experience problems during the neonatal period, 
and long-term health, educational and behavioural issues (60, 61). Since, MLP infants 
compromise a majority of preterm infants, in the UK, they accounted for 85% of the 7% of 
preterm births (62) and in the USA, accounted for 7.17% of live births (19). Therefore, 
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even a slight increase in health problems may create a significant burden to health care 
services and societies (63).  
Preterm infants require extended time in the hospital (47), which will be longer if the infant 
had complications such as infection or/and necrotising enterocolitis (NEC). Infants with 
NEC had been hospitalised 60 days longer than preterm infants without NEC (64). In the 
UK, the median length of hospital stay for infants born at 24 weeks and between 30 and 
31 weeks, were 123 and 44 days respectively (65). In the USA, in 2000, the mean daily 
cost was $1535 for infants born ≤32 weeks compared to $700 for infants born between 33 
and 36 weeks (66).  
Moreover, the costs of preterm infants rise further in childhood and adulthood from 
survival with ongoing problems (67). The Chief Medical Officer 2012 data for the UK, 
reported that the annual cost of preterm infants from birth throughout childhood was £1.24 
billion and the total cost for societies was £2.48 billion (68). This is likely to translate into 
economic costs for health services, families and communities. Hence, research emphasis 
on preterm infants could assist and guide public health policies and decide financial 
priorities. 
To accelerate the progress towards reducing child mortality (MDG4), the United Nation 
(UN) (69) highlighted that focusing on prematurity is critical for improving child survival, 
and outcomes (70-72). Adapting and innovating innervations to improve preterm 
outcomes, were also addressed as an urgent priority research agenda by the WHO (3) 
and the Preterm Birth Research Priority Setting Group (73).   
1.5 Prematurity-related complications  
During foetal life, through the placenta, the mother provides essential nutrients to the 
foetus and excretes metabolic products. The placenta also produces hormones for foetal 
growth and protects the foetus against infection by its mucosal macrophages and transfer 
of maternal IgG (74). Maturation of the foetus occurs throughout the pregnancy to 
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accomplish development and growth of organs and systems to adapt for extra-uterine life. 
Preterm birth disrupts these physiological processes. Therefore, the foetus is born with 
underdeveloped organs and systems that impair their functions, which manifested in 
prematurity-related complications. Those immature fragile organs are susceptible to 
injuries during the perinatal and neonatal periods; they are also influenced by the 
aetiology of the preterm birth and maternal risk factors such as maternal infection  (75). 
Moreover, some of the treatment modalities, medications and procedures, which are 
required for life support, are additional factors that might influence the responses of the 
immature systems. For example, mechanical ventilation and high oxygen therapy 
contribute to the pathogenesis of chronic lung disease (CLD) (76). The risk for 
complications increases with decreasing gestational age, reflecting the degree of 
immaturity; an infant born between 22 and 25 weeks have the highest risk of mortality and 
complications (28, 77, 78). The response of the infant’s organs to the extra-uterine 
environment (including the NICU) and the treatment strategies have a significant impact 
on the short and long-term health outcomes of the infant.     
1.5.1 Short-term complications 
Short-term complications manifested in the neonatal period and during first hospital 
admissions. These complications might prolong hospital stay, increase the risk of 
infections and adverse long-term outcomes. Table 1.1 summarises the foremost 
prematurity-related complications. 
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Table 1.1  Prematurity-related complications 
System Complications Mechanisms 
Respiratory 
RDS (79) Surfactant deficiency  
Poor postnatal adaptation 
Ventilator associated pneumonia 
Oxygen toxicity 
Barotrauma/Volutruama 
Perinatal asphyxia 
Pneumonia 
CLD (80) 
Cardiovascular 
Hypotension/bradycardia (16) Hypovolemia/sepsis/cardiac 
Patent ductus arteriosus (81) Hypoxaemia 
Gastrointestinal 
Feeding intolerance (82) 
NEC 
SIP (83)  
Gastroesophageal reflux (84) 
Immature suckling/swallowing 
  Immature GIT/ 
  enteral feeding/sepsis 
Nutritional 
Parenteral nutrition and its 
sequelae (85, 86) 
Growth impairment 
 
   Poor store and intake/ 
   rapid growth 
Neurological Perinatal asphyxia Fluctuating cerebral blood 
flow/mechanical ventilation 
Immature respiratory centre 
 
IVH (87) 
Apnoea of prematurity (88) 
Haematological 
Hyperbilirubinemia 
Anaemia of prematurity (89) 
 RBCs transfusion (90) 
Immature live enzymes/sepsis 
Blood sampling/erythropoietin 
deficiency 
Metabolic 
Hypoglycaemia (91) Poor glycogen store/decreased 
production 
Hyperglycaemia Stress/immature glycogenolysis  
Hypocalcaemia Poor response to PTH 
Renal 
Poor handling of water, salts and 
acids 
Low glomerular filtration rate 
Temperature 
Hypothermia (92) Large surface area/ low brown fat/ thin 
skin 
hyperthermia Central/sepsis/dehydration 
Immunological 
High risk of infections Deficient cellular and humoral 
immunities 
Eye 
ROP (93) 
Refraction errors (16) 
Oxygen toxicity 
ROP 
RDS: respiratory distress syndrome; CLD: chronic lung disease; NEC: necrotising 
enterocolitis; GIT: gastrointestinal tract; IVH: Intraventricular haemorrhage; PTH: parathyroid 
hormone; ROP: retinopathy of prematurity. RBCs; red blood cells 
1.5.2 Long-term complications 
Preterm survivors are at increased risk of long-term consequences on health and 
development such as: 
- Neurodevelopmental disabilities and global developmental delay (30, 31, 94, 95).  
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- Chronic lung diseases (96, 97) persistent vulnerability to respiratory infection and a 
higher risk of asthma during childhood (98, 99).  
- Retinopathy of prematurity (100), higher risk of refraction errors and late retinal 
detachment especially in ELBW infants (101).  
- Growth failure (102, 103).  
- Hearing impairment and the need for hearing aids (95, 104). 
- Rehospitalisation due to a substantial risk of illness during childhood (37, 105).  
- Short bowel syndrome (95, 106).  
- Higher risk for developing non-communicable diseases like diabetes and 
hypertension (107, 108).  
- Emotional and psychological stress on the family (55).  
1.6 Preterm infant’s immune system  
The immune system is composed of innate and adaptive responses. The innate immunity 
is the first host, non-specific defence mechanism that provides immediate protection 
against pathogens. This immunity does not have persistent immune responses (109) but it 
presents antigens to the adaptive immune system (110). It comprises physical barriers like 
the skin, mucous membranes of respiratory and gastrointestinal tract (GIT), and a cellular 
component including neutrophils, mast cells, macrophages, monocytes and natural killer 
cells; in addition to humoral factors such as complements and cytokines (111, 112).  
The adaptive immune system includes lymphocytes (T and B), antibodies and cytokines; it 
develops during the first few years of life through environmental interactions at the skin 
and mucosal surfaces (109). The adaptive immunity is the second line of defence, based 
on antigen receptors represented on T and B lymphocytes (113) and usually triggered if 
the innate responses failed to fight pathogens, thus, requires more time to being activated 
(112). It is more potent and efficient in targeting pathogens and yield a long-lasting 
immunity. 
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After birth, the newborn infants face complex immune needs to fight infection, prevent 
harmful inflammatory processes and balance the transition from sterile intrauterine life to 
an extrauterine environment that rich in pathogens and antigens (110).  
1.6.1 Neonatal innate immunity  
Newborns are mainly dependent on innate immunity while the adaptive immune system is 
underdeveloped and its linking with the innate immunity is also impaired (114), these 
physiological processes are more compromised in preterm infants depending on the 
degree of maturity (113, 115).  
Preterm infants have fragile, gelatinous skin that is very vulnerable to injury, especially in 
EXP infants (116). Similarly, their protective mucosal and epithelial barriers of the 
respiratory tract and GIT are underdeveloped; these immature natural mechanical barriers 
increase the susceptibility to invasion by pathogens (117). The cellular component 
(neutrophils, monocytes, macrophages, natural killer cells) is also deficient (118). Preterm 
infants have minimal storage pools of neutrophils, which often results in a rapid depletion 
of the circulating neutrophils (neutropenia) particularly during infection (119). Additionally, 
their neutrophils have limited migratory capacity, impaired phagocytosis and degradation 
of ingested pathogens (120); these factors render preterm infants susceptible to infections 
and increase the risk of septicaemia. Moreover, the cytotoxicity of the neonatal natural 
killer cells is weak that could increase the risk for viral infections (121).   
The complement system is one of the principal, potent immune mechanisms that 
regulates inflammatory damage. It composed of a variety of proteins that promote a non-
antibody dependent opsonisation and facilitate phagocytosis (114) of microorganisms 
such as group B streptococci and Gram-negative bacteria, which are common pathogens 
colonise infants admitted to neonatal units (122). In neonates, the levels complement 
proteins were about half of older children, and further reduced in preterm infants, reaching 
the normal levels by 6 to 12 months of age (123, 124). Although preterm infants can 
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activate the complement cascade, the complement proteins are rapidly depleted during 
infection (124). 
Fibronectin is another essential glycoprotein in the immune system; it is an opsonic factor 
for bacteria, such as Staphylococcus aureus and B streptococci. It enhances chemotaxis 
of neutrophils, stimulates the production of inflammatory cytokines by macrophages and 
plays a role in T-cell activation and endothelial function (125). Newborn infants also have 
low fibronectin levels compared to children and adults and are more reduced in preterm 
infants (126).  
Moreover, Preterm infants have low pattern-recognition receptors such as Toll-like 
receptors (TLRs) e.g.TLR4 which has a fundamental role in the inflammatory process and 
could be activated by Gram-negative bacteria (127). Preterm infants expresse high TLR4 
in the intestinal mucosa and lack the capability for suppressing TLR4 signalling that may 
explain their increased risk of NEC (128).  
1.6.2 Neonatal adaptive immunity  
The adaptive immunity is also underdeveloped in preterm infants; it has inadequate 
lymphocyte activation, and cytokines and immunoglobulin productions (129). Therefore, 
preterm infants are deficient in secretory immunoglobulin A (SIgA), which is the main 
mucosal protective factor, due to poor functions of the B-cells and delay in plasma cell 
maturation. Neonatal T-lymphocytes also respond ineffectively to physiological stimuli with 
poor cytokine productions, antigen processing and degradation (130). Though, newborn 
infants have a passive immunity that obtained from their mothers by trans-placental 
transfer of immunoglobulin (IgG). This passive immunity is mostly transferred after 28 
weeks of gestation; hence, preterm infants have a lower IgG level compared to full-term 
infants; 250mg/dl at 28 weeks versus 1500 mg/dl (131, 132).  
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1.7 Necrotising enterocolitis (NEC) 
NEC is a well-known devastating gastrointestinal disease, one of the leading causes of 
deaths and morbidities among preterm infants (133). The incidence of NEC varies 
between counties, from 0.3 to 5.0 per 1000 live births (134), comprising 1-7.5% of NICU 
admissions (135). NEC is inversely related to the GA and birth weight; 90% of cases 
occur in preterm infants (136, 137). In the USA, NEC is high reaching 13% in infants <28 
weeks (138, 139), in Canada, 5.1% among infants <32 weeks gestation (140) while was 
lowest in Japan 1.6% in VLBW infants (141). In the UK, a multicentre randomised 
controlled trial (RCT) found that NEC affected 10% of infants <31 weeks (142); recently, 
severe NEC (confirmed at laparotomy, post-mortem, or causing death), is estimated to 
affect  3.15% of infants <32 weeks (143). Improvement of preterm survival especially of 
EXP has led to an increase in the incidence of NEC from 3% to 11% between 1997 and 
2000 and 5% to 15% between 2003 and 2007 in infants born between 22 to 28 weeks 
(136, 137). However, variation in NEC prevalence could be attributed to underdiagnosis of 
less severe cases and inconsistent case-definitions.  
Although NEC was described a long time ago (the 1950s) and a considerable amount of 
literature has been published on its aetiology and pathophysiology, the definite cause 
remains to be defined. However, prematurity and low birth weight are the main consistent 
risk factors (95, 135, 144, 145). Enteral feeding including, the type of milk and the feeding 
regimens also influences the infant’s susceptibility to NEC (146-149). Other factors, with 
conflicting evidence, could increase the risk of NEC such as, maternal prolonged rupture 
of membrane and chorioamnionitis (95, 150), hypoxic-ischemic insults (151), congenital 
heart diseases, patent ductus arteriosus (152), packed red cell  transfusion (139, 153), 
use of H2 blocker (154) and vasoactive agent such as dopamine, indomethacin (155), 
polycythaemia, and umbilical vessels catheterisations (156).  
NEC is a complicated multifactorial process that involves inflammation and bacterial 
invasion of the immature mucosa of the GIT with resultant mucosal necrosis (157, 158). 
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Immaturity of the GIT, weak immune responses and enteral feeding are the main 
contributing factors for the pathogenesis of NEC (159, 160). Hypo-perfusion and/or 
hypoxia of the bowel stimulate the release of mediators of inflammation from the ischemic 
gut like tumour necrosis factor, which triggers an inflammatory process leading to mucosal 
injury and damage to the intestinal barrier. The injured immature intestinal mucosa, use of 
antibiotics (161, 162) and enteral fasting (147, 148) are participating factors that act 
synergistically to promote intestinal atrophy and abnormal bacterial colonisation of the 
bowel (163); this could lead to overwhelming septicaemia, septic shock and death. 
The onset of NEC is variable from non-specific clinical signs to sudden fulminant course 
and deaths within hours, depending on the GA of the infant (140, 164). Therefore, a high 
index of suspicion is a keystone for managing NEC. Diagnosis of NEC is mainly based on 
the clinical signs and some radiological findings such as pneumatosis intestinalis (gas 
within the bowel wall), portal vein and free peritoneal gases, which are more life-
threatening signs (165). Based on the clinical presentation the severity of NEC is 
classified according to modified Bell’s criteria, commonly used definition (166, 167), into 
three stages; namely I, II and III depending on the clinical, and radiological signs as 
demonstrated in Table 1.2.  Based on the treatment approached, NEC is classified into 
medical and surgical NEC, which has a poorer outcome (168). However, NEC can only 
be confirmed by inspection of gangrenous necrosis, which mainly affects the terminal 
ileum or colon, at laparotomy or histopathological findings of the resected tissues. 
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Table 1.2 Modified NEC criteria (adapted from Kliegman 1987 (167) 
Bell stage Systemic signs Gut signs 
Radiographic 
findings 
Stage I 
Suspected NEC 
 
History of risk factors  
non-specific/Reluctant to 
feed 
lethargy/apnoea/bradycardia 
temperature instability 
High gastric residual (pre-
feed) 
vomiting ± bilious 
mild abdominal distension 
occult blood in the stool 
Normal/mild 
intestinal distension 
Stage II  
Definite NEC: 
IIA: mildly ill 
Increased desaturations 
and/or bradycardia 
temperature instability 
lethargy 
High gastric residual (pre-
feed) 
definite abdominal 
distension  
abdominal tenderness  
possibly bloody stools 
absent bowel sounds. 
Ileus, fixed dilated 
bowel loops, 
pneumatosis 
intestinalis 
IIB: moderately 
ill 
As IIA  
with thrombocytopenia 
and/or mild metabolic 
acidosis 
Same as previous 
Abdominal distension with 
definite tenderness 
possible abdominal wall 
oedema and/or 
discolouration. 
mass at lower right 
abdomen 
As IIA and portal 
vein gas, ascites 
(possible) 
Stage III  
Advanced NEC:  
severely ill 
- IIIA:  bowel 
intact 
As IIB plus hypotension, 
bradycardia, apnoea, sever 
metabolic acidosis, 
respiratory acidosis 
disseminated intravascular 
coagulopathy, neutropenia  
Same as previous, plus 
severe abdominal 
distension and tenderness 
with abdominal wall 
induration (sings of 
peritonitis) 
As IIB with definite 
ascites 
 IIIB As IIIA As IIIA Perforation, 
Pneumoperitoneum  
NEC: necrotising enterocolitis 
 
Despite aggressive and optimal medical and surgical management, NEC is still one of 
the leading causes of death in NICU. The mortality rate for NEC ranges from 10 to 
30% and may reach 50% for surgically treated infants (169). It is inversely related to 
the weight and GA of the infants, reaching up to 100% in extremely preterm infants 
(136, 164). NEC survivors may face further complications during the recovery that 
may lengthen their hospital stays and negatively impact on outcomes and cost to 
health systems (134). In the USA, it was estimated that infants with NEC stay in the 
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hospital 60 days longer than their counterparts without NEC with additional costs of 
$216 666 per survivor and $6.5 million per year for treating infants with NEC (64).  
Moreover, NEC associated with long-term consequences for the survivors especially 
those who have surgical interventions (157, 170); approximately 10 to 30% of 
survivors face long-term complications including intestinal strictures, short bowel 
syndrome, failure to thrive and neurodevelopmental abnormalities (168, 171). Despite 
the proposed measures to prevent NEC, such as modulating enteral feeding 
regimens, use of prebiotics and probiotics and antibiotics, NEC remains a common 
gastrointestinal emergency in NICU with high mortality and long-term sequels, though, 
mother’s milk, due to its immune-protective and growth factors, has been linked with a 
reduction in risk of NEC (149, 172, 173).  
1.8 Late-onset infection (LOI) 
Preterm infants are vulnerable to infection due to the immaturity of their immune systems. 
This susceptibility to infections is influenced by the intensive care that needed for life 
support such as mechanical ventilation, parental nutrition, and intravascular 
catheterisations. 
Infection is one of the leading causes of neonatal mortality especially in preterm infants 
(174). Late-onset infection (LOI) is defined as a blood culture proven microbial growth 
after 72 hours of life (174). The incidence of LOI is approximately 8-9/ 1000 live births in 
VLBW and 26 /1000 live births in ELBW preterm infants. Its rate varies between regions 
and countries from 0.6%-14.2% among neonatal admissions and is inversely related to 
the GA. It was estimated that 36.6% of preterm infants born < 28 weeks GA had at least 
one episode of LOI in comparison to 29.6% and 17.5%, of preterm infants born between 
28-32 weeks GA and 33-36 weeks GA respectively (175). In contrast to respiratory 
distress syndrome, which has been reduced since the surfactant era and with advances in 
neonatal medicine, infections related mortality and morbidities have increased (133).   
 18 
 
The immature immune system is the main risk factor. However, other factors could raise 
the risk of infection in preterm infants such as the need for invasive interventions, which 
may disrupt the fragile mucosal barrier, increase the risk of infection especially in 
extremely preterm infants (118). Additionally, delay to start enteral feeding and to achieve 
full enteral feeds that may lead to more extended stay in a microbial environment at NICU.  
The clinical presentations of LOI are subtle and non-specific, delaying early diagnosis, 
which may have devastating consequences. Therefore, clinical care providers have a low 
threshold to treat and start empirical antibiotics. However, prophylactic antibiotics therapy 
may increase the emergence of drug resistance and influence the intestinal bacterial 
colonisation of the infant (176), providing opportunities for potentially pathogenic bacteria 
to colonise the gut, that may translocate to other organs and tissues, increasing the risk of 
invasive systemic infection (163).                
With the increasing rate of preterm birth (177) and growing survival of VLBW and ELBW 
infants, the morbidity burden will increase. Thus the length of hospital stays and the risk of 
LOI will continue to be a challenge to the neonatal care (2, 178). Despite the use of 
infection control protocols, infections are still the most leading cause of neonatal death 
even in high-income counties (179). A large cohort study by Stoll et al. found that 21% of 
VLBW infants who survived more than three days had at least one episode of LOI. The 
authors also indicated that infections among ELBW infants were associated with poor 
neurodevelopmental and growth outcomes in early childhood (174).  
Thus, new policies are needed to decrease the incidence of nosocomial infections. One 
intervention that might protect against infection is the mother’s colostrum (180, 181). It 
was reported that the incidence of infections in preterm infants is lower in breastfed than 
in formula-fed infants; therefore breast milk is recommended as the "golden measure to 
prevent infection" (182). 
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1.9 Mother’s colostrum and milk  
Breast milk is the natural fluid secreted by mammalian mammary glands to feed their 
offspring and to provide them with the essential nutrition and protection for good health. 
Human milk is produced by the mother during late pregnancy and continues after delivery; 
it offers the optimal early nutrition for growth and healthy development of the infants. The 
benefits and importance of breastfeeding were identified a long time ago and exclusive 
breastfeeding for at least six months is recommended by the WHO and the American 
Academy of Pediatrics (AAP) (181, 183). A unique feature of human milk in contrast to 
other species like cows and rodents is that its composition is less influenced by maternal 
nutrition (184). 
Moreover, human milk has significant immune protective advantages due to various 
biologically active components that have the potential to modulate the immune system of 
the infants and enhance growth and development (185, 186). The antibacterial nature of 
breast milk was first reported in the literature in the late eighteenth century; when Paul 
Ehrlich, a German physician proved that maternal antibodies could be transmitted to 
offspring through breast milk. Such was the importance of this work that Ehrlich was 
awarded the Nobel Prize in Physiology or Medicine in 1908 for his impact on immunology 
(187). Furthermore, the immunological features of milk assisted in the advancement of the 
understanding of immunology (188, 189).  
Human milk is secreted in three stages, colostrum, transitional milk and mature milk. 
Colostrum is the first milk produced during late pregnancy until 3-5 days after birth. It is 
followed by an increasing volume of transitional milk which is in turn replaced by mature 
milk by the end of the second week of life (190). Human milk has great nutritional, 
developmental and protective benefits for newborn infants. The constituents of human 
milk are dynamic, adapt over lactation, diurnally, within a feed and differ between lactating 
women and populations (191, 192). However, the nutritional properties of human milk are 
preserved despite these variabilities. The main nutritional constituents are lactose (6.7 to 
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7.8 g/dl), protein (0.9 to 1.2 g/dl), and fat (3.2 to 3.6 g/dl) with 65 to 70 kcal/dl in addition to 
many micronutrients such as vitamins, iodine (193).  
For this thesis, I focused on the bioactive compositions of human milk and colostrum, as 
these bioactive factors can influence the biological functions of the body and consequently 
affect the health outcomes of the infants. The following section reviews some of the 
bioactive components of colostrum and milk.   
1.9.1 Immunological constituents  
 The principal immune components of human milk and colostrum are as follows:  
1.9.1.1 Secretory immunoglobulin A (SIg A) 
SIg A is the primary immunoglobulin in human milk. It is the first line of defence against 
microbes, and is the predominant Ig in human milk, in contrast to other mammalian 
species (cattle and sheep) where IgG is the main (188). IgA levels change over different 
stages of lactation, the highest concentration presents in colostrum, which contains more 
than 1.5g/L (194, 195).  
IgA is the most crucial defence factors for mucosal surfaces especially the intestinal 
mucosa. It possesses a secretory component, which affords IgA resistance against 
proteolytic enzymes in the gut and helps fixation to the mucosa (196). By a process called 
“immune exclusion”, it prevents bacterial attachment to the mucosal cells, which is a 
necessary process for invasive disease. The Ig A captures the bacteria then, embedded in 
mucus thus facilitating elimination of the bacteria by peristalsis (197). Recently it has been 
recognised that it can reduce the virulence of bacteria, influence the intestinal flora and 
decrease the inflammatory responses associated with pathogenic microorganism and 
potential allergens (198). In addition, colostrum contains IgG but in a lower concentration 
than mature milk. However, it was reported that there were no differences in the level of 
IgG in colostrum from women who delivered preterm or term infants (199).  Conversely, 
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colostrum is deficient in IgM, and no significant difference has been reported with GA 
(200, 201).   
1.9.1.2 Lactoferrin 
Lactoferrin (Lf) is an iron-binding glycoprotein. It is present on mucosal surfaces and in 
biological fluids like tears, saliva, seminal fluid, and milk. Lf is the chief whey protein in 
human milk throughout lactation. Human milk has a higher level of Lf in comparison to 
other species; for example, bovine colostrum contains 5mg/ml while mature bovine milk 
has only 20-200μg/ml, in contrast, to mature human milk, which has a minimum of 1mg/ml 
of Lf (202).  
Lf is a fundamental component of the innate immune system, it has a broad antimicrobial 
activity and is one of the primary mucosal defence factors (203). As iron is an essential 
substrate for bacterial growth, due to its high iron-binding capacity, Lf inhibits the growth 
of potentially pathogenic bacteria by decreasing iron availability. Lf also acts by disrupting 
microbial cell membrane, inhibiting adhesion to host cells and preventing biofilm formation 
(204, 205). Lf can resist intestinal enzymes, and this may facilitate its action in the gut 
lumen as a prebiotic that promotes the growth of beneficial bacteria, therefore, might 
inhibit colonisation of the gut by pathogenic microorganisms (206). 
Moreover, Lf has anti-inflammatory and immunomodulatory properties in the gut by 
activating T-lymphocytes and cytokine expression (204). Recently, it was suggested that 
Lf has a possible antiviral and antibacterial action by direct interaction of its molecules 
with microorganisms (203, 207). Lf is being investigated as a potential immune therapy in 
the prevention of NEC and infection in preterm infants (142, 208).  
1.9.1.3 Oligosaccharides 
Oligosaccharides are biologically active carbohydrates, one of the most vital components 
of human colostrum and milk and present in high concentrations approximately ranging 
from 7 to 12 g/L (209, 210). Human milk oligosaccharides are complex molecules 
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classified into four groups, and more than 100 oligosaccharides have been identified (211) 
in human milk; this might explain their diverse functions. Oligosaccharides’ structural 
complexity is a distinctive feature of human milk compared to bovine milk, which contains 
only a trace of oligosaccharides and less complex structure (212). Oligosaccharides have 
been considered to be the furthermost crucial human milk component that influences the 
intestinal flora in breastfed infants (213).  Oligosaccharides are resistant to the digestive 
enzymes of the GIT and act as prebiotics to promote the growth of non-pathogenic 
bacteria like Bifidobacterium bifidum in the gut (214, 215). Oligosaccharides also function 
as analogues to inhibit the attachment of microorganisms to mucosal cells of the 
respiratory and gastrointestinal tracts, an essential stage for microbial invasion (216, 217). 
It was proposed by in vitro studies that oligosaccharides can activate T-lymphocytes and 
cytokines production (210). Recent evidence suggested that oligosaccharides in human 
milk protect against NEC due to their antimicrobial, anti-inflammatory actions and their 
potential role in the maintenance of intestinal integrity, healing and maturation of intestinal 
wall (210, 218, 219). Moreover, oligosaccharides have the potential as signalling 
molecules and nutrients for the growing brain, therefore, might contribute to postnatal 
neurological development (220). Wang et al. reported that there were higher levels of 
brain gangliosides and glycoprotein sialic acid, which are essential for brain development 
and cognition, in breastfed infants than formula-fed infants (221).    
1.9.1.4 Cytokines 
Cytokines are pluripotent peptides secreted by several various (immune and 
inflammatory) cells. They are present throughout the body as well as in amniotic fluid, 
colostrum and milk. Cytokines collectively act in a network like fashion by interacting with 
distinctive cellular receptors to enhance and regulate the immune system. Human milk 
contains many cytokines, which are secreted by the mammary glands and milk cells and 
have the potential to modify the immune system (222, 223).  
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Many varieties of cytokines have been recognised like interleukin (IL), interferon (IFN-γ), 
tumour-necrosis factor (TNF-α), transforming growth factor β (TGF-β), granulocyte colony-
stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), and 
granulocyte-macrophage-colony-stimulating factor (GM-CSF) (224, 225). Human milk 
cytokines can pass through the intestinal mucosal barrier to interact with the cellular 
receptors to modulate the immune responses. Cytokines modulate the immune system by 
variable actions; pro-inflammatory like IL6, TNF-α and INF-γ that stimulate the immune 
response and the differentiation of B-lymphocytes into IgA plasma secreting cells, 
therefore, might protect against infections. Other cytokines have anti-inflammatory 
properties such as IL10 and IL13 (225). Cytokines have a vital role in response to injuries 
and protection of mucosal surfaces, which are the primary access point for an invasion by 
microorganisms (226). TGF-βs are the principal cytokine in human milk that play an 
essential role in cellular proliferation, intestinal homeostasis and tolerance (227). TGF-β 
involves in T-cell activation and can, via its effect on B-cells, in conjunction with other 
cytokines, initiates production of IgA at the mucosal surfaces to potentiate mucosal 
immunity (228).  
1.9.1.5 Pancreatic secretory trypsin inhibitors (PSTI) 
PSTI is a peptide, which protects the pancreas from auto-digestion. PSTI has also been 
found in the gastric secretion and in intestinal mucosal cells where it protects excessive 
digestion of the mucosa (229).  Recently PSTI was found in a significant concentration in 
human milk especially during the first few days after birth (230). During this early neonatal 
period, with the introduction of feeding, there is a rapid increase in the secretion of acid 
and digestive enzymes of the GIT (231). These changes may increase the risk of 
intestinal injury and could rationalise the higher levels of protective factors such as PSTI in 
colostrum compared to mature milk. Therefore, PSTI might have the potential to prevent 
mucosal damage, facilitate gastric mucosal repair, promote intestinal wall healing and 
create a mucosal defence (232, 233).  
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1.9.2 Growth factors in human milk  
Mother’s milk has various effects on the growth of some of the body organs such as the 
GIT, nervous and vascular systems. These effects are mediated through its numerous 
growth factors, such as epidermal growth factor (EGF), transforming growth factor (TGF) 
and insulin-like growth factor-1 (IGF-1) which have significant effects on cellular 
differentiation, proliferation and maturation and repair of the tissues (234, 235).  It was 
reported that most of the growth factors are present in higher concentrations in colostrum 
compared to mature milk that may indicate their importance for maturation during early life 
(236, 237).  Table 1.3 summarises the main growth factors present in human colostrum.  
Table 1.3  Colostrum growth factors 
Growth factors  Role 
Epidermal growth factor (EGF) 
EGF presents at a very high level in colostrum 
(237). EGF stimulates proliferation and maturation 
of the enterocytes (238). Main intestinal protective 
factor from hypoxic-ischemic injuries (239, 240). 
Heparin-binding growth factor (HB-
EGF) 
Protects against hypoxic and ischemic injuries and 
has an important role in the repair of post-hypoxic-
ischemic injuries, such as resuscitation and NEC 
injuries (240). 
Neuronal growth factors (NGF) 
Have a critical role in the development of the 
nervous system. Promote neuronal maturation of 
the gut and enhance GIT motility (241-243). 
Insulin-like growth factor (IGF) 
Higher level in colostrum. IGF has a role in tissue 
growth (244). Stimulate erythropoiesis   
Vascular endothelial growth factor  
Higher level in colostrum. Regulates vascular 
endothelial and may play a role in reducing the risk 
of ROP (245, 246).  
Erythropoietin  
Stimulate RBCs production and may prevent 
anaemia of prematurity. It also has a trophic effect 
on the intestinal mucosa. (247, 248).  
NEC: necrotising enterocolitis; GIT: gastrointestinal tract; ROP: retinopathy of prematurity; 
RBC: red blood cell. 
1.9.3 Cellular components 
Human milk and colostrum also possess cellular components. They are rich in 
macrophages, lymphocytes, granulocytes, epithelial cells. The presence of maternal cells 
in an active motile form in human milk suggests that these cells could have continuous 
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functions in breast milk feed infants (249, 250). In colostrum, neutrophils and 
macrophages are the predominant cell type; they represent about 40% to 60% and 30% 
to 50% of the total leukocytes respectively.  Lymphocytes account for 5%-10% and T- 
lymphocytes are the predominant type of breast milk lymphocytes (251, 252). These cells 
act by different mechanisms; neutrophil and macrophages act by direct killing of 
microorganisms, and lymphocytes (activated-T-lymphocytes) by producing cytokines 
(253). It was proposed that the infant’s infectious status influence leukocyte and 
macrophage counts in breast milk (254) that may suggest additional potential support of 
breast milk in response to infection. Recently, undifferentiated stem cells have been 
identified in human milk (255).  
1.9.4 Other protective factors  
In addition, to the previously described elements, human milk contains many other factors 
such as nucleotides, lysozymes, free fatty acids, Mucins, soluble CD14, TLRs agonists 
and antagonists (256). Human milk has many enzymes such as lipase an enzyme that 
enhance fat absorption by the intestine (257). Nucleotides represent about 20% of non-
protein nitrogen in human milk (258) and are suggested as central factors in GIT 
maturation and development of the immune function of the infant. Nucleotides also have a 
potentially favourable effect on the gut microflora (259). Long-chain polyunsaturated fatty 
acids (PUFAs) and gangliosides present in higher levels and distinctive form in breast milk 
compared to formula milk; long-chain PUFAs are essential for the cell membrane 
structure, especially in the neuronal and retinal cells (260). Human milk gangliosides have 
also been involved in neuronal development, cellular growth and prevention of infection 
(261, 262). These bioactive components of human colostrum and milk act synergistically 
to promote the growth and the immunity of newborn infants and provide effective 
development and protection against serious illness such as NEC and infections.  
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1.9.5 Colostrum versus mature milk: compositions and 
immune activity 
During lactation, milk constitutes change between, colostrum, transitional and mature milk. 
While the three stages of human milk have enormous nutritional, developmental and 
protective benefits for the newborn infants, they vary in their physical characteristics and 
compositions.  
Colostrum is the first stage of lactation; produced in low volume and it has unique 
characters in comparison to mature milk. Colostrum is rich in immunological constitutes, 
growth factors, minerals, fat-soluble vitamins and proteins but has a relatively low lactose 
level, and lipids (193, 263-265). This unique composition of colostrum indicates that its 
primary functions are protective and trophic. For example, SIgA is approximately 100 
times higher in colostrum than mature milk (266). Lactoferrin is highly concentrated in 
colostrum reaching almost to 7g/ml in contrast to 1g/ml in mature milk; moreover, colostral 
lactoferrin has a higher affinity for iron chelation which explains its bacteriostatic function 
(264) as described in section 1.9.1.2.  IgA and Lf constitute approximately 10% of the 
colostrum weight compared to only 1% in mature milk. However, the lower level in mature 
milk is compensated by increasing milk volume (267). 
Similarly, the concentration of oligosaccharides is higher in colostrum reaching 20g/L that 
decline over the periods of lactation; dropping to 5g/L in mature milk (268). Higher levels 
of bioactive cytokines in colostrum are also reported (185). Growth factors like EGF, TGF-
α and PSTI, which are peptides with a significant healing effect on the injured intestinal 
mucosa, were found in higher concentrations in colostrum (234, 238). Additionally, 
colostrum is more abundant in cells than mature breast milk particularly leucocytes (251). 
These compositions of colostrum seem to compensate for the deficiency of infant’s 
immune responses especially mucosal immunity during the early life.  
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1.10 Preterm infants and mother’s milk 
Mother’s milk has been recommended as the primary food for preterm infants. However, 
from the nutritional aspect mother’s milk is not the optimal feeding alone for preterm 
infants, especially those who are EXP and LBW infants. Preterm infants have a high risk 
of nutritional deficiencies and growth impairment, and they need higher protein, caloric, 
minerals and vitamin intakes to support their growth rates; mother’s milk may not meet 
some requirements such as calcium, phosphorous and iron. (269, 270). Therefore 
additional nutrients may be needed to fortify the mother’s milk (271). However, mother’s 
milk has a unique nutritional advantages over formula milk for preterm infants, due to its 
higher content of cysteine and taurine, long-chain polyunsaturated fatty acids, nucleotides, 
and gangliosides compared to formula milk (217). Mother’s milk also has a high level of 
lipase; an enzyme which, improves fat absorption (193). 
Moreover, the mother’s milk is more tolerable by preterm infants than formula milk and 
promotes gastric emptying. While from the nutritional aspect for the long run it is not the 
optimal feeding alone for preterm infants, mother’s milk has substantial protective 
benefits. The AAP recommended the early introduction of mother’s colostrum and milk for 
feeding preterm infants, and donor human milk (DHM) is the preferred alternative, to 
formula, when mother’s milk is unavailable or inadequate (272). From a nutritional point of 
view, preterm milk has higher levels of protein, amino acids, fat and sodium compared to 
full term milk, while it contains similar concentrations of minerals as term milk except for 
the calcium which, is lower in preterm milk (193, 273).  
In comparison to mothers who have term infants, colostrum secreted by mothers who 
have preterm infants has higher concentrations of biologically active immune factors, such 
as IgA, lactoferrin and some interleukins, and growth factors (192, 195, 201, 274). The 
levels of these biofactors are inversely related to the duration of pregnancy. Growth 
factors like EGF, TGF-α and PSTI were also found in higher concentrations in colostrum 
of mothers of EXP infants compared to MLP infants (236). These-gestational age 
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associated concentrations in the bioactive factors suggest that preterm colostrum has 
been distinctively expressed to support extra-uterine adaptation and protect the preterm 
infants against infection, during the early postnatal weeks.  
The high concentration of bioactive substances in colostrum produced by mothers of 
preterm infants is linked to the open tight junctions of the mammary epithelium, which 
allow para-cellular transport of immune factors from maternal circulation to the milk (184, 
274). These tight junctions fuse steadily over the first few days following birth and close 
entirely with the production of mature milk. Additionally, some studies have postulated that 
colostrum of mothers who have preterm infants may continue longer than mothers with 
full-term infants that may extend for almost seven days (274, 275).  
Nevertheless, during foetal life, the growth of the foetus occurs throughout the third 
trimester of pregnancy, and approximately 15% depends on the nutrients and growth 
factors from the swallowed amniotic fluid (276). The amniotic fluid has an essential role in 
the development and growth of the GIT, which occurs mainly during late pregnancy (158). 
Similarity between the compositions of colostrum and the amniotic fluid has been 
established (277),  therefore, providing colostrum to preterm infants during the early 
neonatal period may substitute the infant with the trophic effects of the amniotic fluid on 
intestinal growth and development (278) and may support these vulnerable infants against 
the higher risk of NEC and infection.  
In summary, preterm infants had a deficient immune response and delayed production of 
immune and growth factors, the higher levels of bioactive components in mother’s 
colostrum and prolonged colostrum phase of the lactation period could compensate this 
deficiency. Mother’s milk has been linked with lower risks of some of the prematurity-
related morbidities such as sepsis (279, 280), NEC (173, 281) retinopathy of prematurity 
(282, 283) and neurodevelopmental outcomes (284, 285). Therefore, it is evident that 
colostrum could protect the preterm infants especially extremely preterm infants during the 
critical early neonatal period. 
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1.11 Enteral feeding challenges for preterm infants 
Enteral feeding is the provision of food into the GIT, whatever the route used. Feeding 
preterm infants safely and adequately is one of the major challenges in the care of these 
infants. During the early postnatal period, preterm infants especially those EXP and ELBW 
are critically ill, clinically unstable and cannot tolerate enteral feeding. Thus, 
commencement of enteral feeding will be delayed, leading to prolongation of parenteral 
nutrition (PN), which requires placement of indwelling intravenous catheters leading to 
increased risk of invasive sepsis (286). Moreover, prematurity associated conditions that 
affect intestinal perfusion commonly prevent enteral feeding. Despite the evolution of 
perinatal and neonatal medicine that improved preterm survival, the introduction of enteral 
feeding and the provision of adequate enteral feeds remain a continuing challenge for 
neonatal professionals, patients and parents (287).   
During the neonatal period, the objective regarding nutrition of preterm infants is to 
achieve a postnatal growth by a rate similar to the intrauterine growth of a foetus with the 
same GA (288) with adequate functional development. Preterm infants are a 
heterogeneous group with a variable degree of immaturity that is influenced by many 
factors such as the cause of preterm birth, maternal illnesses, intrauterine and postnatal 
environments (16). Therefore, introducing enteral feeds requires a balanced clinical 
decision between these factors and the extent of the immaturity of the organs and the 
infant’s clinical status. The concern of serious diseases such as NEC further complicates 
the provision of enteral feeds to these vulnerable infants (289).  
1.11.1 Strategies for feeding preterm infants 
Enteral feeding is the best and safest way for providing nutritional requirements and is 
preferable to PN, which has been linked to severe complications such as sepsis and liver 
disease (85, 86). However, PN is an essential adjunctive or exclusive therapy to optimise 
the nutritional needs in critical cases especially for EXP and ELBW infants (290, 291). 
Enteral feeding is also considered as one of the modifiable risk factors for NEC in preterm 
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infants (292). Yet, there is still variability in the practice of enteral feeding for preterm 
infants internationally and between neonatal units within a country (293, 294). 
To achieve full breastfeeding or/and bottle feeding, preterm infants usually pass through 
different stages before they start to swallow, coordinate and then gather appropriate 
attachment and sucking. Different practices have been used to provide enteral feeding to 
preterm infants during the neonatal and transitional periods. However, there is still no 
consensus about an approach for feeding preterm infants, particularly during the neonatal 
period, due to the lack of sufficient evidence for the optimal time to start, type of milk to 
use, the safest volume to begin with and the speed of advancement (147, 291, 293, 295).  
In the subsequent four sections, I review some of the challenges that may face the 
feeding of preterm infants 
1.11.1.1 Type of milk 
Human milk is a central constituent of any strategy for enteral nutrition of all infants 
including preterm infants. There is robust and consistent evidence that mother’s own milk 
is associated with a reduction in prematurity-related complications (296-298). Therefore, 
feeding mother’s own milk was highly recommended by the WHO and the AAP and the 
European Society of Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) 
as the primary option for feeding preterm infants (181, 183, 270). Early provision of human 
milk has been linked with decreased mortality, morbidities, especially protection against 
NEC (172, 173, 281), and better neurodevelopmental outcomes (284).  However, human 
milk needs to be fortified to meet the necessary nutritional requirements for optimal growth 
and development of preterm infants (295).  Human milk fortifiers are usually indicated in 
infants born before 32 weeks of gestation and VLBW infants. Improvement in health 
outcomes that associated with the use of mother’s milk is related to the volume of 
mother’s milk received by the infants especially during the first two weeks of life (173, 
281). Pasteurised DHM is an alternative if mother’s milk is unavailable or insufficient 
(299). However, DHM has lower energy, nutritional constituents such as fat, protein and 
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less protective factors such as IgA and lactoferrin (300) that might be related to the effect 
of pasteurisation; additionally, DHM usually collected after months of birth (301, 302). 
Formula milk is another option for feeding preterm infants if the mother’s milk is 
unavailable or insufficient and DHM is also unavailable, or the infant is unable to feed 
DHM (303). Although formula milk feeding resulted in better short-term postnatal growth, it 
is associated with a higher risk of NEC compared to human milk (304). However, the 
benefits of DHM over formula milk still uncertain (143, 295). 
1.11.1.2 Trophic feeding 
Feeding preterm infants is commonly initiated as minimal enteral feeds or trophic feeding. 
Trophic feeding is defined as providing a small volume of milk (10-20ml/kg/day) without 
increasing the rate for 5 to 7 days (305). Trophic feeding was initiated in the late 1980s; it 
is hypocaloric non-nutritional feeds that have been recommended to stimulate the 
development of the immature gut of preterm infants without worsening the severity of 
diseases (306). Other terms have been used; gut priming, minimal enteral nutrition and 
hypocaloric feeding. Trophic feeds enhance gut motility (306), modify intestinal 
disaccharidase enzymes, alter microflora, and stimulate gut hormone secretions, which is 
essential in the postnatal adaptation of the GIT (307). It has been linked with improvement 
in feeding tolerance, earlier attainment of full enteral feeds, shorter hospital stay and 
better postnatal weight gain (305, 306). Early trophic feeding is also associated with a 
reduction in the incidence of infection (286) and did not increase the risk for NEC (308).  
However, due to the concern that early introduction of enteral feeds may increase the risk 
of NEC, some clinician delays the initiation of enteral feeding to preterm infants (147). The 
nil per oral state and use of antibiotics can lead to intestinal mucosal atrophy and 
inflammation, decrease the digestive enzymes and mucosal IgA, and promotes 
colonisation by a pathogenic microorganism, which worsen by the use of antibiotics as 
part of the care of preterm infants increasing the risk for sepsis, NEC and feeding 
intolerance (309).  
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Furthermore, delayed commencement of enteral feeding is accompanied by prolonged 
use of PN that might prolong hospital stay and increase the risk of PN-associated 
complications (85, 86). Therefore, early trophic feeding is the most common approach to 
start enteral feeding in preterm infants. However, in certain clinical situations, trophic 
feeding could not be given, and nil per mouth status is unavoidable.   
1.11.1.3 Progression of enteral feeding 
Debate continues about the best strategies for progressing the feeds and the rate of 
advancement due to the concern that early and rapid progress of enteral feeding might 
increase the risk of NEC (310, 311). A Cochrane review reported that delay in the 
introduction of progressive enteral feeding more than four days has no significant effects 
on the incidence of NEC, mortality, and other morbidities in very preterm infants, however, 
the delay resulted in more days to attain full enteral feeding (312). Another Cochrane 
review evaluated the effects of slow advancement of enteral feeds (less than 24ml/kg/day 
daily increment) versus fast speeds (30 to 40 ml/kg/day) found that slow rates did not 
decrease the risks of feeding intolerance, NEC or mortality, however, the faster speeds 
group achieved  full enteral feeds and regained birth weight earlier (313). Thus, feeding 
practice should be balanced between the risk and benefits, considering different health 
outcomes. 
1.11.1.4 Method of feeding  
Preterm infants have poor sucking and swallowing/breathing coordination that increase 
the risk of aspiration. Organised oesophageal function develops after 32 weeks of 
gestation and coordination at 33 to 34 weeks (314, 315).  Therefore, tube feeding, either 
nasogastric or orogastric tube, is commonly used as an initial method to feed preterm 
infants.  
Nasal resistance accounts to about 40% of airway resistance, thus, the nasogastric tube 
may increase the work of breathing and may lead to respiratory problems such as apnoea 
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and desaturation (316). An orogastric tube is preferred in feeding preterm infants 
especially those who have respiratory distress or at increased risk of apnoea. (316, 317).  
However, orogastric and nasogastric feeding tubes are both used in neonatal units due to 
limited evidence (318).  
There is also uncertainty whether continuous or enteral bolus feed is the optimal method 
(319). Some studies reported that bolus enteral feeding associated with increased 
incidence of apnoea, respiratory compromise and fewer weight gains and continuous 
feeds are more tolerated by preterm infants (320) while others found no differences in the 
incidence of apnoea or growth (321, 322). Therefore, the method of feeding should be 
balanced; continuous feeding may be more advantageous initially while bolus can be used 
when the infants developed sucking and swallowing/coordination and in stable infants. 
Table 1.4 summaries strategies used in the practice of enteral feeding of preterm infants  
(323).  
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Table 1.4  Strategies of enteral feeding in preterm infants 
Type of milk  Mother’s own milk is the best and first option  
Donor breast milk only if the mother’s own milk is 
not available or insufficient. 
Formula an alternative if a mother’s own milk is not 
available or insufficient or paternal choice. 
Breast milk fortifiers, when milk feeding reached 
100ml/kg/day especially for extremely preterm 
infants. 
Method of feeding Nasogastric or orogastric tube, and intermittent 
intra-gastric (bolus) feeding or continuous enteral 
feeding. No evidence to support significant 
differences. 
Cup feeding, bottle and breast or all are usually 
started later when infants reach full enteral feeds  
Time to start As early as the infant’s clinical status permits but 
mostly within the first 3 to four days after birth. 
Trophic or minimal enteral 
feedings 
Highly recommended than complete fasting. 
Trophic feedings 1ml/kg/hr is usually to start with   
Progression of feeding  Early provision of progressive enteral feeds and 
fast advancement of milk feeds (30–35ml/kg/day) 
is safe and does not increase the incidence of 
NEC. 
Daily increment 10 to 30 ml/kg/day until reaching 
150ml/kg/day. Demand feeding when the infant 
reaches full enteral feeds 
Frequency of feeding One or two hourly feedings are common to 
commence. 
If tolerated and full enteral feeds reached, 
lengthened to 3 to 4 hourly feeding. 
Supplementation  Vitamins are commenced when the infant 
achieved full enteral feeds. Zinc, calcium and 
phosphorus. Iron usually started at 6 to 8 weeks 
postnatal age. 
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Although the early introduction of enteral feeds and faster advancement are an acceptable 
approach for enteral feeds (324, 325), feeding intolerance and NEC are still threatening 
factors that restrain enteral feeding. Preterm infants especially those born before 28 
weeks of gestation and lowest birthweight infants are at high risk for growth restriction 
during the neonatal period and hospital stay (303). Therefore, interventions, which might 
improve feeding tolerance for preterm infants are likely, improve their short and long-term 
health outcomes. For instance, in the1960s, before the establishment of NICU, the UK 
reduced deaths of preterm infants during hospitalisation after modifying the feeding 
practice for those infants (326). Therefore, optimising feeding practice and nutritional 
support for preterm infants have been emphasised as one of the UK research priorities for 
preterm infants (327).  
1.12 Response of gastrointestinal tract to enteral feeding 
During intrauterine life, the foetus is nourished from the mother through the placenta. After 
birth, with the interruption of the placental circulation, the newborn should adapt to the 
new nutritional mode through the GIT to obtain the nutrient necessary for the growth and 
development. Maturation of the GIT occurs during the last trimester of pregnancy (328); 
therefore, preterm infants have immature GIT with poor digestion and absorption. Various 
aspects of intestinal dysfunctions appear to be critical challenges causing feeding 
intolerance in preterm infants, such as intestinal dysmotility and delayed gastric emptying 
that may lead to stasis and overgrowth of pathogenic bacteria (158). Digestive functions, 
such as gastric acid and enzymes secretions are also impaired (158). 
Additionally, immature immunity and fragile mucosal barriers are thought to render 
preterm infants particularly susceptible to intestinal inflammation and injury; consequently, 
the GIT could not fulfil its functions. Therefore, during the neonatal period, feeding 
intolerance is commonly recorded in the preterm infant that reflects the anatomical and 
functional immaturity of the GIT. Nevertheless, in some cases, the signs of feeding 
intolerance, such as high gastric residuals, vomiting and abdominal distension, could not 
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be differentiated from NEC (82). Therefore, interruption of the feeding is needed that lead 
to the prolonged use of PN and delayed full enteral feeds with unfavourable effects on 
length of hospital stays, infant growth and other health outcomes.  
Suboptimal nutrition during this critical period of life might alter the structures and 
functions of organs and systems of the body, which is described as “nutritional 
programming”, (329) for example, the promotion of neurodevelopmental outcomes of 
preterm infants by human milk (285, 330). Early life nutrition has not only short-term 
impacts on growth and functional development of the body but also has long-term 
influences on neurodevelopment, morbidities and mortality in adulthood (331, 332).   
The GIT also has major endocrine and immune functions. Many growth factors and 
hormones, which regulate gastrointestinal growth and development in newborn infants, 
have been identified. Gut hormones such as gastrin, peptide tyrosine-tyrosine, pancreatic 
polypeptide, incretins and ghrelin, are peptides produced by the neuroendocrine cells of 
the gut and play a vital role in many gastrointestinal functions such as digestion (enzyme 
secretion), mucosal growth, blood flow and motility (328).  
Evidence suggested that blood levels of gut hormones were increased after trophic and 
enteral feeding in term and preterm infants (306) and feeding intolerance may lead to 
disturbance in gut hormones secretions increasing the risk of NEC (333). As described in 
section 1.11.2, human milk and colostrum are abundant in many growth factors, which 
have direct influences on the functions of GIT (234, 237, 238) and they might also exert 
an indirect trophic effect by increasing the secretion of certain gut hormones (334, 335). 
Gut hormone responses in preterm infants is further discussed in section 5.1.2.  
1.13 Oropharyngeal administration of colostrum (OPC) 
Given the potential benefits of colostrum, it is essential to consider the method for 
administering it in the first few days of life. In preterm infants, colostrum is commonly 
administrated by orogastric or nasogastric tubes, as trophic or enteral feeds, when the 
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infant’s clinical status permits. However, by this route colostrum will bypass the oral and 
pharyngeal cavities so that the oropharyngeal mucosa will not be exposed to the 
protective factors of colostrum. Consequently, pathological microorganisms may take the 
opportunity to colonise the mouth while the potential immunomodulation of the colostrum 
biofactors via contact with oropharyngeal mucosa are bypassed. Hence, a different 
approach for providing colostrum to preterm infants is required.  
Moreover, the oral mucosa is one of the main routes for entry of pathogens; thus, oral 
care appears to be essential in certain preterm infants particularly ventilated infants and ill 
infants who cannot receive oral feeds. Most of the current oral care marketed products are 
not approved for use in neonates. Therefore, normal saline or sterile water have been 
used for oral care in neonatal intensive care units (336). Regular use of normal saline 
alters the innate antimicrobial properties of the upper airway secretions increasing 
infection risk (337). Although sterile water appears to be more safe than saline, may not 
protect against infection. Colostrum is natural; probably safe product might protect these 
compromised infants against colonisation by pathological organisms and promote the 
growth of beneficial bacteria.  
1.13.1 Proposed mechanisms of OPC as a protective intervention 
As described in Section 1.11, there are similarities between the constituents of colostrum 
and the amniotic fluid (277, 338). Fetal intestinal growth occurs mainly during the last 
trimester, promoted by fetal swallowing of amniotic fluid which is loaded with antibodies, 
cytokines and growth factors (158). Interruption of the continuous influx of amniotic fluid to 
the intestinal lumen by preterm birth may have a negative impact on the healthy growth 
and development of the GIT (158, 278). Coating the oropharynx with a small volume of 
colostrum could continue the effects of the amniotic fluid in utero. Rodriguez et al. (339) 
have suggested that cytokines in colostrum may stimulate the oropharyngeal associated 
lymphoid tissues (OFALT) and gut-associated lymphoid tissues (GALT) to modulate the 
immune system of ELBW infants (339). OFALT and GALT are well-known components of 
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the Mucosal-associated lymphoid tissues (MALT) (340), which represents an 
immunological system that function independently from the systemic lymphoid tissues. 
MALT function as the principal mucosal location where immune responses are initiated 
and activated lymphocytes can then reach more effector sites (341). MALT contains 
approximately 40% to 60% of lymphocytes of the body. MALT comprised of anatomically 
distinguished lymphoid tissues including; GALT such as the Peyer patches, the appendix 
and isolated follicles in the intestine, the bronchial associated lymphoid tissues (BLAT) 
and the OFALT(Waldeyer’s ring) at the entrance of the respiratory and GIT (342).  
OFALT, the lymphatic tissue of the oropharyngeal cavity, includes adenoids (pharyngeal 
tonsil), tubal tonsils, Tonsils (palatine tonsil) and the lingual nodules (lingual tonsil) 
interspersed with microscopic lymphoid tissues throughout the oropharyngeal mucosa to 
make the Waldeyer’s ring (Figure1.3). The Waldeyer’s ring acts as a promising frontline of 
defence against the entry of microorganisms (343). The OFALT lymphocytes and 
monocytes have more direct contact with cytokines found in breast milk or pharmaceutical 
compounds compared to GALT where peristalsis and the mucus may intervene between 
the lymphocytes and the immune factors (344). Furthermore, OFALT has almost a neutral 
pH and minimum peptidases that diminishes proteolysis of cytokines; however, the 
cyclical swallowing of saliva may reduce contact time with OFALT. Cytokines 
administrated by the oropharyngeal route, activate the OFALT immune cells leading to 
secretion of cytokines that in turn activate other cells. Additionally, some of the activated 
cells from the OFALT migrate through the lymphatic ducts to reach local lymph nodes of 
the neck and enter the bloodstream to be disseminated to distant sites such as other 
lymphoid tissues, lung, liver and bone marrows (344) (Figure 1.3). 
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Figure 1.3 Delivery of cytokines by the oropharyngeal route 
A schematic diagram presents activation of the immune system by oropharyngeal 
administration of cytokines. PhT: pharyngeal tonsil; TuT: tubal tonsil; PalT: Platine tonsil; 
LT: lingual tonsil; LN: lymph node; OFALT: oropharyngeal-associated lymphoid tissues; 
GALT: gut-associated lymphoid tissues; BALT: bronchial-associated lymphoid tissues.  
Diagrams adapted from Bocci 1991 (344).  
 
The potential interaction of drugs or milk cytokines had been arising long time ago by 
Bocci (344) after reporting of a positive effect of low dose of interferon-α in HIV positive 
patients in 1987 (345). The administration of cytokines like interferon by the oromucosal 
route and its benefits have been reported in experimental animal and human research. 
Oromucosal administration of low dose Interferon-α/β has been provided to humans in 
different clinical situations including influenza outbreaks, acquired immune deficiencies, 
and chronic hepatitis (346-348). Currently, the Oromucosal route is increasingly 
considered as a desirable route for vaccination due to its potential ability to induce local 
and systemic immune responses (349, 350). Therefore, OPC was proposed as an 
immune modulator for preterm infants.  
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It was hypothesised that administration of colostrum by the oropharyngeal route allows the 
bioactive components of colostrum to modulate the immune system and protect against 
infection by the following potential mechanisms (351-353):  
- inhibition of the attachment of microorganisms to the oropharyngeal mucosa by 
colostrum factors such as IgA, lactoferrin and oligosaccharides  
- absorption of bioactive components of colostrum by the oropharyngeal mucosa 
into the circulation 
- interaction and stimulation of the MALT by colostrum cytokines 
- prebiotic effect of colostrum factor such as oligosaccharides 
- anti-inflammatory effects of colostrum cytokines, PUFA and other factors 
- antioxidant effects of the various component of the mother’s colostrum such as 
lactoferrin, peroxidase and catalase. 
Administration of colostrum by the oropharyngeal route does not involve swallowing by the 
infant but allows colostrum instilled in the oral cavity to act locally and be absorbed by the 
buccal mucosa to modulate the infant’s immune system. Different terms have been used 
to describe the procedure like oral swabbing, colostrum oral care, buccal care, 
oropharyngeal colostrum, oral priming or swabbing, oral immune therapy and oromucosal 
but the principal hypothesis is identical.  
Recently emerging evidence has suggested the potential benefits of OPC on health 
outcomes for preterm infants (354-358). Research studies to date contain some significant 
drawbacks that limit generalisability, such as small sample sizes, inconsistent methods of 
application and the data are from retrospective or pilot studies. However, there are some 
studies with relevant results; in a retrospective study conducted after OPC was included in 
the care of preterm infants in the neonatal unit (353). A sample of 369 ELBW infants was 
evaluated for clinical outcomes before and after introducing OPC practice. The colostrum 
group commenced enteral feeding earlier than the pre-colostrum group and weighed more 
at 36 weeks. The authors speculated that exposure of the infants to growth factors in 
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colostrum might have promoted growth and function of the GIT, but there were no 
differences in day to full enteral feeds, the incidence of NEC and mortality between the 
two groups. However, this study included only ELBW infants, limited to gastrointestinal 
complications and potential confounders were not considered. Another observational 
study reported a trend towards reduction of positive tracheal aspirate and blood cultures 
after the implementation of colostrum for oral care in ventilated preterm infants (355). 
Lee et al. (356), in a RCT, reported an increase in urinary (SIgA, lactoferrin and IL-1β) and 
salivary (TGF-β and IL-8) immune factors within two weeks and a decline in the incidence 
of clinical sepsis with OPC versus sterile water. They suggested that OPC use in EXP 
infants (< 28 weeks of gestation) may have the potential to enhance the immune system 
of the sick preterm and prevent infection and mucosal inflammations; however, it was a 
very small RCT included only 48 infants. In 2016, another RCT (358) demonstrated that 
OPC was associated with a shorter hospital stay and a higher rate of breast milk feedings 
at discharge home with no significant difference in salivary immune peptides.   
1.13.2 Procedure for OPC administration 
OPC involves placing a small amount (0.2-0.5ml) of preferably freshly expressed 
colostrum over the buccal mucosa by syringing and gentle swabbing. Alternatively, a 
swab, soaked in colostrum can be used to coat the oral mucosa with colostrum. Previous 
studies have followed the procedure for OPC, which initially described by Rodriguez et al. 
(354). The procedure comprises placing the tip of a syringe filled with 0.2 ml of colostrum 
along the right side of the infant’s mouth and slowly delivering 0.1 ml of colostrum into the 
infant’s mouth directing posteriorly towards the oropharynx. While the syringe inside the 
infant’s mouth redirected to the left side, another 0.1 ml is delivered guided in the same 
manner (Figure 1.4), the oral mucosa then swabbed gently for a few seconds. OPC 
administration was started within the first 48 hours after birth and provided two hourly for 
48 hours (354).  
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In 2015, the protocol for OPC was updated that OPC to be started within the first 96 hours 
of life and administered two hourly for 48 hours followed by three hourly administration for 
a more extended period depending on the infant’s gestational age (359). Neonatal units 
(360-363) increasingly use OPC in the care of preterm, and ill neonates. However, there is 
no standard protocol for OPC administration and different methods have been used 
regarding the frequency, the volume of colostrum (fresh or frozen) per dose, duration of 
treatment, and the technique (syringe or swab) (356-358).  
 
Figure 1.4  Administration of colostrum by the oropharyngeal route 
Source: A: Lee et al. (356); B: Page et al (364).  
1.14 Rationale of the thesis  
 Although there have been massive advances in neonatal medicine and improvements in 
survival rates; preterm infants still carry a considerable burden of short and long-term 
morbidities including a high risk of invasive infections, and NEC (133, 134). Both of these 
conditions are particularly important because of their high prevalence and association with 
other long-term morbidities such as poor growth and adverse neurodevelopmental 
outcome (139, 365). They are also associated with prolonged hospital stays and 
significant rises in the cost of care, to hospitals, families and societies (47, 68) that 
rationalises more research into preventive measures and potentially cost-effective aimed 
at reducing the incidence of infection and NEC. The WHO reported that approximately 
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75% of prematurity-related complications could be overcome with cost-effective 
interventions, such as Kangaroo mother care for thermal care and support for 
breastfeeding and maternal antenatal steroids therapy in the preventions of respiratory 
distress syndrome (69).  
Premature infants have immature immune responses. Mother’s own colostrum contains 
many immunological and trophic factors that promote immunological and gastrointestinal 
maturity (185, 186). Many of these factors are present in higher concentration in colostrum 
than mature milk (264). Moreover, studies postulated that colostrum from mothers who 
delivered preterm infants has higher levels of immunological factors than colostrum from 
mothers with term infants (192, 201). Therefore, mother’s colostrum could be an 
appropriate immune therapy for infection control and improving outcomes for the preterm 
infants.  
OPC use in the first few days of life might stimulate the infant’s immune system and 
protect from infections and other conditions such as NEC (339), and improve the rate of 
breastfeeding (366). There are limited studies that addressed the effects of early OPC on 
health outcomes of preterm infants. Previous studies mostly included VLBW, ELBW 
or/and EXP infants (353). This thesis considered all preterm categories including 
moderate and late-preterm infants, who contribute to approximately 72% to 85% of 
preterm births (19, 62) and have a higher risk compared to full-term infants especially in 
long-term developmental outcomes (367, 368). To the best of my knowledge, no previous 
study has evaluated OPC in the UK, although, some neonatal units have adopted OPC in 
the care of preterm infants (360, 362, 369).  
OPC is a simple, easy and low-cost procedure, can be performed by nurses, doctors, 
caregiver, and parents. It does not require high technology equipment and no significant 
additional resources will be needed to implement OPC administration, which, if its efficacy 
and safety proved, could be adopted rapidly across neonatal services at a low cost that 
could be used in low and moderate-income sittings. OPC practice may also encourage the 
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parents of preterm infants to have an active role in the care of their infants, which may 
have a positive effect on the feeling of helplessness experienced by the parents.  
Based on incidents occurring during early life, especially during the critical period of brain 
growth, may permanently influence health and wellbeing of later stages of life (331, 332, 
370); early action and preventive strategies are essential to impact on the burdens of 
diseases (68, 371). The WHO reported in 2014 that worldwide there were disappointing 
reductions in neonatal mortalities, and prematurity-related complications are the leading 
cause of neonatal deaths (71). WHO also highlighted that caring for preterm, LBW and 
sick newborn infants are crucial for reducing deaths, disability, and long-term 
complications, and considered neonatal deaths as a sensitive marker for effective health 
system (71). The ongoing challenges of preterm births emphasise the need for better 
understanding of this preventive intervention and its effects.  
1.15 Generic view of the thesis  
As described in this chapter, the broad benefits of mother’s milk are well known and the 
unique composition of mother’s colostrum indicates that its primary functions are 
protective and trophic. I am particularly interested in the protective benefits of colostrum 
and the potential impacts of providing mother’s colostrum during the early life on health 
outcomes of preterm infants.  
This thesis was conducted according to the University of Nottingham (UoN) Code of 
Research Conduct and Research Ethics (372) and the UK policy framework for health and 
social care research (373). All the studies included in this thesis were conducted at the 
UoN at the Division of Child Health, Obstetrics & Gynaecology (COG) and ethically 
approved by the Medical School Ethics Committee at the UoN. Where the study involves 
National Health Services (NHS), ethical approval was granted from the UK Research 
Ethics Service (RES). Human tissue samples were dealt with under the Human Tissue Act 
2004  (374).  Ethical considerations for each study will be described in the individual 
chapter.  
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1.16 Hypothesis and aims 
1.16.1 Hypothesis  
Based on the protective properties of mother colostrum as potential immunotherapy, I 
hypothesised the following:  
- oropharyngeal administration is a useful route to deliver colostrum to preterm and 
sick infants. This route allows the bioactive components of colostrum to contact 
directly with the oropharyngeal lymphoid tissues to stimulate the infant’s immune 
system 
- OPC protects against infection and NEC, promotes infant growth and improves 
health outcomes of preterm infants 
- OPC could be implemented efficiently in neonatal practice.  
1.16.2 Aims of the thesis 
The aims of this PhD research were as follows: 
- to explore the current practice of OPC in the care of preterm infants in the UK 
- to collate the evidence regarding oropharyngeal administration of mother’s own 
colostrum in preventing mortality and morbidities of preterm infants 
- to evaluate the feasibility of providing colostrum by the oropharyngeal route to 
preterm infants in the UK 
- to assess the effects of OPC on the health outcomes of preterm infants.  
The subsequent studies were designed to achieve these aims as follows:   
Chapter 2:  Oropharyngeal administration of mother’s own colostrum to  
preterm infants: a survey of practice 
Some neonatal units adopted the practice of OPC administration as a part of the standard 
care for preterm infants as a potential preventive measure to reduce complications and 
improve growth and outcomes of the infants. This chapter describes the current use of 
OPC in the UK neonatal units by surveying neonatal professionals in the UK regarding 
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OPC administration in the care of preterm infants. Such surveys may provide reference 
standards and help health professionals to evaluate their practices.  Surveys also can 
highlight gaps in health practices; therefore, may guide further research.  
Chapter 3: Oropharyngeal colostrum in preventing mortality and morbidity in 
preterm infants: a Cochrane systematic review 
Based on the findings of a survey of the UK neonatal professionals (Chapter 2), OPC is 
increasingly adopted by the UK neonatal units and has been recommended by some 
neonatal professionals. To bridge the gap, I systematically reviewed currently available 
evidence on the use of OPC in the care of preterm infants. This chapter presents the 
results of a Cochrane systematic review and meta-analysis assessed RCTs investigating 
the effects of using OPC on health outcomes of preterm infants.   
Chapter 4: The impact of oropharyngeal administration of mother’s colostrum on 
the clinical outcomes of preterm infants: a case-control study 
A matched case-controlled study was conducted to evaluate the effects of OPC on short-
term health outcomes of preterm infants, in Nottingham neonatal units after the 
implementation of OPC for the care of preterm infants. Cases were preterm infants born 
before 32 weeks of gestation and received OPC during the early neonatal period. Controls 
were matched for; infant's sex, gestational age and the closet birth weight, and selected 
from those infants who were admitted to Nottingham neonatal units before the adoption of 
OPC administration. 
Chapter 5: Gut hormone responses to oropharyngeal administration of mother’s 
colostrum to infants in neonatal intensive care 
This study was conducted to investigate the response of a set of gut hormones to OPC in 
preterm and sick infants requiring neonatal intensive care.  Plasma samples from 
participant infants were analysed using Multiplex magnetic-beads immunoassay. This 
study was an observational, non-randomised comparison; compared infants who received 
mother’s colostrum by the oropharyngeal route (OPC group) during the early neonatal 
period with those infants who did not receive OPC (No-OPC group).  
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Chapter 6 Conclusion  
This chapter will summarise the key findings and consider the strengths and limitations of 
this PhD project. The implications for clinical practice and future research will be 
highlighted.  
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Chapter 2. Oropharyngeal administration of mother’s 
own colostrum to preterm infants: a survey of practice 
 
2.1 Chapter overview 
This chapter aimed to explore the current practice of oropharyngeal administration of 
colostrum (OPC) in the UK. Neonatal professionals make a good target population for 
gathering information about the care of newborn babies (375). It is within this context that 
the current study was designed as a survey to evaluate the practice of OPC and assess 
the knowledge, attitudes of the UK neonatal professionals towards the use of OPC in the 
care of preterm infants.  
2.2 Background  
OPC is a new additional route introduced to deliver colostrum to preterm infants and those 
who are critically ill and cannot tolerate enteral feeds during the early neonatal period.  
More details about OPC administration are described in Section 1.14.  The use of OPC is 
progressively increasing among neonatal units in different countries; some neonatal units 
have introduced the use of colostrum for oral care, and OPC (360, 361, 376, 377) with the 
aim of promoting infant’s immune function and protecting against infection and necrotising 
enterocolitis (NEC) (351, 352). However, neonatal units vary in their guidelines and 
strategies for using OPC. 
2.2.1 Surveys in research  
Surveys are commonly used in epidemiological studies, for service evaluations in health 
and to provide information for policy-makers (378, 379); they can also evaluate the 
attitude and beliefs of health care providers and may identify the knowledge gap (380).  
Surveys are a valuable tool for collecting information from a target population regarding 
their knowledge, perceptions, practices and expectations of a specific topic for research. 
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In surveys, a sample is selected to be representative of the population of interest to collect 
data for a particular study. Surveys can be conducted in multiple modes as, face-to-face 
interviews, via post, telephone or as an internet-based survey and they are classified into 
interviewer-completed and self-completed surveys (381, 382). Face-to-face and mail 
questionnaires have been the most widely used format in survey-based research (383, 
384).  
Each method of conducting a survey has advantages and limitations; the study topic, the 
targeted participants and the aims of collected information could guide the selection of the 
best method (382). For example, face-to-face interview surveys are flexible and might 
increase cooperation and response rates. However, this type of survey might be limited by 
interviewer bias, sample size and coverage of the target population and may induce 
anxiety, especially with sensitive questions (384). Additionally, they are less cost-effective 
and more time-consuming than postal and online surveys (385). Self-completed surveys 
are independently completed by the respondents; have the advantages of ease, less cost, 
quicker and wider distribution. Generally, surveys may contain questions which are 
considered unnecessary or misunderstood by the participants; therefore, the questions 
might be ignored by the respondents.  
Recently with the extensive use of the internet, there has been an expansion for the use 
of an online web-based survey especially in large sample research (386-389). Online 
surveys have the advantages of lower cost, faster distribute, more accessible to a specific 
and large population across a large geographic area (nationally and internationally) (390). 
Respondents could also complete the questionnaire at times convenient for them, as well 
as divide their responses over multiple sessions (391). Performing surveys by online self-
completion reduce the risk of reporting bias by decreasing the possibility of researchers’ 
influencing on the responses (384).  
However, online surveys may have lower response rates in comparison to paper 
questionnaires and interviews (392, 393). Through, the low cost and ease of sending 
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emails, online surveys offer the researchers a promising way to follow up non-
respondents by sending reminder emails (394). Criticisms of online surveys that are such 
emails could be perceived as junk mails and that they may also be influenced by 
technological variabilities such as the use of networks connections, browsers and 
computers’ configurations (391, 392).  
As this study was a survey of a clinical practice across the UK, an online web-based 
survey was chosen to achieve efficient distribution and response (381). Firstly, our 
targeted participants were neonatal professionals could be reached by emails (395). 
Secondly, this method offered the benefits of saving time, being cost-efficiency, 
practicality and that the responders directly completed their responses into the software, 
facilitating later data analysis. Furthermore, directing the responders to questions 
according to the previous answer given by the participant decreased the load of non- 
applicable questions presented to the respondents. The online survey also enabled the 
use of compulsory questions helping to reduce the risk of missing data and neonatal 
professionals could complete the online survey when it was convenient for them and 
across multiple sessions.  
2.2.2 Rationale of the study 
OPC administration is increasingly adopted by the UK neonatal units (360, 362, 369, 396, 
397) though it is not yet known whether using OPC in the care of preterm infants, will 
improve health outcomes and promote the growth of these vulnerable infants. A few 
studies have been conducted to assess this question with variable results.  
Considering the uncertainty about OPC use, and to the best of my knowledge following a 
comprehensive literature search, there are no published studies that focus on the practice 
of OPC in the UK.  A survey of neonatal professionals provides an initial step to assess 
OPC use in UK neonatal units. The results may provide important information to health 
services and decision makers and a step toward obtaining the required evidence for 
ongoing practices, informing future practices and providing a base for future research. 
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2.2.3 Hypothesis and aims  
The hypothesis was that most of the neonatal units in the UK did not use OPC for the care 
of preterm infants. I also hypothesised that those who are practising OPC in their units did 
not have a standard policy. 
This survey aimed to:  
- ascertain the use of OPC in UK neonatal units 
- determine the current practice of OPC such as patient characteristics and 
indications 
-  determine the variation in OPC administration 
- describe the knowledge and attitude of neonatal professionals in the UK regarding 
the use of OPC. 
2.3 Methods 
The study was approved by the Medical School Ethics Committee at the University of 
Nottingham: R16042015 SoM CHOG (Appendix1). 
2.3.1 Study design 
It was a prospective, cross-sectional study consisting of an online internet-based survey. 
A web-based structured questionnaire was designed and conducted using the Bristol 
online survey (BOS) software (www.survey.bris.ac.uk). Bristol online survey (currently 
Online surveys: www.onlinesurveys.ac.uk) is a useful tool designed for academic 
research, education and public sector organisations for creating online surveys of 
unlimited numbers for unlimited respondents. BOS is managed by the Joint Information 
Systems Committee (Jisc) (398), which is an organisation providing digital services for UK 
education and research. BOS is a practical, easy to use tool, entirely compliant with UK 
data protection and meets UK accessibility requirements. It was thought to meet the 
needs of this study; furthermore, the University of Nottingham offers free access to BOS 
to postgraduate research students within the university.  
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The questionnaire was designed to allow the potential respondents to complete the 
questionnaire online; therefore, a web-based design was chosen instead of an email-
survey (a questionnaire attached to an email).  
2.3.2 The questionnaire  
There was no previous survey focused on OPC administration; therefore, the 
questionnaire was developed based on a previous similar survey study that aimed to 
determine the practice of heated humidified high-flow nasal cannula oxygen in UK 
neonatal units (399). The previous survey was also a web-based survey, and it has been 
successful in collating data on clinical practice and perceptions from neonatal 
professionals. 
The survey was comprised of four sections (Appendix 2): 
- Section One; this section provided the participants with a summary of OPC 
administration and the objective of the study. It explained the nature of 
participation and that confidentiality would be maintained. The participants were 
directed to the next relevant question or section according to a designed route. 
Routing allows respondents to be directed through an online survey based on their 
answers. Routing can also help to branch the survey into sections that designed to 
specified groups of participants.  
- Section Two; completed by OPC users answering questions exploring the practice 
of OPC.  
- Section Three; was completed by those participants who were not using OPC.   
- Section Four; professionals’ information section, included questions such as job 
description and work experience. 
The questions were mainly closed-ended questions in a multiple choice format or single 
answers; this form of questioning facilitates completion of the survey and reduce variability 
between the respondents enhancing comparisons (400). Though, closed-ended questions 
may miss options that would be limited to the respondents; to minimise this possibility, a 
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response option of ‘Other’ was included.  Additionally, some questions were open-ended 
that allows the participants to comment on what they wanted in response to the question 
that had not been asked, or wanted to make it known. This type of question may prevent 
any potential understanding issues (400). However, open-ended questions are likely to 
take a longer time, particularly with such clinical professionals; therefore, they may lower 
the response rate. Furthermore, the unstructured format may introduce variability in 
coding the answers, that could affect the validity of the study (400).   
To ensure the effectiveness of the survey and to estimate how long it took to complete, 
colleagues (including; consultant neonatologist, research fellow, paediatrician, dietician 
and PhD students) in the Division of Child Heath, Obstetrics & Gynaecology (COG), at the 
UoN, piloted the questionnaire. Comments from this piloting process were used to revise 
the survey tool further. The adjusted questionnaire was then submitted to the ethical 
committee for approval. The approved questionnaire was sent to the neonatal 
professionals within the UK.  
2.3.3 Participants 
The targeted population was neonatal professionals from neonatal units in the UK, 
regardless of the level of the neonatal unit. Doctors and nurses were included in the study. 
The participants were identified via the British Association of Perinatal Medicine (BAPM) 
(401). BAPM is a non-governmental, professional association. It was founded in 1976 with 
the aim to improve and optimise the standard of perinatal care within the UK by providing 
support and advocacy for perinatal professionals, and babies and their families (402). 
BAPM also manages the UK neonatal networks web page, as well, it promotes and 
supports research and innovation in perinatal and neonatal medicine (402).  
Neonatal networks are clinically managed Operational Delivery Networks (ODNs) for 
neonatal services within the UK.  Neonatal networks were established in 2004 to provide 
neonatal care by clinically managed networks with the aim to reduce perinatal mortality 
and improve the quality of care (403). ODNs enable communication, share knowledge and 
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collaboration between neonatal units. Each network consists of a group of neonatal units 
according to the geographical area covered.    
The BAPM classifies neonatal units into three categories according to the level of care 
they provide (404).  
- Neonatal Intensive Care Units (NICUs), provide care for ill and unstable babies 
who need mechanical respiratory support (mechanical ventilation, continuous 
positive airway pressure (CPAP), low birth weight, preterm < 28 weeks of 
gestation, surgical care and any additional support such as central line insertion, 
and exchange transfusion. NICUs also provide high dependency and special care. 
- Local Neonatal Units (LNU), provide high dependency and special care for babies 
who need CPAP, parenteral nutrition, tube feeding and babies needing short-term 
intensive care (e.g. following apnoeic episodes). 
- Special Care Units (SCU), provide care for babies who require respiratory and 
cardiac monitoring, oxygen therapy, phototherapy, tube feeding and babies 
recovering from other levels of care. 
Neonatal networks in the UK were identified from a list available at the BAPM website that 
accessed April 2015 (www.bapm.org/neonatal-networks). The contact details of the 
neonatal network staff were ascertained from a list on the website of BAPM that provided 
an avenue to approach the potential study participants.  
2.3.4 The survey process  
Invitation emails explaining the purpose of the study were sent to the neonatal network 
staff (lead doctor, lead nurse, administrator or manager) to provide the contact details of 
the lead doctors and lead nurses of their corresponding neonatal units (Appendix 3). The 
invitation emails were followed by two reminder emails to those networks who did not 
provide contact details of their units.  
A list was prepared including lead doctors and nurses of neonatal units whose contact 
details have been provided by their neonatal network staff.  
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Emails with the survey link were sent to the lead doctor and nurse of each neonatal unit 
(Appendix 4). To improve the response rate, following the initial email launching the 
survey, three reminder emails (Appendix 4) were sent to potential participants at two-week 
intervals. Reminder emails can increase a survey response rate by about 33% (405). 
Telephone follow up was planned to approach those who did not respond to these 
approaches by completing the survey. However, trials of the phone calls were conducted, 
and it was found not feasible. To find those units who did not respond, the respondent 
units, which were identified through BOS software, were compared to the list of the 
neonatal units that have been identified via BAPM website (401). Phone numbers were 
found from the hospital website of each nonresponding unit. Those who responded to the 
telephone call (only 3 neonatal units) preferred the survey link resent rather than to 
complete it over the phone. The survey was launched on May 18th, 2015 and closed on 
October 30th, 2015. 
2.3.5 Data management  
- Participants completed their responses directly into the BOS software. The data 
were exported as anonymous Microsoft Excel and SPSS files for analysis. 
- The Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA) version 
22 for Windows was used for the analysis. 
Descriptive statistics (frequencies and percentage) were used to analyse the responses of 
the survey. 
2.3.5.1 Ethical consideration 
2.3.5.2 Consent 
Participation in the survey was voluntary, and consents were not obtained. Completion of 
the online survey was taken as implied consent.  No payments or incentives were offered 
to the participants. 
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2.3.5.3 Safety considerations  
This survey did not include patients nor families. It included neonatal health professionals, 
was estimated to take the participants a maximum of approximately ten minutes to 
complete. 
2.3.5.4 Confidentiality  
The questionnaire was identified by the neonatal unit and not by individual respondents 
except for those who had provided their emails in response to an optional question (Q 
27.a “If you would like to join study research to assess buccal colostrum administration, 
please could you provide your contact details, if possible”).  Responses were not identified 
by individual and compiled together, and analysed as a group, this has been highlighted in 
the first section of the questionnaire.  
2.3.5.5 Data protection 
The survey administrator collected the data, which were stored by the research team 
securely in the Division of COG at the UoN during the data collection period, or their 
nominated replacement, for seven years or longer if needed. The anonymised electronic 
data were saved on a password-protected computer, provided by the UoN. Any personal 
data was dealt with according to the UK new General Data Protection Regulation (406) 
and Data Protection Act 2018 (407). 
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2.4 Results  
Almost all of the contacted neonatal networks had responded by providing the contact 
details of the lead doctors and nurses of their corresponding neonatal units. Of the 21 
neonatal networks who were contacted, 12/21 (57.1%) networks responded to the 
invitation email. Six networks (6/21 (28.5%)) responded to the first reminder email. Two 
networks (2/21 (9.5%)) responded to a second reminder email while one network did not 
provide the contact details of the lead doctors and nurses and requested that they send 
the survey link to their local units on my behalf. Figure 2.1 demonstrates the survey 
process. 
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Figure 2.1  The study flow chart 
Selection of included questionnaires in the final analysis 
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2.4.1 Survey response and sample characteristics  
A total of 267 neonatal professionals working in the UK neonatal units were sent the 
survey link.  Responses were received from 166/267 (62%) of the neonatal professionals 
who were surveyed (doctors: 80/166 (48%); nurses: 86/166 (52%), and 52% of them have 
been working in neonatal care for more than 20 years (Figure 2.2). It was not possible to 
precisely assess how many potential respondents viewed the survey link and did not 
complete the questionnaire.  
 
Figure 2.2  Respondents' length of work in neonatal care 
Response to the survey question: “Please state approximately how many years you have 
been working in neonatal care?”. Bar: percentage of responding units 
There were 41 duplicate responses (two responses from the same unit, one from the 
nurse and one from the doctor). Considering the duplicates; 166 responses represented 
125 neonatal units which accounted for 60% of 206 neonatal units in the UK according to 
data from the BAPM website, April 2015. Responses were received from almost all 
neonatal networks within the UK with variable rates (Table 2.1). Designation levels of the 
responding units compared to the UK neonatal units are presented in Table 2.2. 
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Table 2.1  Distribution of respondents units by neonatal network 
Neonatal network (BAPM, 2015) 
Responding units  
(n = 125) 
Network units  
(n = 206) 
Percentage 
(%) 
Central* 6 8 75 
Trent* 4 6 67 
East of England 11 17 65 
London: North Central & East 7 12 58 
London: North West London 3 7 43 
London: South 7 10 70 
Cheshire & Merseyside ≠ 5 9 56 
Greater Manchester ≠ 7 8 88 
Lancashire & South Cumbria ≠ 3 5 60 
South East Coast 6 13 46 
South West 10 12 83 
Southern West Midlands 6 10 60 
Staffordshire, Shropshire, & Black County 5 7 71 
Thames Valley & Wessex 11 16 69 
Yorkshire & Humber 12 19 63 
Wales 5 13 38 
North of Scotland 0 3 0 
South East Scotland & Tayside 3 6 50 
West of Scotland 5 8 63 
Northern 6 11 55 
Northern Ireland 2 7 29 
BAPM: British Association of Perinatal Medicine; *East Midlands Neonatal operational delivery 
network (ODN); ≠ North West Neonatal ODN 
 
Table 2.2  Level of respondent units versus UK neonatal units  
Unit level 
UK NUs* 
(n = 206) 
Respondent units 
(n = 125) 
Percentage 
(%) 
Neonatal Intensive Care Unit 61 51 84 
Local Neonatal Unit 88 57 65 
Special Care Unit 57 17 30 
NU: neonatal unit; *: data according to British association of Perinatal medicine, 2015); n: 
number  
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Duplicate responses from the same unit were further reviewed to determine consistency 
among the respondents. There was a perfect agreement between duplicate responses 
received from the same unit (Cohen’s Kappa coefficient ranged from 0.71 to 1). 
Discrepancies were found only in two questions namely, “Do you have written guidelines 
on the use of oropharyngeal colostrum?” and “Do you document oropharyngeal colostrum 
on the infant's record charts?” (Section 2.4.3.4).  
Exclusion of one response from each duplicate was done randomly by the statistical 
software (SPSS). The data analyses that follow were carried out on a sample of 125 units 
except for questions considering individual perceptions that the analysis was conducted 
using the total responses (166 responses) as a dominator, Figure 2.1.   
2.4.2 Use of colostrum in the UK neonatal units 
According to responding neonatal unit lead doctors and nurses, almost all neonatal units 
used colostrum 120/125 (96%) when have been asked, “Do you administer colostrum to 
preterm infants in your unit?” 
Colostrum was administered to preterm infants by different routes. With the multiple 
options available for answering this question, many respondents gave more than one 
answer that reflecting the use of several routes by neonatal units (nasogastric tube (NGT): 
116/349 (33%); orogastric tube (OGT): 100/349 (29%); in the mouth: 96/349 (28%); bottle: 
37/349 (10%) responding units. 
Human colostrum was the only type of colostrum used in the UK neonatal units and the 
mother’s own milk was the most used type of milk (Figure 2.3). 
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Figure 2.3  Type of Colostrum used 
Response to the survey question: “Which type of colostrum do you use?”   
Bar: percentage of responding units 
 
2.4.3 OPC administration in the UK neonatal units 
2.4.3.1 Use of OPC by the neonatal units 
Of the responding units that use colostrum 86/120 (71%) administer OPC to preterm 
infants. This accounts to 40% of the UK neonatal units. Out of the 86 units that use OPC; 
31/86 (36%) were NICU, 42/86 (49%) LNU and 13/86 (15%) SCU. OPC use has been 
introduced for more than four years by approximately one third of responding units (Figure 
2.4). 
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Figure 2.4  Duration of OPC use by the neonatal units 
Responses to the survey question: “How long has it been since OPC administration was 
introduced in your unit?”  
Bar: percentage of responding units; OPC: oropharyngeal colostrum; m: month 
 
2.4.3.2 Patients characteristics and OPC administration  
Data about the use of OPC in preterm infants was analysed using the number of the units 
using OPC (86 units) as a dominator.  
2.4.3.2.1 Infant’s gestational age 
OPC was administered to preterm infants at different gestational ages, and many 
respondents gave more than one answer, which is probably because some units use 
more than one gestational age group. Approximately 50 % of the respondent units use 
OPC at any gestational age of the infants (Table 2.3). ‘Other’ criteria were answered by 
only five units (4%), and free texts were:  
- “It depends on the condition of the baby.”  
- “No specific policy but generally they are above 27 weeks.” 
- “No specific guideline but try to administer colostrum oropharyngeally to all under 28 
weeks or otherwise 'high risk for NEC' infants, e.g. <1000g, Absent /Reversed EDF.” 
- “31 weeks onwards.”  
- “Term babies.” 
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Table 2.3  Infant’s gestational age for OPC administration 
“Based on gestation in which group of preterm infants do you use oropharyngeal 
colostrum?” 
Gestational age 
      (GA) 
Responses  
(n=124) 
Respondent units using 
OPC (n = 86) (%) 
< 28 weeks 14 11 
28- <32 weeks 24 19 
32-<37 weeks 21 17 
Any GA 60 49 
Other 5 4 
n= number of responses; OPC: oropharyngeal colostrum; Any GA: all gestational age  
 
2.4.3.2.2 Infant’s birth weight   
Most of the responded neonatal units administered at any birth weight range (Table 2.4). 
Multiple answers reflect units who use several birth weight ranges for OPC administration. 
Table 2.4  Infant’s birth weight for OPC administration 
Responses to the survey question: “Based on birth weight, for which range do you use 
oropharyngeal colostrum?” 
Birth weight  
        (g) 
 Responses  
(n= 114) 
Respondent units using OPC 
(n = 86) (%) 
< 1000 10 9 
1000-1500 13 11 
1500-2000 10 9 
2000-2500 g 7 6 
Any weight 74 65 
n= number of responses; OPC: oropharyngeal colostrum 
2.4.3.2.3 Infant’s postnatal age  
Administration of OPC to preterm infants was commenced regardless of the infant’s 
postnatal age by about half of the respondent units. Once more, the multiple answers 
were probably reflecting units who administer OPC in several postnatal ages (Table 2.5). 
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Table 2.5  Infant’s postnatal age for OPC administration 
Responses to the survey question: “At what age of the baby do you commence 
administration of oropharyngeal colostrum?”  
Age of infant 
(hours since birth) 
Responses  
(n=119) 
Respondent units using OPC 
(n = 86) (%) 
Within 24 hours 37 31 
24 to 48 hours 19 16 
48 to 72 hours 4 4 
72 to 96 hours 3 2 
Any postnatal age 56 47 
n= number; OPC: oropharyngeal colostrum 
 
2.4.3.2.4 Infant’s clinical status to give OPC 
OPC administration had been used whatever the infant’s clinical status by 32/86 (37%) of 
the respondent units (Figure 2.5). ‘Other’ reasons for OPC not being given were reported 
by 12/86 (14%) units, and free texts were:  
- “No colostrum available (mother or donor)”. 
- “Maternal HIV”. 
- “Known Upper GIT- anatomical anomalies”. 
- “No guidelines/policy, it was personal practice”. 
- “NEC or surgical interventions”. 
- “Critically ill infants”.  
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Figure 2.5  Infant’s clinical status to give OPC 
Response to the survey question; “In which situation would oropharyngeal colostrum not 
be given?” Bar: percentage of responses; OPC: oropharyngeal colostrum; inotropes: 
intravenous infusion of inotropes; IC: intensive care; MV: mechanical ventilation; any 
clinical status: regardless of infant’s clinical condition. 
 
2.4.3.2.5 Infant’s feeding regimen and milk type 
Participants were asked about giving OPC with other feeding regimens, OPC 
administration had been used with variable feeding regimens i.e. trophic feeds (<1ml/kg/hr 
of milk): 24/86 (28%) units; enteral feeding (>1ml/Kg/hr of milk): 20/86 (23%); parenteral 
nutrition: 19/86 (22%); nil per oral stat: 12/86 (14%); nil via OGT/NGT: 11/86 (13%).  
OPC had been given to preterm infants receiving different types of milk; all milk options 
were used by 48/86 (56%), mother’s milk only 9/86 (11%), mother’s own milk combined 
with formula 21/86 (24%), and mother’s own along with donor milk 8/86 (9%). No units 
used donor human milk along with formula milk. Mother’s milk was, therefore, a 
requirement in all units for this feeding approach. 
2.4.3.3 Adverse effects associated with OPC administration 
Almost all the units that administer OPC (82/86 (95%) reported no significant adverse 
effects related to OPC administration whereas 4/86 (5%) reported adverse effects; one, a 
decrease in oxygen saturation (Spo2) to below 80%, and another 3 units reported both a 
decrease in SpO2 and bradycardia (heart rate below 100 beats/min), Figure 2.6. 
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2.4.3.4 OPC guidelines and documentation  
OPC administration had been mostly used without written guidelines or policies to follow 
69/86 (80%) units, Figure 2.6.  
In answering the survey question: “Do you have written guidelines on the use of 
oropharyngeal colostrum?”, discrepancies (where the nurse and the doctor responded 
differently) were found from only four units (4/86 (5%)) among duplicate responses. A 
reliability analysis using Cohen’s kappa statistics was conducted to determine consistency 
among duplicate respondents (408, 409). There was a moderate agreement between 
doctors and nurses, Kappa coefficient (ĸ) = 0.53 (p = 0.02).  
OPC administration was often not documented on the infant’s clinical record charts. 54/86 
(63%) of the neonatal units who were using OPC responded that they do not document it 
and 32/86 (37%) documented the OPC use on the clinical chart (Figure 2.6). 
Discrepancies were found between the duplicate responses from eight units (Kappa 
coefficient (ĸ) = 0.15; p = 0.4) which is considered a slight agreement (408, 409). The 
eight units with discrepant responses were excluded from the analysis for the variable; 
“documentation of OPC on the infant’s record chart”. Sensitivity analysis was also 
conducted by considering both responses of nurses and doctors. Based on the nurses’ 
responses, 49/86 (57%) of the units did not document OPC and 29/86 (33%) documented 
the use of OPC on the infant’s record chart. Considering the doctors’ responses; 51/86 
(59%) did not document OPC use and 27/86 (31%) documented the use of OPC on the 
infant’s record chart.  
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Figure 2.6  OPC adverse effect, documentation and guidelines 
 Responses to the survey questions: 
“Have you experienced any adverse effects with the use of oropharyngeal colostrum?” (n 
= 86) 
“Do you have written guidelines on the use of oropharyngeal colostrum? (n = 82) 
“Do you document oropharyngeal on the infant's record charts?” (n = 78) 
 Documentation: recording OPC administration on infants’ charts; Blue bar: No; Brown 
bar: Yes; Bar: percentage of responses 
 
2.4.3.5 Individual perception towards OPC administration 
This section describes individual perceptions of neonatal professionals who administer 
OPC; these questions were analysed using the total respondents. 
2.4.3.5.1 The procedure of OPC administration  
Almost all OPC users (107/166 respondents) felt that it was easy to administer colostrum 
by the oropharyngeal route. However, they responded with different individual perceptions 
(Figure 2.7). 
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Figure 2.7   Ease of OPC administration 
Response to the survey question; “How easy is it to administer colostrum by the 
oropharyngeal route?” Bar: percentage of cases; OPC: oropharyngeal colostrum  
 
2.4.3.5.2 Recommendation of OPC use to other sites  
All the OPC users, 107/166 respondents (64%) recommended oropharyngeal colostrum 
as part of the standard care of preterm infants with variable levels of recommendation     
(Figure 2.8). 
 
Figure 2.8  Recommendation of OPC administration to other sites 
Response to the survey question: “Would you recommend OPC as part of the standard 
care of preterm infants?” Bar: percentage of responses; OPC: oropharyngeal colostrum  
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2.4.4 Units not currently using OPC 
Of the 120 responding neonatal units that use colostrum, 34/120 (28%) units did not 
practise OPC administration (OPC non-users). Of these 34 units, 18/34 (53%) were 
NICUs, 12/34 (35%) LNUs and 4/34 (12%) SCUs. Data from the units not currently using 
OPC was analysed using the number of these units (34 units) as a dominator.  
2.4.4.1 Reasons for not using OPC  
Not being knowledgeable about OPC administration was the most common reason for not 
using OPC by those units who were not currently using OPC administration (Figure 2.9). 
“Other” was answered by 3/34 (9%) units, and they commented that “their units were 
SCUs and mostly admitted babies who can tolerate enteral feeding and were able to 
swallow”  
 
Figure 2.9  Reasons for not using OPC 
Response to the survey question: “Why are you currently not using oropharyngeal 
colostrum (OPC) in your unit?” Bar: percentage of responses.  
 
2.4.4.2 Use of colostrum by the units currently not using OPC  
Although the units who did not practise the administration of OPC, most of these units 
were giving colostrum to preterm infants down a gastric tube when asked “Do you give 
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colostrum down a gastric tube?”; 19/34 (56%) responded “mostly” and 11/34 (32%) 
“always” while 3/34 (9%) answered “sometimes” and 1/34 (3%) “occasionally”.  
Colostrum was given to preterm infants down a gastric tube regardless of the infant’s 
feeding regimen; 14/34 (41%) units give colostrum with trophic feeding, 12/34 (36%) 
enteral feeding, 7/38 (21%) parenteral nutrition and 1/34 (2%) units give it with nil by 
mouth or nil per oral status. These units were mostly administering mother’s own milk in 
the order that it is expressed when asked “Do you administer mother’s own milk in the 
order that it is expressed ?”; they answered; 29/34 (85%) “mostly”: 22/34 (65%); “always”: 
7/34 (20%); “sometimes”: 4/34 (12%); “occasionally”: (3%). 
2.4.4.3 Introduction of OPC by neonatal units currently not using it   
Of the 166 respondent neonatal professionals, 52/166 (31%) did not use the 
oropharyngeal route in their neonatal units, many indicated the intention to introduce it in 
the future (Figure 2.10).  
 
Figure 2.10  Introduction of OPC administration by units not using OPC 
Responses to the survey question: “If you are not currently giving oropharyngeal 
colostrum, how likely are you to introduce it in   the future?” Bar: percentage of responses; 
OPC: oropharyngeal colostrum 
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2.4.5 Interest in a research study 
Most respondents 106/166 (64%) indicated that they would be interested in joining a 
research study to evaluate oropharyngeal administration of mother’s own colostrum to 
preterm infants and provided their contact details. Table 2.6 presents the characteristics of 
the respondents.  
Table 2.6  Characteristics of the respondent professionals who were interested in 
research evaluating OPC administration  
Criteria Description 
Job title Doctors: 64/166 (39%); Nurses: 42/166 (25%) 
Years of work 
> 20 years: 52/166 (31%); 10-20 years: 41/166 (25%); 5-10 years: 
12/166 (7%) 
OPC use  Using OPC: 65/166 (39%); not using OPC: 41/166 (25%) 
OPC: oropharyngeal colostrum.  
 
2.5 Discussion 
2.5.1 Key findings  
Of the 267 neonatal professionals surveyed, 166 submitted completed questionnaire 
giving a 62% response rate, represented 125 neonatal units. The respondent units 
represented almost all neonatal networks within the UK (Table 2.1); this could enhance 
the generalisability of the survey findings. Responses were mainly received from NICU 
and LNUs, whilst, SCUs were poorly represented. In this type of survey, a response rate 
of 62%  is considered a good response (395). It is important to attain the highest 
achievable response rate to minimise non-response bias in health care surveys, and web-
based questionnaires (392, 410). Therefore, this survey was designed to avoid the 
reported problems of internet surveys. The target population was neonatal professionals 
who are expected to have easy access to email and are comfortable with this tool (411). 
To enhance the survey response rate three reminder emails were sent to the targeted 
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population, and almost all the neonatal units across the UK were approached to 
participate.  
 Administration of OPC was used by approximately 40% of UK neonatal units and, this is 
consistent with the international progressive increase in the use of OPC for the care of 
preterm infants (353, 355). OPC administration was mostly used by NICUs and LNUs 
whilst it was less used by the SCUs. This finding was expected as SCUs usually admits 
babies who can tolerate enteral/oral feeding (404), in contrast to the NICUs and LNUs, 
that admit more sick infants who cannot tolerate enteral feeding or infants who may 
tolerate enteral feeding by gastric tube and could have OPC as well. It could also be 
attributed to less responses from SCUs versus NICUs and LNUs.  
2.5.2 Practice of OPC administration in the UK  
Three-quarters of the respondent units practising OPC administration used it without 
written guideline and policy so that 76% of the OPC users had no pre-defined criteria for 
its use. This finding highlighted the need for the creation of guidelines and continuous 
evaluation and education.  
Based on the responding neonatal units that use OPC, OPC was administered for all 
gestational age, any birth weight, and regardless of the infant’s postnatal age, contrary to 
previous studies where OPC has mainly been used in extremely preterm and very low 
birth weight infants within the early postnatal period (353, 356, 412). The previous studies 
were observational and randomised controlled trials that focused mainly on the impacts of 
OPC on the health outcomes of preterm infants. However, these studies had small sample 
sizes and some drawbacks in their methodology, in particular, some were trials not 
blinded (356, 357). OPC was provided to preterm infants regardless of the clinical status 
and the infant’s feeding regimen which is comparable with other studies as OPC was not 
given as a part of feeding protocols (355, 357, 413).  
There was very likely to be marked variations in which babies were given OPC and in 
administration methods, as approximately two-thirds of the OPC users had no pre-defined 
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criteria or guideline for its use. This variability in the practice of OPC administration could 
result from OPC as a novel intervention recently implemented in UK neonatal units. As 
reported by the responding neonatal units, only one-third of the respondent units 
introduced OPC for more than four years whilst the others had introduced if from six 
months to less than two years. However, variation in neonatal practice is a well-known 
challenge in perinatal and neonatal care among units, regions and countries (414, 415). 
Interestingly, ninety-five per cent of the units using OPC reported that they were not aware 
of any significant adverse effects with the procedure. This finding is comparable with the 
results of previous studies that have explored the administration of OPC to preterm infants 
(< 32 weeks gestation) (353-355, 416-418). Despite, variation in the procedure of OPC 
administration between these studies (some using the syringe technique described by 
Rodriguez et al. (352, 417, 419) and others used a swab for OPC application (413)), they 
have consistently reported no adverse effects related to the OPC procedure. This finding 
suggests that OPC is potentially a safe intervention, which could be used in the care of 
preterm infants. However, this study and the previous studies were not designed nor 
powered to assess the safety of this new intervention. Another important finding in this 
survey was that 83% of neonatal professionals surveyed reported that administering 
colostrum by the oropharyngeal route was easy. This clinical survey demonstrated 
uncertainty about OPC use in UK neonatal units and highlighted the knowledge gap in this 
specific intervention. 
2.5.3 Perception of neonatal professionals towards OPC 
The neonatal professionals responding to the survey would highly recommend OPC use 
as part of the standard care of preterm infants as reported by those surveyed (92% of 
OPC users highly recommended OPC use for other sites). Similarly, 62% of those who do 
not use OPC were planning to introduce it in their units. Moreover, they reported that lack 
of knowledge (46%) and lack of guidelines (28%) were the reasons for not administering 
colostrum by the oropharyngeal route. These findings highlighted the need for education 
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and written guidelines and also that who respond are more likely to be engaged with the 
OPC use. 
Despite the lack of high-quality evidence to support the use of OPC in the care of preterm 
infants, there is a progressive increase in the use of OPC within neonatal units. The 
progressive increase in the use of OPC, in neonatal units, might be driven by engagement 
of the neonatal professionals with the protective effects of mother’s colostrum and its 
potential benefits for preterm infants (137, 193, 420, 421) and the suggested feasibility of 
OPC use in preterm infants especially in those infants who are not able to tolerate enteral 
feeds (353-355, 358, 422). The focus on improving the health outcomes of preterm infants 
may also encourage the use of a potentially safe and cost-effective intervention, which 
does not require any advanced technology.  
2.5.4 Strengths and Limitations  
To the best of my knowledge, there was no previous study have explored the practice of 
OPC administration within the UK neonatal units. Besides, no studies have focused on the 
perceptions, attitudes of neonatal professionals or parents/caregivers towards the use of 
OPC in preterm infants. Some previous surveys focused on the knowledge, attitude and 
practice of mothers towards colostrum and breastfeeding (423-426). This survey provided 
data about the use and perception of OPC by obtaining information from neonatal 
professionals within the UK neonatal units. 
The study covered several aspects of using OPC in the UK, including practices of OPC 
and the professional knowledge and perceptions toward it, enabling the evaluation of 
many fundamentals related to the OPC use within neonatal units. Moreover, opinions 
were sought from both doctors and nurses. In neonatal practice, feeding and OPC 
administration, and documentation in the infant clinical charts, are often a nursing 
prerogative, and hence, their opinions about the use of such new intervention would be 
valuable. 
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This survey had some limitations, which include that as a survey, the results may indicate 
self-reported experience and not describe actual practice. The findings of this study reflect 
the knowledge and attitude of neonatal professionals who participated in the survey and 
could not necessarily be generalised to all neonatal units in the UK due to a possible 
nonresponse bias that is expected in any survey study (427). No differences between the 
respondents and non-respondents were predicted assuming nonresponse was at random 
as all the surveyed professionals were lead doctors and lead nurses of neonatal units 
(428). However, the non-respondents may have different practice and perceptions 
towards OPC administration to preterm infants.  
Reporting bias could have emerged as those neonatal units who do not use OPC were 
more represented among the non-respondents. However, to enhance the response rate, 
every effort was made in the form of three reminder emails that followed by telephone 
follow-up. Contrary to interview surveys, as a self-completed questionnaire, potentially 
biased questions may have been included; however, this should have been minimised by 
piloting the questionnaire.  
Another limitation of the study may have been the identification and verification of the 
participants’ contact details such as error messages were received saying “invalid email 
address” or the participants are no longer working in the National Health Services (NHS). 
Moreover, emails may not have reached target participants from either automatic blocking 
or the survey email received as a junk email or not precedence for some clinicians 
working to assist patients in very busy neonatal units (390).  
Additionally, duplicate responses were received from some of the responded neonatal 
units with discrepancies between doctors and nurses in answering certain questions that 
raises concern about the ability of the survey to capture the actual use of OPC within the 
unit. However, units with discrepancies in specific questions were excluded from the 
analysis of those questions and reliability analysis was conducted, which showed, 
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generally, there was a good consensus relating to OPC administration among doctors and 
nurses from the same neonatal unit. 
2.6 Conclusion 
This study has shown that: 
- OPC has been introduced into UK neonatal practice despite a lack of high-quality 
evidence regarding its use.  
- OPC administration varies among UK neonatal units. OPC was frequently used 
without written guidelines or policy. The variation in the use of OPC by the UK 
neonatal units, reported in this survey indicates a need for the development of 
clinical guidelines and policies to practice OPC administration. 
- Administering colostrum by the oropharyngeal route appears to be an easy and 
practical procedure that is well tolerated by preterm infants. This observation might 
be reassuring to those neonatal units considering using OPC.  
- More research is needed to assess the safety, and efficacy of OPC administration 
in the care of preterm infants. 
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Chapter 3. Oropharyngeal colostrum in preventing 
mortality and morbidity in preterm infants: 
Cochrane systematic review 
 
3.1 Chapter overview 
Based on the findings of a survey of the UK neonatal professionals (Chapter 2), 
oropharyngeal administration of mother’s colostrum (OPC) is increasingly adopted by 
neonatal units and recommended by neonatal professionals. To bridge the knowledge 
gap, I systematically reviewed currently available evidence on the use of OPC in the care 
of preterm infants. This chapter presents a Cochrane systematic review and meta-
analysis assessing the available randomised controlled trials (RCTs), which have 
evaluated the effects of OPC in preventing mortality and other morbidities in preterm 
infants. The review was published in the Cochrane Database of Systematic Reviews 
(CDSR) (429).  
3.2 Background  
3.2.1 Evidence-Based Medicine (EB-Medicine) 
Evidence is the information used in making conclusions and can be strong or weak 
depending on the quantity and quality of the source. EB-Medicine involves the explicit 
integration of reliable, objective, critically evaluated, high-quality evidence with clinical 
experience and patient’s preferences, by systematically searching the best existing 
medical and clinical research (430). EB-Medicine aims to improve the quality of 
healthcare by ensuring health care decisions are taken by incorporating the clinical 
practices, patients’ preferences and their clinical circumstances, societal expectations 
and the best available evidence from research relevant to the clinical problems (431). 
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Furthermore, utilising an EB-Medicine approach keeps healthcare professionals up to 
date with the growing medical research. The practice of EB-Medicine follows basic 
steps (430, 432): 
- translating clinical issues into answerable questions,  
- finding the best evidence, 
- critically appraising the available evidence for internal and external validities, 
- assessing the applicability of the results, making decisions and incorporating into 
practice, 
- evaluating the performance of the applied strategies regularly (433).     
3.2.2 Systematic reviews  
Health-care professionals commonly use review articles as a summary of evidence for a 
specific medical topic (434). There are two types of literature reviews; narrative and 
systematic. Narrative reviews are generally subjective, deal with an overview of a 
particular topic, and frequently have no predefined inclusion criteria for studies selection, 
and they typically do not explicitly describe their methodology. Therefore, they have a high 
risk of bias (435).  
Systematic reviews are a form of secondary analysis that focuses on a specific question, 
use predefined inclusion criteria, and precise, structured methods for searching and 
critically appraising primary studies for the review question, resulting in a synthesised 
summary of the available literature (435). They, therefore, produce findings that are more 
objective by evaluating the consistency and generalisability of the studies, which could not 
be apparent in individual research or narrative literature reviews.  
Moreover, systematic reviews often include quantitative meta-analysis, which limits bias 
and may improve the power and precision of conclusions (436). Systematic reviews can 
be conducted to answer questions related to healthcare issues, such as interventions, 
prevention, diagnosis, adverse effects and diagnostic tests, and may also identify a new 
hypothesis, suggest further research and resolve conflicting bodies of evidence (437). The 
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primary objective of the systematic review is to help people decide about a specific issue 
(438); therefore, reviewers should consider who will use the results of the intervention 
studied. There are essential steps for conducting systematic reviews including the 
followings (439): 
- A focused review question should be defined. 
- A comprehensive search of available databases. 
- Selection of primary studies. 
- Data extraction and analysis. 
- Assessment of studies’ quality. 
- Synthesis of the results of included studies.  
-  Interpretation of the results and reporting.  
Systematic reviews have been criticised because of potential publication bias (publication 
of research with positive results and non-publication of trials with negative or null results), 
reporting bias (selective reporting of outcomes with favourable results), validity of the 
studies and knowing the findings of potential studies (440). Conclusions of systematic 
reviews thus need to be cautiously interpreted and integrated with practice (441).   
3.2.3 Randomised controlled trials 
There are many designs used to conduct clinical research, such as RCTs, non-RCTs, 
quasi-control, cross-sectional and longitudinal observational studies. These designs differ 
in their power to investigate the effectiveness of interventions. A principle of EB-Medicine, 
therefore, is to rank studies at different strengths according to their design in a “hierarchy 
of evidence” (442). Since the introduction of EB-Medicine, several versions of the 
hierarchy of evidence have been described (443, 444), and most of them indicate which 
study designs should be more potent in answering a research question but there is no 
universal standard hierarchy (445). RCTs and systematic reviews and meta-analysis were 
placed at the top of the pyramid (445, 446). Although hierarchy of evidence, for instance, 
the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence (447), presents 
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a useful tool to find the most rigorous evidence for many clinical questions,  the definitive 
assessments of the quality of the evidence are not provided. It has been argued that using 
hierarchy overlooked the potential risk of bias in RCTs and systematic reviews (448). It 
might also reduce the use of judgment by systematic review authors (449). Therefore, 
critical appraisal of the evidence is essential to evaluate the validity and strength of 
recommendation of evidence when making decisions. Evidence should not be thought 
valid because it is a systematic review of RCTs but appraising the systematic review can 
be considered specifically for issues related to the validity of the review studies, the size 
and precision of the effect of the assessed intervention and the applicability of the findings 
(435).   
RCTs are considered the gold standard design for healthcare interventions (435). 
However, RCTs are also prone to bias in the methodology, during analysis and reporting 
of the trials (450), such as failure to conceal allocation and blind, loss to follow-up, 
inappropriate consideration of the intention-to-treat principle, stopping early for benefit and 
selective reporting of outcomes according to the results. Nevertheless, observational 
studies were placed down in the hierarchy of evidence; these study designs can be more 
appropriate for evaluating potential adverse effects, long-term outcomes and diagnostic 
tests (451) 
3.2.4 Meta-analysis  
Meta-analysis is a statistical method used to combine data (considered to be combinable) 
from different studies for synthesising estimates of outcomes. The data are pooled 
quantitatively and reanalysed using a specific statistical method with the aim of producing 
results that provide more consistent evidence from across numerous studies (452). Meta-
analysis has the potential for increasing the statistical power, improving precision, 
answering questions not proposed by individual studies and resolving disagreements from 
conflicting statements (453). In meta-analysis, the effect of an intervention is reported as a 
point estimate and its 95% confidence intervals (CI) along with the exact P value for each 
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study included (453), as they are helpful for assessing the clinical usefulness of 
intervention (454). Meta-analysis estimates the magnitude of the effect of an intervention, 
establishes the direction of the effect and investigates the consistency of the effect across 
studies but does not provide information concerning the strength of evidence  (435, 453). 
The Forest plot provides a visual presentation of the data that being pooled into the 
analysis, an overall summary estimate of the results, the degree of variability across 
studies and the risk of bias in each study (455). Whilst, meta-analysis is increasingly used 
to present health care evidence, meta-analyses of separate studies can be misleading, 
especially if within study bias and reporting biases are not carefully considered (456). 
Therefore, reviewers should be transparent about the main question that the trials are 
addressing.  
3.2.5 Cochrane systematic reviews (CSRs) 
The Cochrane Collaboration was founded in 1993 as a collaborative centre with the aims 
of creating and maintaining a database of up-to-date systematic reviews of RCTs of health 
care interventions that can be accessed through electronic media (457, 458). It was titled 
in honour of the British epidemiologist Archibald Cochrane who endorsed the importance 
of RCTs as evidence for medicine collaboration in 1979: “It is surely a great criticism of 
our profession that we have not organised a critical summary, by speciality and 
subspecialty, adapted periodically, of all relevant randomised controlled trials” (459). 
CSRs are acknowledged as one of the best sources for healthcare professionals to obtain 
evidence in an accessible and robust format for practice in medicine (460, 461). 
Therefore, they primarily focus on the search of RCTs of the effects of interventions (or 
diagnostic test accuracy) (462), as RCTs are more likely to yield unbiased results about 
the effects of interventions than other review methods (463). Non-randomised studies can 
be included especially if RCTs are not available and if evidence could not be obtained 
from RCTs, such as rare and long-term outcomes, or in consideration of the safety of 
intervention (464).  
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CSRs use a standard, rigorous method to reduce bias to provide the best and most 
current evidence to guide decision-making (463, 465). Cochrane adopted the approach 
developed by the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) Working Group (443, 466) to transparently assess and classify the 
quality of evidence (467). GRADE is an organised and transparent process for creating 
and reporting summaries of evidence for systematic reviews and recommendations in 
healthcare and is perceived as the most effective approach that links assessments of the 
quality of evidence to clinical recommendations (467). It differentiates between the quality 
of evidence and the strength of a recommendation in practice. The GRADE approach has 
been adopted by many organisations such as the World Health Organization (WHO), 
American College of Physicians, British Medical Journal (BMJ) Clinical Evidence and the 
UK National Institutes of Health and Care Excellence (443, 468, 469). The evidence is 
then combined and analysed to provide robust, explicit recommendations that can be 
appropriately used to inform clinical practice.   
Moreover, CSRs are maintained in the CDSR within the Cochrane Library and regularly 
updated to monitor the emergence of new evidence (470). This electronic publication 
facilitates search and contribution across the world. CSRs can also assist with patient 
care in places which are resource poor and cannot undertake full, robust evidence 
reviews because of lack of expertise and access to medical journals. Free access is 
available for users from countries classified as low-or middle-income by the World Bank 
(460).  
CSRs have been criticised for often being inconclusive (471); however, such reviews can 
still be beneficial by highlighting areas of research where further studies are required. 
Others argue that CSRs can under-estimate reporting bias, which is influenced by their 
conclusion (472). However, Cochrane regularly updates its methodology to ensure that 
CSRs are a high-quality source of evidence (473). Another criticism is that review titles 
are added according to the preference of the reviewers not based on the needs of public 
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health. Nevertheless, review authors are divers in term of being worldwide volunteers from 
different backgrounds including health professionals, researchers and consumers (460).  
3.2.5.1 Process for conducting CSRs    
The process of conducting CSR starts at registration of the title to prevent duplication and 
ensure relevance and practicability of the proposed question to health care. A well-
formulated review question will also direct other stages of the review process, such as 
specifying eligibility criteria, planning the search strategy to search for studies, defining 
and collecting data (474).  Registration is followed by the preparation of the protocol, 
which is submitted for peer review and publication. Authors then start searching and 
analysing the results. Next authors are draft review and submit it for peer review and 
publication. The published review should be periodically updated. 
3.2.5.2 Methodology of CSRs 
Cochrane has developed a standard method for conducting systematic reviews (463). 
CSRs have a uniform structured format to help readers to find the results of research 
rapidly and to evaluate the validity, applicability and implications of the finding, ensure 
explicit and concise reporting of the reviews and minimise reviewers’ effort, facilitates 
electronic publication and regular update of reviews and allows the conductions of 
overviews reviews (475). Review Manager (RevMan) (476) is a required software to use 
when preparing protocols and conducting reviews (475). In 2016, Cochrane introduced 
updated standards for conducting and reporting CSRs (Methodological Expectations of 
Cochrane Intervention Review (MECIR)) (473) to ensure transparency in interpretation 
and representation of the reviews at the highest possible quality, which is crucial to inform 
clinical practice and health policy decisions. The CSRs are conducted following 
fundamental steps; further details of the steps are given in Section 3.3 and Table 3.2 
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3.2.6 Rationale of the review  
OPC in the first few days of life is a new intervention that it has been proposed as a route 
to deliver the benefits of colostrum to preterm infants (339, 413). OPC being widely 
introduced as it may offer potential benefits which may, or may not, outweigh the extra 
work that OPC administration requires (360, 361, 396, 397). Further discussion of OPC is 
given in Section 1.14.   
A systematic review of the evidence, to identify benefits and harms, might be useful 
evidence before recommendations can be made for, or against, OPC. This review was the 
first Cochrane review evaluating OPC use in preterm infants. The proposed review 
question was assessed by the Cochrane Neonatal Group (CNG) to identify duplication 
and overlap with other systematic reviews.  The importance and priorities of the review 
question were based on the global burden of diseases. There is one systematic review 
(413) that reported the safety and feasibility of OPC with unclear effects on the health 
outcomes of preterm infants. However, the previous review included studies with different 
study designs; RCTs, observational, cross-sectional and longitudinal studies and clinical 
audit. Additionally it was a qualitative analysis and did not involve a quantitative meta-
analysis (413). The review presented in this chapter included only RCTs, the gold 
standard for clinical research and in E-B-M (477) with recognition of the limitations and 
disadvantages of RCTs (442, 448).  
This Cochrane review was conducted to collate the existing evidence to assess whether 
early OPC safely prevents mortality and morbidity in preterm infants. It was anticipated 
that in the presence of sufficient evidence, an evidence-based recommendation could be 
made for the use of OPC in preterm infants during the neonatal period.   
The review question was, therefore “is OPC compared to controls, effective in preventing 
mortality and morbidity and improving outcomes for preterm infants?”  
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3.2.7 Objectives of the review 
3.2.7.1 Primary objective  
To evaluate the effect of early (during the first 48 hours of life) oropharyngeal 
administration of mother’s own colostrum on morbidities, including NEC, late-onset 
invasive infection and mortality in preterm infants compared to control.  
3.2.7.2 Secondary objectives  
To assess studies for evidence of safety and harm such as aspiration pneumonia. 
To compare the effects of early OPC versus no OPC, placebo, late OPC (after 48 hours of 
life), and nasogastric colostrum.  
3.3 Methods   
This review followed the MECIR and the guidance of the CNG (478). Dr Amna Widad 
Nasuf (AN, author of this thesis) was the principal reviewer; Dr Shalini Ojha (SO) and Dr 
Jon Dorling (JD) were co-reviewers. 
Before conducting the systematic review, a review protocol was written by AN and edited 
by SO and JD. The review protocol was published in the CDSR (479). Publication of the 
protocol before undertaking the review reduces the effect of authors’ biases and the 
potential for duplication. Additionally, an electronic publication of the protocol in the CDSR 
(480), enables users to forward their comments, permits peer review of the planned 
methods and enhances transparency (481).  
3.3.1 Eligibility criteria  
Studies have only been included if they met the pre-set criteria and measured at least one 
of the pre-specified outcomes. 
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3.3.1.1 Types of studies   
Published RCTs where the unit of randomisation was the infant or cluster randomised 
trials where the neonatal unit was the unit of randomisation were considered for this 
review. Quasi-randomised or non-randomised trials such as controlled before and after 
studies were excluded. The review was not limited to any particular region or language. 
This review also included unpublished data (as recommended by Cochrane) to reduce 
publication bias which has an important influence on the validity of the review (440). 
Whilst, the inclusion of unpublished data may introduce bias (data are not peer reviewed), 
it has been widely supported by many of review authors (482) and journal editors (483).  
3.3.1.2 Participants   
Trials were only considered if they enrolled preterm infants (less than 37 weeks’ gestation) 
receiving care in any neonatal unit.  
3.3.1.3 Interventions   
Studies were included if they involved OPC to preterm infants in the first 48 hours of life. 
OPC usually involves the instillation of a small amount of colostrum (0.1 to 0.5 ml) inside 
the cheeks of the infant by oral syringe or using a sterile swab soaked with colostrum 
(352). The procedure was usually given every two to three hours within the first 48 hours 
of life. This review considered trials that used OPC by any regimen and technique such 
as, instillation by a syringe, direct application to the oral mucosa by swab or any other 
ways such that the fluid is absorbed by the oral mucosa. OPC procedures could also be 
described by different terms such as oral care, oral swabbing oral colostrum, oromucosal 
route, oropharyngeal or/and oral immune therapy. 
The following interventions were included:  
- Administration of fresh or frozen/thawed OPC to preterm infants in the first 48 
hours of life, irrespective of when enteral feeding is introduced, type of milk or feed 
advancement regimen is used for enteral feeding. 
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- Colostrum instillation inside the infant’ s cheeks by oral syringe or by gentle 
application over the tongue, around the gums, and along the lips using a swab or 
sponge soaked with a small amount of colostrum (0.1 to 0.5 mL), at least once and 
usually repeatedly in the first 48 hours of life. 
- Any procedure for OPC administration by which colostrum could be absorbed by 
the oral mucosa. 
3.3.1.4 Comparison  
This review considered trials, comparing early OPC versus sham administration of water, 
oral formula, or donor breastmilk, or no intervention. Trials comparing OPC versus 
nasogastric or nasojejunal administration of colostrum were also considered.  
The following comparisons were planned:  
-  Early OPC, defined as OPC commenced before 48 hours of age, versus sham 
administration of water, oral formula, donor breast milk, or no intervention. 
-  Early OPC versus early colostrum administration by nasogastric (NGT) or 
nasojejunal (NJT). 
-  Early OPC versus late OPC, defined as OPC commenced after 48 hours of age. 
However, the review search did not retrieve any study that compared early OPC versus 
colostrum administration by NGT/NJT, nor versus late OPC, therefore this review only 
compared early OPC versus sham administration of water, normal saline, oral formula, 
donor breast milk, or no intervention. 
3.3.2 Outcome measures   
3.3.2.1 Primary outcomes   
- Incidence of NEC (Bell’s stage 2 or 3 (167)) until discharge to home. 
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- Incidence of microbiologically confirmed LOI until discharge to home with LOI 
defined as positive blood or cerebrospinal fluid culture for microbial infection after 
72 hours of life (174). 
- Death before discharge to home. 
3.3.2.2 Secondary outcomes   
- Days to full enteral feeds. 
- Length of hospital stay (days) from birth to discharge home. 
- Pneumonia (defined as chest X-ray changes/treated with at least five days of 
antibiotics) before discharge to home. 
- Formally reported adverse effects (e.g. aspiration, gagging/choking on 
administration, bradycardia, desaturation, increase in oxygen requirement, 
disturbances in vital signs) between the start of the intervention and discharge 
home. 
- Chronic lung disease (defined as the need for oxygen supplementation at 36 
weeks’ postmenstrual age).  
- Retinopathy of prematurity (all stages and severe stage > 2). 
- Weight gain from birth to discharge home (using weight percentiles or Z-scores) 
and time to regain birth weight. 
- Days of parenteral nutrition before discharge to home. 
- Days of antibiotic therapy before discharge to home. 
- Rate of receiving any breast milk at discharge to home. 
- Rate of receiving only breast milk (and not formula) at discharge to home.  
- Death in the first year of life. 
- Neurodevelopmental outcome at 18 to 24 months assessed by a clinician or 
parent-reported questionnaire. 
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3.3.3 Search methods for identification of studies   
3.3.3.1 Electronic searches 
The criteria and standard methods of the CNG were used for the search strategy (484). 
The first search was conducted in March 2015, repeated in September 2015 and April 
2016. NA updated the search in August 2017. 
A comprehensive search was conducted using bibliographic databases, which are related 
to health care: Cochrane Controlled Register of Trials (CENTRAL) 2017, Issue 8 in the 
Cochrane Library; Medical Literature Analysis and Retrieval System Online (MEDLINE) 
via PubMed (1966 to August, 2017); Excerpta Medica Database (EMBASE) (1980 to 
August, 2017); and Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
(1982 to August, 2017) using the following search terms: (colostrum, 
oropharyngeal*colostrum, oral*care), plus database-specific limiters for RCTs and 
neonates (Appendix 5). Clinical trials registries were also searched for ongoing or recently 
completed trials (clinicaltrials.gov, the World Health Organization’s International Trials 
Registry Platform and the International Standard Randomised Controlled Trial Number).  
3.3.3.2 Searching other resources   
An additional search was conducted using the proceedings of the annual meetings of the 
Paediatric Academic Societies (1993 to 2017), the European Society for Paediatric 
Research (1995 to 2017), the Royal College of Paediatrics and Child Health (2000 to 
2017), the Perinatal Society of Australia and New Zealand (2000 to 2017) and the 
National Association of Neonatal Nurses. The reference lists of the included studies and 
published reviews, which are usually appropriate sources (485), were also used for finding 
relevant studies. 
Trials reported as abstracts only were eligible if sufficient information to fulfil the inclusion 
criteria was available from the abstracts, or their authors. Authors of completed and 
unpublished trials were contacted to provide additional information.  
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3.3.4 Data collection and analysis 
3.3.4.1 Selection of studies   
The standard process recommended by the Cochrane Handbook was followed (Chapter 7 
(486)). To ensure transparency and enhance detection of errors, two reviewers (AN and 
SO) independently screened the title and abstract of all articles retrieved through the 
above search. Studies, which did not consider early OPC and those not described as 
RCTs were excluded (Table 4.1).  
AN and SO independently assessed the full text of potential articles selected by the 
principal reviewer (AN) to determine which studies were eligible for inclusion and 
consideration of duplicate reporting of the same trial. As studies might be reported in 
different articles or abstracts, a review search may retrieve several reports for potentially 
relevant studies. Therefore, identification of duplicate publications of the same study is a 
vital step in selecting studies for inclusion in the review; as inadvertent multiple inclusion 
of studies can introduce significant bias in the meta-analysis (487). Duplicate reports were 
identified using the name of the authors, numbers of participants, date, duration and 
setting of the study, intervention details and baseline characteristics of participants. Any 
disagreements were settled by discussion until consensus was reached and with 
adjudication as needed by the third author (JD). The process of selecting eligible studies 
was presented using the Preferred Reporting Items for Systematic reviews and Meta-
analysis (PRISMA) flow diagram (488), Figure 3.1. 
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Figure 3.1  Preferred Reporting Items for Systematic reviews and Meta-analysis 
(488)  
 
3.3.4.2 Data extraction and management 
Data were extracted independently by AN and SO, and compared. Discrepancies were 
resolved through discussion and by involving JD. NA modified the Cochrane data 
collection form template based on the review eligibility criteria and outcome measures.  
The following data were extracted from each study:  
- Study ID, trial authors and their contact details. 
- Method of the research (design, duration of the trial, the setting of the trial, 
sequence generation, allocation concealment, blinding). 
- Participants (total number, gestational age, sex, country, socioeconomic & ethnic 
group, diagnosis and status). 
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- Intervention (number, time, technique, dose and duration, any additional 
interventions). 
- Outcomes (time of outcome, reporting method, effect size). 
The study authors were contacted for clarification of unclear data and any additional 
information when necessary. 
AN entered the collected data into the RevMan software version 5.3  (476) which is the 
software mandated by the Cochrane Collaboration for reviews under its protocols. The 
included studies were presented as a ‘characteristics of included studies’ table. 
3.3.5 Assessment of risk of bias in included studies 
As data from studies vitally influence the finding of a systematic review, assessment of the 
validity of included studies is a fundamental component of a CSR. There are two types of 
validity, external and internal. External validity refers to generalisability and applicability of 
the study results in other populations. Internal validity refers to the confidence in any 
causal associations between the variables and is determined by how the study minimises 
systematic bias (489). Risk of bias (ROB) assessment strengthens the relationship 
between the features of the study design and their potential impact on the results of the 
trial. The Cochrane ‘Risk of Bias Assessment Tool’ (490)  was used to evaluate the 
methodology and ROB of the included studies; the tool has been implemented in RevMan 
software. AN and SO separately assessed the ROB for all included studies. Any 
disagreement was resolved by discussion or by consultation with JD.  
For each study, the following sources of bias and their related domains were evaluated 
and presented in the ‘Characteristics of included studies’ table:  
- Selection bias (Random sequence generation and Allocation concealment). 
- Performance bias (Blinding of participants and care providers).  
-  Detection bias (Blinding of outcome assessors); the methods used to blind 
outcome assessors from knowledge of which intervention a participant received. 
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- Attrition bias (Incomplete outcome data assessment through withdrawals, 
dropouts, or protocol deviations). Completeness was classified according to the 
percentage of missed data. 
- Reporting bias (Selective outcome reporting).  
- Other biases, any important concerns about other possible sources of bias that 
could put it at high risk of bias were defined (for example, whether there was a 
potential source of bias related to the specific study design or whether the trial was 
stopped early due to some data-dependent process).  
Within a study, each domain was assessed as low (bias unlikely to modify the results), 
high (a bias that reduces confidence in the results), or unclear risk of bias (a bias that 
makes some concern on the results due to lack of information or uncertainty). This was 
achieved by precise judgment depending on what has been described in the study report 
as detailed in Table 3.1. The possible extent and direction of the bias and its potential 
impact on the results were considered. Sensitivity analysis has been planned to explore 
the impact of the level of bias if needed.  
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Table 3.1  Cochrane’s Risk of Bias tool (adapted from Higgins 2017 (490)) 
Domain Low risk High risk Unclear risk 
Selection bias 
- Random sequence 
generation 
 
- Allocation concealment  
any truly random process, e.g. 
random number table; 
computer random number 
generator 
 
telephone or central 
randomisation; consecutively 
numbered sealed opaque 
envelopes 
any non-random process, e.g. 
odd or even date of birth; 
hospital or clinic record number 
 
using open random allocation; 
unsealed or non-opaque 
envelopes, alternation; date of 
birth 
No sufficient description to 
judge 
Performance bias 
- Blinding of participants 
and personnel 
effective blinding  not blinded trials No sufficient description to 
judge 
Detection bias  
- Blinding of outcome 
assessors  
effective blinding not blinded trials No sufficient description to 
judge 
Attrition bias 
- Incomplete outcome data  
<10% missing data  >10% missing data No sufficient information 
reported nor provided by the 
author 
Reporting bias 
 
All of the study’s pre-specified 
outcomes and all expected 
outcomes of interest to the 
review were reported 
not all the study’s pre-specified 
outcomes were reported. The 
study fails to include results of a 
key outcome that would have 
been expected to be reported 
No sufficient information to 
make a judgment  
Other bias  any concerns possible sources 
of bias not covered above  
no other bias No sufficient information to 
make a judgement  
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3.3.6 Data analysis and management 
RevMan 5.3 software (491) was used for data analysis. Meta-analysis, which is an 
essential step in CSRs, was conducted using the fixed-effect model that assumes a 
common, true effect in a set of studies, and estimates the best effect for an intervention 
(492). While, random effects modelling was used when there was moderate or high 
heterogeneity (I2>50%) between the included studies, this model assumes that the true 
effect is variable between the studies and estimated the average effect (453). 
3.3.6.1 Measures of treatment effect 
Effect estimates were calculated using risk ratios (RR) for dichotomous data and mean 
differences (MD) for continuous data, with respective 95% Cl along with the exact p 
values. When continuous data were reported as median and range or interquartile range, 
trial’ authors were contacted to provide the mean and standard deviation (SD), and if not 
provided, the mean and SDs were estimated using a formula (interquartile range (IQR) = 
approximately 1.35 of the SD) recommended by the Cochrane Handbook (Chapter 7.7.3.5 
(486)). When it was considered applicable to combine two arms of a trial, treatment 
effects were obtained from the combined data using the RevMan calculator (493). Forest 
plots were used for graphical presentation of meta-analysis results and the area to the left of 
the line of no effect was in favour of OPC.  
3.3.6.2 Unit of analysis issues 
The unit of analysis was the participating infant in each of the included trials. An infant 
was considered only once in an analysis. For cluster RCTs, it was planned that the 
participating neonatal unit or a section of the neonatal unit would be the unit of analysis. 
However, no cluster randomised trial was identified for this review. 
3.3.6.3 Dealing with missing data 
The principle reviewer (AN) contacted trial investigators to request essential missing data 
in the outcomes or unclear data. Intention-to-treat analyses were conducted. 
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3.3.6.4 Assessment of heterogeneity 
Heterogeneity between effect sizes of the included studies was determined by inspecting 
the forest plot (overlapping of the studies CI), the Chi² test (with a P value of < 0.1) and 
the I2 for heterogeneity. The percentage of the variability in effect estimates was used to 
describe inconsistency between trials that was due to heterogeneity rather than due to 
chance in accordance with the guidelines recommended by the CNG for interpreting the I2 
statistic: < 25% = none, 25% to 49% = low, 50% to 74% = moderate, and > 75% = high 
heterogeneity. If moderate or high heterogeneity was detected (I² > 50%), potential 
causes (for example, differences in study design, participants, interventions and 
definitions and measurement of outcome assessments) were explored in subgroup and 
sensitivity analyses. 
3.3.6.5 Assessment of reporting biases 
Assessment of potential reporting bias using funnel plotting was planned. However this 
was not conducted as only six trials were included in the review as a minimum of 10 
studies are required for the funnel plot to be valid and could detect asymmetry (494, 495). 
3.3.6.6 Subgroup analysis  
If sufficient data were available, the following subgroup analyses were planned to assess 
the intervention in specific participant groups: 
- Infants born < 30 weeks’ gestation. 
- Infants born < 1500 grams. 
- Infants who were small for gestational age at birth (birth weight less than 10th 
centile). 
However, subgroup analysis was not performed as the gestational age, and birth weights 
of the participants were matched between the included studies. Moreover, the outcomes 
were not reported in sufficient detail, and they were not available on request. 
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3.3.6.7 Sensitivity analysis 
Sensitivity analyses were planned to determine if findings were affected by including only 
studies using adequate methods (low risk of bias). 
3.3.7 Assessing the Quality of evidence 
The quality of evidence for the main comparison at the outcome level was evaluated 
according to the GRADE approach (467) using the online version (GRADEpro GDT) 
software (www.gradepro.org). GRADEpro software has the advantages to import data 
directly from RevMan, assisting in calculating relative and absolute risks related to the 
examined intervention and producing a table in a format which can directly be imported 
into RevMan as a Summary of finding (SOF) table (496), this software can save time and 
ensure consistency.  
RCTs were considered as high quality that can be downgraded based on five categories: 
risk of bias within and across studies (type of evidence), inconsistency (heterogeneity), 
indirectness (applicability and generalisability), imprecision of the estimates of effect 
(sample size, number of events and 95% CI) and publication bias (positive studies, profit 
interest). 
For each outcome, every category was assessed as not serious, serious and very serious 
depending on the characteristics of the studies reported that outcome. The quality of 
evidence was downgraded by one level for serious concern and two level for very serious 
and graded according to the GRADE approach as one of the following four grades (496, 
497): 
- “High: We are very confident that the true effect lies close to that of the estimate of 
the effect”.  
- “Moderate: We are moderately confident in the effect estimate. The true effect is 
likely to be close to the estimate of the effect, but there is a possibility that it is 
substantially different”. 
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- “Low: Confidence in the effect estimate is limited. The true effect may be 
substantially different from the estimate of the effect”. 
- “Very Low: We have very little confidence in the effect estimate. The true effect is 
likely to be substantially different from the estimate of effect”. 
AN and SO independently assessed the quality of the evidence and AN created the final 
SoF table for outcomes rated as critical or important for clinical decision making. Any 
disagreement was resolved by discussion with JD. According to the policies of CNG, a 
maximum of seven outcomes to be included in the SoF table, therefore, the following 
clinically critical and important outcomes were included in the SoF table (Table 3.3) 
- Incidence of NEC (Bell stage 2 or 3) until discharge to home. 
- Incidence of LOI until discharge to home. 
- Death before discharge to home. 
- Time to full enteral feed. 
- Length of hospital stay (days) from birth to discharge to home. 
- Pneumonia.  
- Reported adverse effects. 
If the ROB was arising from inadequacies in allocation concealment, assignment 
randomisation, completeness of follow-up or outcome assessment blinding such that 
confidence in the effect estimates was reduced, the quality of evidence was downgraded 
accordingly (498). The directness of evidence was judged by the applicability of the 
evidence to the review question not to the generalisability of the evidence (499). 
Consistency was assessed by the similarity of point estimates, the extent of overlap of 
confidence intervals of the studies and statistical measurement of heterogeneity (I2). The 
quality of evidence was downgraded when inconsistency across study results was large 
(I2 >50%) and unexplained (i.e. some studies suggest important benefit and others no 
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effect without a clinical explanation; (500). Precision was assessed by the sample size, 
number of events and with the 95% CI around the pooled estimation (501).  
3.4 Results  
3.4.1 Search results  
The search strategy retrieved 287 records from the database and 29 additional records 
from the clinical trials registers (Figure 3.2). After duplicates were excluded, screening of 
the titles and abstracts of 294 articles and after exclusion of clearly irrelevant titles, 14 
articles using OPC in preterm infants for potential inclusion were retrieved.  
On further reviewing of full reports of the potential 14 trials, two papers were excluded as 
they were duplicate publications of trials included from other publications with the most 
data (McFadden 2012 (502) and Rodriguez 2011 (417)). Two studies were excluded; Lee 
2015 (356) and Zhang 2017 (419) (Table 3.2) because the intervention (OPC) was started 
after 48 hours of life which is not consistent with the pre-defined inclusion criteria of the 
review (Section, 3.5.1). One study, Rodriguez 2015 (352) was a published protocol of an 
ongoing trial, and one record was an uncompleted clinical trial (503), both were classified 
under ongoing studies. Another study was published in Spanish and after translation to 
English, was excluded because it was a non-RCT (504) and one was a feasibility study for 
OPC (422) (Figure 3.2). Six trials fulfilled the inclusion criteria of the review protocol. 
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Figure 3.2  Study flow chart 
Flow chart illustrating selection of studies included in this review. 
RCTs: randomised controlled trials; OPC: oropharyngeal colostrum. 
 
3.4.2 Included studies 
Six original RCTs were eligible for inclusion in this review and data extraction (Rodriguez 
2011(417); McFadden 2012 (502); Sohn 2015 (357); Romano-Keeler 2016 (358); Mota-
Ferreira 2016 (505)  (referred in the published review: NCT02912585); Glass 2017 (506)). 
29 additional records identified 
through other sources  
 
294 records after duplicates removed 
 
294 records screened 
280 records excluded 
not relevant to the 
research question or not 
RCTs 
14 records of full-text 
articles assessed for 
eligibility  
 
- Two were duplicate publications:  
a. one a conference 
presentation of included 
study 
b.  one was a publication of the 
same trial with different title  
- Two were uncompleted clinical 
trials 
- Two, OPC was started after 48 
hours of life 
- One was non-RCT (after 
translation from Spanish to 
English) 
- One was a feasibility study for 
OPC  
Six studies included in 
qualitative synthesis 
 
Six studies included in 
quantitative synthesis 
(meta-analysis) 
287 records identified through 
database searching  
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All included studies compared the administration of early oropharyngeal colostrum versus 
sham administration of water, placebo, or donor breast milk, or no intervention. Five 
studies were published, and Mota Ferreira 2016 (505) was only described in an 
unpublished report that we obtained from the study author. Five of the included studies 
took place in the USA and one in Brazil. Individual preterm infants were the unit of 
randomisation in all of the included studies as no cluster-randomised trials were identified. 
Four of the studies; McFadden 2012 (502), Sohn 2015 (357), Romano-Keeler 2016 (358), 
and Glass 2017 (506) were designated as not blinded and only two trials; Rodriguez 2011 
(417) and Mota-Ferreira 2016 (505), were described as blinded RCTs. Table 3.2 presents 
the features of the included studies.  
Table 3.2  Characteristics of included studies 
Study ID Rodriguez 2011 (417) 
Methods 
A blinded, placebo-controlled, randomised controlled trial. 
Setting: Level III neonatal unit, NorthShore University Hospital, 
Chicago, USA. January 2006 to August 2007 
Participants 
Sixteen infants (9 intervention, 7 control). 
Inclusion criteria: birth weight <1000 gm and/or gestation < 28 
weeks; appropriate weight for gestational age  
Exclusion criteria: presence of congenital anomalies, 
gastrointestinal or renal disorders, receipt of vasopressor 
medications at a dosage >10 mcg/kg/min, maternal 
chorioamnionitis, history of substance abuse, positive HIV. 
Interventions 
0.2 ml of Own Mother Colostrum (OMC) or sterile water 
(placebo) according to the infant’s group assignment. 
Using a syringe 0.1 ml was administrated by placing the tip of 
the syringe into the infant’s mouth, alongside the right buccal 
cavity, and directing it posteriorly towards the oropharynx over a 
period of at least two minutes, then on the left side. The 
procedure was started within 48 hours of life, every two hours 
over 48 consecutive hours. 
Outcomes 
Primary outcomes: level secretory immunoglobulin A, 
Lactoferrin, and interleukin-10. 
Secondary outcomes: NEC*, days to full enteral feeds, days to 
full per oral feeds, length of hospital stay, bacteraemia, 
pneumonia, CLD*, Retinopathy of prematurity (ROP)**, 
Corrected gestational age at discharge and death. 
Notes 
The study protocol is not available. * Diagnostic criteria not 
specified; ** Data provided by the author. 
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 Study ID McFadden 2012 (502) 
Methods 
A prospective randomised trial. Not blinded 
Setting: NICU, The Woman’s Hospital of Texas, USA. August 
2011 to January 2012 
Participants 
Twenty-nine infants (11 intervention and 18 control). 
Inclusion criteria: gestational age 26 to 34 weeks, Intubation and 
mechanical ventilation, or support with nasal continuous positive 
pressure (CPAP). 
Exclusion criteria: age > 24 hours, major congenital anomalies, 
infants diagnosed with an infection in the first 24 hours of life or 
born to mothers with active infection, parental refusal, mothers 
not speaking English and mothers not wishing to breastfeed. 
Interventions 
Oral care: moisten a swab with sterile water (control A), normal 
saline (control B) or colostrum/human milk (intervention). Gently 
swirl swab along inside of mouth - wiping cheeks, tongue, palate 
and lips. Oral care was administrated every 3 to 6 hours or more 
often as indicated. 
Outcomes 
Primary outcomes: oral colonisation (oral culture) and time to 
oral colonisation. 
Secondary outcomes: ventilator-associated pneumonia (VAP), 
NEC*; days of antibiotics; days to reach full enteral feeds; length 
of hospital stay;  length of time on ventilation, NCPAP and CLD* 
Notes No protocol was available. * diagnostic criteria not specified 
Study ID  Sohn 2015 (357) 
Methods 
A randomised controlled clinical trial. Not blinded. 
Setting: NICU, University of California Davis Children’s Hospital 
in Sacramento, California, USA. November 2013 to October 
2014  
Participants 
Twelve infants (6 intervention and 6 control).  
Inclusion criteria; birth weight < 1500g, aged under seven days, 
intubated within 48h of birth and maternal colostrum available. 
Exclusion criteria; a lethal medical condition. 
Interventions 
0.2 ml of the mother’s colostrum via sterile syringe into the 
baby’s oral cavity (0.1 ml into each buccal pouch) every two 
hours for 46 hours. The comparison group received routine care. 
Outcomes 
Primary outcomes: oral microbiota and VAP  
Secondary outcomes: ventilator days, days of antibiotics, age at 
first feeding (days), days to full feeds; NEC (stage 2, 3), early 
and late-onset sepsis, other pneumonia; CLD and death. 
Notes Registered at clinicaltrials.gov: (NCT02306980). 
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Study ID Romano-Keeler 2106 (358) 
Methods 
An open-label, prospective randomised clinical trial.  
Setting: NICU, Monroe Carell Jr. Children’s Hospital at 
Vanderbilt, USA.  February 2013 to July 2014. 
Participants 
Ninety-nine infants (48 intervention and 51 control). 
Inclusion criteria: gestational age <32 weeks  
Exclusion criteria: refusal to participate, enrolment in competing 
studies or Spanish-speaking only. 
Interventions 
Oral priming with mother's colostrum that involved administration 
of 0.1 mL colostrum to each cheek every 6 hours for five days 
started in the first 48 hours of life. 
Comparison group; no oral priming with mother's colostrum. 
Outcomes 
Primary outcomes; salivary immuno-peptides before/after oral 
colostrum priming. Oral microbiota in a subgroup. 
Secondary outcomes; length of hospital stay, total days 
intubated, age at feeding initiation, days to 100ml/kg/day of 
enteral feeds, days of antimicrobial exposure, incidence of NEC 
and late-onset bacteraemia; type of feed at hospital discharge. 
Notes Registered at clinicaltrials.gov: NCT01776268 
Study ID Mota Ferreira (NCT02912585)* (505) 
Methods 
A double-blinded, randomised, placebo-controlled trial. 
Setting: NICU, Clinics Hospital of Federal University of 
Uberlandia, Brazil. From 15 July 2013 to 15 July 2015. 
Participants 
One hundred forty-nine infants (81 intervention and 68 control). 
Inclusion criteria: birth weight < 1500 g; gestational age < 34 
weeks. 
Exclusion criteria: congenital anomalies; gastrointestinal 
disorders; maternal history of substance abuse; positive HIV 
status. 
Interventions 
OPC (interaction) and placebo (sterile water). They followed the 
same protocol used by Rodriguez et al. that is; "0.2 ml of Own 
Mother Colostrum (OMC) or sterile water (placebo) according to 
the infant’s group assignment. 
Using a syringe 0.1 ml was administrated by placing the tip of 
the syringe into the infant’s mouth, alongside the right buccal 
cavity, and directing it posteriorly towards the oropharynx over a 
period of at least two minutes this was repeated on the left side 
and carried out every two hours over for 48 consecutive hours". 
The procedure was started within 48-72 hours of life. 
Outcomes 
Primary outcomes: Incidence of late-onset sepsis and serum 
and urinary IgA levels. 
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Secondary outcomes: NEC (Bell's stage 2 or 3); 
Bronchopulmonary dysplasia (diagnostic criteria not specified); 
ROP (grade 3); length of hospital stay; death before discharge 
Notes 
Registered at clinicaltrials.gov: NCT02912585  
Unpublished data. The investigator has provided the results of 
the study at request. * study ID in the published review 
Study ID Glass 2017 (506) 
Methods 
Open-label, placebo-controlled, randomised study. 
Setting: NICU, Penn State Milton S. Hershey Medical Center, 
Hershey, Pennsylvania, USA. January 2011 to January 2016. 
Participants 
Thirty infants (17 interventions and 13 control). 
Inclusion criteria: birth weight <1500gm, mothers planning to 
provide colostrum. 
Exclusion criteria: major congenital anomalies or chromosomal 
syndromes incompatible with life, mothers not willing to provide 
colostrum for their infant in the first week of life, or infants of 
mothers with known HIV, hepatitis B, or hepatitis C 
Interventions 
“Oral care with either mother’s own colostrum (intervention) or 
sterile water (control) every 3 hours from day of life two until 7. 
For the oral care procedure, 0.2 mL of mother’s colostrum or 
sterile water was applied to the oral mucosa by an intensive care 
nurse using a cotton-tipped applicator every 3 hours during care 
times”. 
Outcomes 
Primary outcomes: change in salivary secretory Ig-A 
concentration from baseline to 2 weeks of age 
Secondary outcomes: Incidence and severity of NEC; culture-
positive sepsis; feeding tolerance; days of the first enteral 
feeding; time to full enteral feedings (defined as 140 mL/kg/d). 
Notes 
Registered at Clinicaltrials.gov: NCT01443091 
Results were initially available as a conference abstract. The 
trial author provided additional information at request. Review 
data included information from the subsequent publication (506) 
and information provided by the author. 
NICU: neonatal intensive care unit; NEC: necrotising enterocolitis; CLD: chronic lung disease; 
VAP: ventilator-associated pneumonia 
All the studies were small and from single centres. They enrolled 335 infants with sample 
sizes between 12 and 149 participants. Four studies; Rodriguez 2011, Sohn 2015, Mota 
Ferreira 2016 and Glass 2017, prespecified prematurity with birth weight < 1500 grams as 
an inclusion criterion. Two studies; McFadden 2012 and Sohn 2015, included only infants 
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who were mechanically ventilated. Overall, the infants had a gestational age ranging from 
25 to 32 weeks of gestation and birth weights from 410 to 2500 grams. Table 3.3 details 
the participants’ criteria by a study, which varied between studies.  
Table 3.3  Characteristics of participants in the included studies 
Study  
Participants 
(number) 
Gestational age 
(weeks) 
Birth weight 
(grams) 
Rodriguez 2011(417) 16 25-28 410-1250 
McFadden 2012 (502) 27 27-32 590-2530 
Sohn 2015 (357) 12 25-30 490-1300 
Romano-Keeler 2016 (358) 99 28-31 905-1602 
Mota Ferreira 2016* (505) 149 26-31 787-1217 
Glass 2017 (506) 30 27-29 1020-1169 
* Unpublished data provided by the author 
 
3.4.3 Interventions and comparisons  
The included studies randomised infants to receive mother’s own colostrum by the 
oropharyngeal route and the time of starting the OPC was within the first 48 hours of life. 
Four trials; Rodriguez 2011 (417), Sohn 2015 (357), Romano-Keeler 2016 (358) and Mota 
Ferreira 2016 (505), followed the protocol for OPC described by Rodriguez et al. 
(administration of 0.2 mL colostrum/control by syringe: 0.1 mL on each side of the 
oropharynx) (354). The other two used different protocols; McFadden 2012  (502) used 
0.2 mL colostrum for oral care administered via “gentle swab along the inside of the 
mouth”; Glass 2017 (506) also administrated 0.2 ml colostrum using a cotton-tipped 
applicator.        
All trials reported early OPC administration in preterm infants compared to a control (sham 
water, normal saline, a placebo, or no intervention). Therefore only one comparison was 
evaluated; that is early oropharyngeal colostrum versus sham water, normal saline, 
placebo, or no intervention. Two studies; Sohn 2015 (357) and Romano-Keeler 2016 
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(358), did not use a placebo and provided no additional intervention to participants 
randomised to the control group. Three studies; Rodriguez 2011 (417), Mota Ferreira 
2016 (505), and Glass 2017 (506), administered sterile water to infants in the control 
group, and McFadden 2012 (502) included two control groups; one receiving sterile water 
and the other normal saline. Investigators similarly administered control interventions to 
colostrum’s administration to the intervention group. However, Mota Ferreira 2016 gave 
human donor milk in the absence of the mother’s colostrum. Therefore, infants who 
received donor milk have been included in the OPC group (as they were randomised to 
receive OPC) to maintain the intention to treat analyses. 
3.4.4 Reported outcomes    
All the included trials reported short-term outcomes (participants have been followed up 
until hospital discharge). No study reported long-term follow up.  
3.4.4.1 Primary outcomes  
All the included studies reported the pre-specified primary outcomes of the review (section 
4.5.2); ‘incidence of NEC’, ‘incidence LOI’ and ‘death before discharge home’. Four trials; 
Sohn 2015 (357), Romano-Keeler 2016 (358), Mota Ferreira 2016 (505) and Glass 2017 
(506), defined NEC as Bell’s stage 2 or 3, whereas two trials; Rodriguez 2011 (417) and 
McFadden 2012 (502), provided no specific diagnostic criteria. Three studies; Sohn 2015 
(357), Mota Ferreira 2016 (505) and Glass 2017 (506), defined LOI as clinical signs and a 
positive blood culture. Glass 2017 provided additional criteria for defining LOI (onset after 
day three of life and antibiotic therapy for at least five days), and three studies; Rodriguez 
2011 (417), McFadden 2012, Romano-Keeler 2016 (358), did not provide a pre-specified 
definition.  
3.4.4.2 Secondary outcomes 
Secondary outcomes were variably reported by the included trials; ‘time to full enteral 
feeds’ was reported by all the included trials; ‘length of hospital stay’ was reported by four 
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trials; Rodriguez 2011 (417),  McFadden 2012 (502), Romano-Keeler 2016 (358) and 
Mota Ferreira 2016 (505). ‘Pneumonia’ and ‘chronic lung disease’ were reported by three 
studies; Rodriguez 2011 (417), McFadden 2012 (502), Sohn 2015 (357). Sohn 2015 
defined CLD (oxygen required at 36 weeks’ corrected gestational age, or at discharge, if 
sooner). Mota Ferreira 2016 reported bronchopulmonary dysplasia as an outcome but did 
not define the diagnostic criteria used. ‘Days of parenteral nutrition’ was reported by two 
trials; Mota Ferreira 2016 (505) and Glass 2017 (506); ‘days of antibiotic therapy’ was 
reported by three trials; McFadden 2012 (502), Sohn 2015 (357) and  Romano-Keeler 
2016 (358). ‘Retinopathy of prematurity’ was reported by Rodriguez 2011 and Mota 
Ferreira 2016. Three outcomes were reported by only one trial; ‘weight gain from birth to 
discharge home’ was reported by Mota Ferreira 2016 (505); ‘receiving only or any breast 
milk at discharge home’ were reported by Romano-Keeler 2016 (358) and ‘ventilator-
associated pneumonia’ by Sohn 2015 (357).  
Adverse events associated with OPC were reported on by all the included trials. However, 
there were no clear definitions for adverse events were described, and adverse events 
were narratively reported. As no numerical data were provided, this outcome was 
presented as a narrative summary. None of the included trials reported ‘death in the first 
year of life’ and ‘neurodevelopmental outcomes at 18 to 24 months’. 
3.4.5 Excluded studies  
Two studies were excluded from this review because OPC was provided after 48 hours of 
life. Lee 2015 (356), was a double-blind, placebo-controlled RCT that included 48 infants 
born at < 28 weeks’ gestation who were randomised to receive 0.2 mL of their mother’s 
colostrum or sterile water (control) via the oropharyngeal route every three hours for three 
days. However, most of the infants included in this study received colostrum after 48 
hours of life; therefore, this study was excluded from the analysis. Similarly, Zhang 2017 
(419)  was a double-blind, placebo-controlled trial, including 64 with birth weight < 1500 
grams, compared administration of mother’s colostrum (0.1ml) to each side of the cheek 
 109 
 
versus similar administration of normal saline. Mean age at the first dose of colostrum or 
normal saline was > 48 hours in both groups; hence this study was not included in the 
review. 
3.4.6 Risk of bias in included studies                                                
In general, the included studies had a variable risk of bias across the domains. Most of the 
included studies were not blinded, and there were concerns about allocation concealment. 
One study consisted of unpublished data (Mota Ferreira 2016 (505)). The risk of bias of 
the six included trials was considered as high to unclear. Table 3.4 summaries studies 
criteria for judging the risk of bias for each study. 
3.4.6.1 Selection bias 
All trials indicated that treatment was allocated randomly; however, two trials; McFadden 
2012 (502) and Sohn 2015 (357), did not specify the process used to generate the 
random sequence. Similarly, two studies (Romano-Keeler 2016 and Mota Ferreira 2016) 
did not state the methods of allocation concealment, and Glass 2017 (506) reported that 
the allocation method was “not applicable”.  
3.4.6.2 Performance and detection bias 
Only two studies; Rodriguez 2011 (417) and Mota Ferreira 2016 (505) , were blinded and 
described these aspects appropriately (used opaque syringes to deliver treatment); 
therefore they were judged as having a low risk. Four trials were not blinded; McFadden 
2012 (502), Shon 2015 (357), Romano-Keeler 2016 (358) and Glass 2017 (506), these 
trials were judged as being at high risk for performance and detection bias. However, in 
this review detection bias for the outcome of death before discharge home was 
considered as having a low risk as death is unlikely to be influenced by blinding. 
3.4.6.3 Attrition bias 
Four trials; Rodriguez 2011, Sohn 2015, Romano-Keeler 2016 and Mota Ferreira 2016, 
were assessed to be at low risk of attrition bias. Mota Ferreira 2016 reported that 32 
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infants from the colostrum group were excluded and received human donor milk. The trial 
(Mota Ferreira 2016) investigators provided information for the 32 infants, and this was 
added to the OPC group. Therefore, this trial was categorised as low risk for attrition bias. 
Two trials; McFadden 2012 and Glass 2017, were judged as having a high risk of attrition 
bias. McFadden 2012 reported that three participants were not included in the final 
analysis for the outcome; ‘length of hospital stay’. Those three infants were still in the 
hospital when the analysis was conducted, and intention-to-treat was not applied. Glass 
2017 excluded 13 participants due to trial constraints and data from those infants were not 
included in the analysis and intention-to-treat was not conducted in the final analysis of 
the trial.  
3.4.6.4  Reporting bias  
All the pre-specified expected outcomes of interest for the review were reported except for 
two outcomes namely, ‘death in the first year of life’ and ‘neurodevelopmental outcomes at 
18 to 24 months’. Four of the included studies; Sohn 2015, Mota Ferreira 2016, Romano-
Keeler 2016 and Glass 2017, were registered in a trial register (clinicalTrials.gov). Two 
studies; Rodriguez 2011 and McFadden 2012 (502) did not publish a protocol; however, 
all the outcomes described in the methods section were reported in their results. 
3.4.6.5 Other bias  
All included studies were at low risk of other bias except for one trial (Glass 2017), which 
was considered as having a potential source of other bias because there were data from 
13 participants which were not analysed; this was determined from additional information 
provided by the study author explaining this. Furthermore, the estimated sample size in 
the protocol, as published at ClinicalTrials.gov (NCT01443091), was 60 infants while in 
the published report, it was 30 infants and no explanation is stated in the published report 
(506).  
The overall risk of bias was high across all included studies as four out of six studies were 
not blinded and due to concerns about allocation concealment and incomplete outcome 
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data.  Judgements on the risk of bias in the studies are presented in “Risk of bias” 
summary (Figure 3.3) and “Risk of bias” graph (Figure 3.4).
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Table 3.4  Criteria of the risk of bias for included studies 
Study Selection bias Performance bias Detection bias Attrition bias Reporting bias 
Risk  Sequence 
generation 
Risk  Allocation 
concealment 
Risk  
 
Blinding of 
participants/ 
personnel 
Risk Blinding  
of 
outcome 
assessors 
Risk Incomplete 
outcome 
data 
Risk Selective reporting 
Rodriguez 
2011 (417) 
Low Details of 
randomisation 
were provided 
by the author.   
Low Adequate 
concealment 
before 
enrolment 
 
Low The blinding 
procedure 
was 
described  
Low Sufficient 
information  
Low Additional 
information 
provided by 
the author 
and 
intention-to-
treat applied 
Unclear Outcomes described 
in the methods were 
reported in the 
results. The study 
protocol was not 
available  
McFadden 
2012 (502) 
Unclear No sufficient 
details of the 
randomisation 
methods were 
given 
 
Low Adequate 
concealment 
prior to 
enrolment 
 
High Not blinded  High Not blinded Low Three 
infants were 
still in the 
hospital 
when the 
study was 
completed. 
intention-to-
treat applied 
Unclear No protocol was 
available 
 
Sohn 2015 
(357) 
Unclear No details 
were given on 
how 
randomisation 
was done 
Low "Neonates 
were randomly 
assigned to the 
colostrum 
group using 
sealed opaque 
envelopes." 
High Not blinded High Not blinded Low All 
randomised 
infants were 
included in 
the final 
analysis 
Low The study protocol 
was available at 
clinicaltrials.gov 
(NCT02306980) 
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Study Selection bias Performance bias Detection bias Attrition bias Reporting bias 
Risk  Sequence 
generation 
Risk  Allocation 
concealment 
Risk  
 
Blinding of 
participants/ 
personnel 
Risk Blinding  
of 
outcome 
assessors 
Risk Incomplete 
outcome 
data 
Risk Selective reporting 
Romano-
Keeler 
2016 (358) 
Low “a numeric list 
generated a 
priori to 
receive an 
intervention” 
Unclear No details were 
provided 
High Not blinded 
 
High Not blinded 
 
Low Randomised 
infants were 
included in 
the final 
analysis 
Low Outcomes described 
were reported. 
Clinicaltrials.gov 
(NCT01776268) 
Mota -
Ferreira 
2016 (505) 
Low Computer 
random 
number 
generation. 
 
Unclear No details were 
provided 
regarding 
allocation 
concealment. 
 
Low Adequate 
blinding 
procedure 
was 
described. 
Low Adequate 
blinding 
procedure 
was 
described. 
Low "32 
randomized 
to colostrum 
group were 
excluded 
because 
colostrum 
was not 
available". 
The author 
provided 
additional 
information 
regarding 
this group. 
Intention-to-
treat applied  
Unclear the protocol was 
available at 
clinicaltrials.gov: 
NCT01776268). 
Unpublished data 
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Study Selection bias Performance bias Detection bias Attrition bias Reporting bias 
Risk  Sequence 
generation 
Risk  Allocation 
concealment 
Risk  
 
Blinding of 
participants/ 
personnel 
Risk Blinding  
of 
outcome 
assessors 
Risk Incomplete 
outcome 
data 
Risk Selective reporting 
Glass 2017 
(506) 
Low "Random 
number 
generation"; 
additional 
information 
provided by 
the author 
High "Not 
applicable"; 
additional 
information 
provided by the 
author 
 
High Not blinded High Not blinded High 13 
participants 
were 
excluded 
and not 
analysed  
 
High Sample size in the 
protocol 
(clinicaltrials.gov 
NCT01443091) was 
60 infants. The report 
included only 30 (no 
explanation was 
provided)  
Unclear: lack of information or uncertainty  
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Figure 3.3  Risk of bias summary for the included studies 
Individual assessment of risk of bias items for each included study.  
Green ball: low risk; Red ball: high risk; Yellow; unclear (uncertainty or lack of 
information). Rodriguez 2011(417); McFadden 2012 (502); Sohn 2015 (357); 
Romano-Keeler 2016 (358); Mota-Ferreira 2016 (505); Glass 2017 (506). 
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Figure 3.4  Overall risk of bias for each domain in the included studies 
Assessment of risk of bias for each item presented across all included studies. Each bar 
presents a risk of bias item. Green bar: low risk; Red: high risk; Yellow: unclear risk of bias.  
 
3.4.7 Effects of the intervention 
3.4.7.1 Main review comparison  
This review included only one comparison as no available data for the other planned 
comparisons. Early OPC versus control (water, normal saline, placebo, or no intervention) 
was the main comparison included in the final data analysis of this review. 
3.4.7.2 Primary outcomes  
3.4.7.2.1  Incidence of NEC until hospital discharge  
All included trials; Rodriguez 2011(417), McFadden 2012 (502), Sohn 2015 (357), Romano-
Keeler 2016 (358), Mota-Ferreira 2016 (505) and Glass 2017 (506), reported on the 
incidence of NEC in 335 enrolled preterm infants (OPC: 172; control: 163 infants).  Meta-
analysis did not show an effect on the risk of NEC (Figure 3.5). The estimate is based on four 
studies including 290 participants, as two studies had no cases of NEC (Rodriguez 2011 and 
McFadden 2012). The typical risk difference was 0.01 (95% CI -0.03 to 0.06). There was no 
evidence of heterogeneity between the studies for this outcome (I2 = 0%). The quality of 
evidence was very low due to imprecision (small sample size and wide Cl) and high to 
unclear risk of bias. 
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Figure 3.5  Forest plot comparing the incidence of NEC for infants receiving OPC or 
control 
Each trial is represented by a horizontal line; width of the line: 95% CI. Blue box: mean effect 
estimate and the weight assigned to the trial. Middle vertical line (1): no effect. Black 
diamond: overall effect of estimate (upper and lower angles: effect size; width: 95% CI); MH: 
Mantel-Haenszel; Fixed: analysis model; CI: confidence interval; Chi2: Chi-square; df: 
degrees of freedom; P: p-value; I2: I-square: statistical heterogeneity; Z: test for statistical 
significance. NEC: necrotising enterocolitis; OPC: oropharyngeal colostrum. 
 
3.4.7.2.2  Incidence of LOI until hospital discharge  
All included trials; Rodriguez 2011(417), McFadden 2012 (502), Sohn 2015 (357), Romano-
Keeler 2016 (358), Mota-Ferreira 2016 (505) and Glass 2017 (506), reported on the 
incidence of late-onset infection in 335 enrolled preterm infants (OPC: 172; control: 163 
infants). There was no statistically significant difference in the incidence of LOI; meta-
analysis did not show an effect (Figure 3.6). There was no evidence of heterogeneity 
between the studies for this outcome (I2 = 0%). The quality of evidence was very low due to 
imprecision (small sample size and wide Cl) and high to unclear risk of bias. 
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Figure 3.6  Forest plot comparing the incidence of LOI for preterm infants receiving 
OPC or control 
Each trial is represented by a horizontal line; width of the line: 95% CI. Blue box: mean effect 
estimate and the weight assigned to the trial. Middle vertical line (1): no effect. Black 
diamond: overall effect of estimate (upper and lower angles: effect size; width: 95% CI); MH: 
Mantel-Haenszel; Fixed: analysis model; CI: confidence interval; Chi2: Chi-square; df: 
degrees of freedom; P: p-value; I2: I-square: statistical heterogeneity; Z: test for statistical 
significance; LOI: late-onset infection; OPC: oropharyngeal colostrum 
 
3.4.7.2.3  Death before discharge to home 
All the trials; Rodriguez 2011(417), McFadden 2012 (502), Sohn 2015 (357), Romano-Keeler 
2016 (358), Mota-Ferreira 2016 (505) and Glass 2017 (506), reported on death before 
discharge home in 335 enrolled preterm infants (OPC: 172; control: 163 infants). There was 
no statistically significant difference in mortality between the two groups; meta-analysis 
showed no effect (Figure 3.7). One study (Glass 2017) had no death in the enrolled infants. 
Therefore, the estimate is based on five studies in 305 infants. No evidence indicates 
heterogeneity between studies for this outcome (I² = 0%). The quality of evidence was very 
low due to imprecision (small sample size and wide Cl) and high to unclear risk of bias. 
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Figure 3.7  Forest plot comparing death before discharge home for preterm infants 
receiving OPC or control 
Each trial is represented by a horizontal line; width of the line: 95% CI. Blue box: mean effect 
estimate and the weight assigned to the trial. Middle vertical line (1): no effect. Black 
diamond: overall effect of estimate (upper and lower angles: effect size; width: 95% CI); MH: 
Mantel-Haenszel; Fixed: analysis model; CI: confidence interval; Chi2: Chi-square; df: 
degrees of freedom; P: p-value; I2: I-square: statistical heterogeneity; Z: test for statistical 
significance; OPC: oropharyngeal colostrum. 
 
3.4.7.3 Secondary outcomes  
3.4.7.3.1 Days to full enteral feed 
The six included trials; Rodriguez 2011(417), McFadden 2012 (502), Sohn 2015 (357), 
Romano-Keeler 2016 (358), Mota-Ferreira 2016 (505) and Glass 2017 (506), reported on 
time to full enteral feed in 335 enrolled preterm infants (OPC: 172; control: 163 infants). 
Meta-analysis demonstrated that infants who received early OPC attained full enteral feeds 
earlier compared with controls (Figure 3.8). At the study level, only two trials reported an 
effect in favour of OPC; Rodriguez 2011 and Mota Ferreira 2016. There was moderate 
heterogeneity (I2 = 53 %) across the studies which could be due to variability between trials 
in the definition of time to reach full enteral feeds (100 to 150 mL/kg/d). Additionally, two 
studies reported the data as median and interquartile range; hence, the means and SD were 
estimated. As the heterogeneity could be explained, a fixed-effect model was used for 
analysing this outcome because it is more powerful and estimates the best effect for an 
intervention. Further exploration of heterogeneity demonstrated that excluding Sohn 2015’s 
study reduced the heterogeneity from I2 = 53% to 29%, Figure 3.8. 
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Figure 3.8  Forest plot comparing days to full feeds for preterm infants receiving OPC 
or control 
Each trial is represented by a horizontal line; width of the line: 95% CI. Green box: mean 
effect estimate and the weight assigned to the trial. Middle vertical line (0): no effect. Black 
diamond: overall effect of estimate (upper and lower angles: effect size; width: 95% CI); SD: 
standard deviation; IV: Inverse Variance; Fixed: analysis model; CI: confidence interval; Chi2: 
Chi-square; df: degrees of freedom; P: p-value; I2: I-square: statistical heterogeneity; Z: test 
for statistical significance; OPC: oropharyngeal colostrum. 
 
 
 
Using random-effects model, meta-analysis showed that infants who received OPC attained 
full enteral feeds earlier compared with controls with minimal reduction in the effect estimate. 
However, the 95%CI widened that could explain the statistical non-significant difference. 
Similarly heterogeneity decreased by excluding Sohn’s trial, Figure 3.9 
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Figure 3.9  Forest plot comparing days to full feeds for preterm infants receiving OPC 
or control (Random-effects model)  
Each trial is represented by a horizontal line; width of the line: 95% CI. Green box: mean 
effect estimate and the weight assigned to the trial. Middle vertical line (0): no effect. Black 
diamond: overall effect of estimate (upper and lower angles: effect size; width: 95% CI); SD: 
standard deviation; IV: Inverse Variance; Fixed: analysis model; CI: confidence interval; Chi2: 
Chi-square; df: degrees of freedom; P: p-value; I2: I-square: statistical heterogeneity; Z: test 
for statistical significance; OPC: oropharyngeal colostrum 
 
3.4.7.3.2 Length of hospital stay  
Four trials; Rodriguez 2011(417), McFadden 2012 (502), Romano-Keeler 2016 (358) and 
Mota-Ferreira 2016 (505), reported on the length of hospital stay in 293 enrolled preterm 
infants (OPC:149; control: 144 infants). There were no significant differences in the length of 
hospital stay between the two groups in individual studies; meta-analysis did not show an 
effect (Figure 3.10). There was low to moderate heterogeneity (I2 = 49%) across the trials 
suggesting variability between the studies. This Heterogeneity was retrospectively explored; 
one study included infants with a larger birth weight (McFadden 2012). Exclusion of this 
study reduced heterogeneity to I² = 12% and did not alter the estimated effect in the meta-
analysis for the length of hospital stay. The quality of evidence was very low due to 
imprecision (small sample size and wide CI), high to unclear risk of bias, and moderate 
heterogeneity. 
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Figure 3.10  Forest plot comparing length of hospital stay for preterm infants receiving 
OPC or control 
Each trial is represented by a horizontal line; width of the line: 95% CI. Green box: mean 
effect estimate and the weight assigned to the trial. Middle vertical line (0): no effect. Black 
diamond: overall effect of estimate (upper and lower angles: effect size; width: 95% CI); SD: 
standard deviation; IV: Inverse Variance (statistical method); Fixed: analysis model; CI: 
confidence interval; Chi2: Chi-square; df: degrees of freedom; P: p-value; I2: I-square: 
statistical heterogeneity; Z: test used for statistical significance; OPC: oropharyngeal 
colostrum. 
 
3.4.7.3.3 Pneumonia  
Three trials; Rodriguez 2011, McFadden 2012, and Sohn 2015, reported the occurrence of 
pneumonia in 57 enrolled preterm infants (OPC: 26; control:31 infants). There was no 
significant difference between the two groups; meta-analysis did not show an effect on rate 
of pneumonia before discharge home (Figure 3.11). There was no evidence of heterogeneity 
(I2 = 17%). The quality of evidence was very low due to imprecision (small sample size, very 
wide CI), performance bias (one trial was not blinded) and selection bias.  
 
Figure 3.11  Forest plot comparing the incidence of pneumonia for preterm infants 
receiving OPC or control 
Each trial is represented by a horizontal line; width of the line: 95% CI. Blue box: mean effect 
estimate and the weight assigned to the trial. Middle vertical line (1): no effect. Black 
diamond: overall effect of estimate (estimate (upper and lower angles: effect size; width: 95% 
CI); M-H: Mantel-Haenszel; Fixed: analysis model; CI: confidence interval; Chi2: Chi-square; 
df: degrees of freedom; P: p-value; I2: I-square: statistical heterogeneity; Z; test used for 
statistical significance; OPC: oropharyngeal colostrum. 
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3.4.7.3.4 Chronic lung disease (CLD) 
Three trials (Rodriguez 2011, McFadden 2012, and Sohn 2015) reported on the incidence of 
CLD in 57 enrolled preterm infants (OPC: 26; control:31 infants). There was no significant 
difference in the incidence of CLD between the two groups; meta-analysis did not show an 
effect. There was no evidence of heterogeneity between the studies (I2 = 0%). There was 
another trial (Mota Ferreira 2016) reported bronchopulmonary dysplasia as an outcome but 
did not provide pre-defined criteria. However, including this study did not alter the result of 
the meta-analysis significantly (Figure 3.12). The quality of evidence was very low due to 
imprecision (small sample size and wide CI) and performance (one study unblinded) and 
reporting bias.  
 
Figure 3.12  Forest plot comparing the incidence of CLD for preterm infants receiving 
OPC or control 
Each trial is represented by a horizontal line; width of the line: 95% CI. Blue box: mean effect 
estimate and the weight assigned to the trial. Middle vertical line (1): no effect. Black 
diamond: overall effect of estimate (upper and lower angles: effect size; width: 95% CI); CLD: 
chronic lung disease; M-H: Mantel-Haenszel; Fixed: analysis model; CI: confidence interval; 
Chi2: Chi-square; df: degrees of freedom; P: p value; I2: I-square: statistical heterogeneity; Z; 
test used for statistical significance; OPC: oropharyngeal colostrum. 
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3.4.7.3.5 Days of antibiotic therapy 
Three trials; McFadden 2012, Sohn 2015 and Romano-Keeler 2016, reported on the ‘days of 
antibiotic therapy’ in 140 enrolled preterm infants (OPC: 65; control: 75 infants). There was 
no a significant difference between the two groups for the outcome ‘days of antibiotic 
therapy’; meta-analysis did not show an effect (Figure 3.13). There was a very high 
heterogeneity across the studies (I2 = 91%).  
At the study level, one trial (McFadden 2012) found that infants who received oral care with 
colostrum required more days of antibiotic therapy when compared with those who received 
oral care with saline or sterile water. This heterogeneity was retrospectively explored and 
identified that McFadden 2012 enrolled infants with larger birth weight. Excluding data from 
this study eliminated the heterogeneity but did not change the effect estimate. The quality of 
evidence was very low owing to imprecision (very small sample size and very wide CI), 
performance (the included trials were not blinded) and reporting bias, and very high 
heterogeneity.  
 
Figure 3.13  Forest plot comparing days of antibiotics therapy for preterm infants 
receiving OPC or control 
Each study is represented by a horizontal line; width of the line:  95% CI. Blue box: mean 
effect of estimate and weight of the study. Middle vertical line (1): no effect. Black diamond: 
overall effect of estimate (upper and lower angles: effect size; width: 95% CI); IV: Inverse 
Variance; Random: analysis model; CI: confidence interval; Chi2: Chi-square; df: degrees of 
freedom; P: p value; I2: I-square: statistical heterogeneity; Z: test used for statistical 
significance; OPC: oropharyngeal colostrum. 
 
3.4.7.3.6 Days of parenteral nutrition 
Two trials; Mota Ferreira 2016 and Glass 2017, reported ‘days of parenteral nutrition’ in 179 
preterm infants; (OPC: 98; control: 81 infants). There was no significant difference in the 
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days of parenteral nutrition use between the OPC and control groups; meta-analysis did not 
show an effect (Figure 3.14). No evidence suggested heterogeneity across the studies (I2 = 
0%). The quality of evidence was very low due to imprecision (very small sample size, very 
wide CI) and performance and reporting bias detected in these studies. 
 
Figure 3.14  Forest plot comparing days of parenteral nutrition for preterm infants 
receiving OPC or control 
Each study is represented by a horizontal line; width of the line: 95% CI. Blue box: mean 
effect of estimate and weight of the study. Middle vertical line (1): no effect. The black 
diamond: overall effect of estimate (upper and lower angles: effect size; width: 95% CI); SD: 
standard deviation; IV: Inverse Variance; Fixed: analysis model; CI: confidence interval; Chi2: 
Chi-square; df: degrees of freedom; P: p value; I2: I-square: statistical heterogeneity; Z: test 
used for statistical significance; OPC: oropharyngeal colostrum. 
 
3.4.7.3.7 Weight gain from birth to discharge home 
One unpublished trial, Mota Ferreira 2016, reported weight gain from birth to discharge home 
in 149 enrolled preterm infants (OPC: 81; control: 68 infants). There was no significant 
difference in the weight gain from birth to discharge home between the two groups (MD -
15.00 (95% CI - 50.83 to 20.83); participants: 149; P = 0.60).  The quality of evidence was 
very low due to imprecision, unclear selection and reporting bias, and the data were obtained 
from only one unpublished trial. 
3.4.7.3.8  Receiving breast milk at discharge home 
Only one trial, Romano-Keeler 2016, included the outcome measure of receiving breast milk 
at discharge home in 99 enrolled preterm infants (OPC: 48; control: 51infants). This outcome 
was described for two subgroups, received any fortified breast milk at discharge and any 
unfortified breast milk, and reported as two separate outcomes. There were no statistically 
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significant differences between OPC and control groups for both types of feeding; receiving 
any fortified breast milk at discharge and receiving any unfortified breast milk at discharge 
(Figure 3.15). Combining these outcomes meta-analysis showed an effect of OPC on 
receiving any breast milk at discharge compared with controls (Figure 3.14. The quality of 
evidence was very low because data were obtained from only one not blinded study with a 
small sample size. Although meta-analysis is not appropriate for a single study, Figure 3.14 
presents information drawn from two reports of the same study.          
 
Figure 3.15  Forest plot comparing receiving breast milk at discharge home for 
preterm infants receiving OPC or control 
A single trial reported the outcome receiving breast milk at discharge home. Width of the line:  
95% CI; Blue box: mean effect of estimate. Black diamond: overall effect of estimate (upper 
and lower angles: effect size; width: 95% CI); the black diamond at the bottom of the graph: 
overall effect of estimate for combing the two outcomes (fortified and unfortified breast milk); 
M-H: Mantel-Haenszel; Fixed: analysis model; CI: confidence interval; Chi2: Chi-square; df: 
degrees of freedom; P: p value; I2: I-square: statistical heterogeneity; Z: test used for 
statistical significance; OPC: oropharyngeal colostrum. 
 
3.4.7.3.9 Retinopathy of prematurity (ROP) 
Two trials; Rodriguez 2011 and Mota Ferreira 2016, reported the rate of ROP in 165 enrolled 
preterm infants; (OPC: 90; control: 75 infants). There was no statistically significant 
difference in the incidence of ROP between the two groups (Figure 3.16). There was no 
 127 
 
heterogeneity across the trials, I² = 0%. The quality of evidence was very low due to 
imprecision and performance and reporting bias. 
 
Figure 3.16  Forest plot comparing Retinopathy of prematurity for preterm infants 
receiving OPC or control 
Each trial is represented by a horizontal line; width of the line: 95% CI. Blue box: mean effect 
estimate and the weight assigned to the trial. Middle vertical line (1): no effect. Black 
diamond: overall effect of estimate (upper and lower angles: effect size; width: 95% CI); M-H: 
Mantel-Haenszel; Fixed: analysis model; CI: confidence interval; Chi2: Chi-square; df: 
degrees of freedom; P: p value; I2: I-square: statistical heterogeneity; Z: test used for 
statistical significance; OPC: oropharyngeal colostrum. 
 
3.4.7.3.10 Reported adverse effects  
Five trials; Rodriguez 2011, McFadden 2012, Romano-Keeler 2016, Mota Ferreira 2016 and 
Glass 2017, reported adverse effects narratively indicating that all infants tolerated the 
intervention and no adverse events were observed during the study period. No specific 
definitions for adverse effects were described by the studies. However, two reports only 
briefly described the adverse effects; Rodriguez 2011 reported "no recorded episodes of 
apnoea, bradycardia, desaturation or other adverse effects" but did not define the adverse 
effects. Glass 2017 stated, “Apnoea and bradycardia events during the procedure as well as 
the occurrence of aspiration pneumonia were charted according to unit policy”. As no 
numerical data were provided by these trials, a meta-analysis was not performed, and the 
adverse effects were narratively presented in the SoF table (Table 3.5). The quality of 
evidence was very low owing to imprecision and high to unclear risk of bias. 
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3.4.8 Quality of evidence  
All outcomes with pooled data from the included trials were assessed for the quality of 
evidence applying the GRADE approach. Based on the recommendation of the CNG seven 
outcomes were only included in the SoF table. Assessment of the quality of evidence for 
each outcome is presented in the SoF table. (Table 3.5).  
The overall quality of evidence ranged from low to very low across all the outcomes of 
interest for this review. It was downgraded due to concerns about allocation concealment 
and blinding in the highest weighted studies, concerns about incomplete outcome data, small 
sample sizes with few events, wide confidence intervals crossing the line of no effect in 
almost all the outcomes and high heterogeneity in some outcomes.  
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      Table 3.5  Summary of Finding (SoF) table:  
        Oropharyngeal colostrum (OPC) compared to control (water, saline, or no intervention) in preterm infants 
Outcomes 
Absolute effects* (95% CI) Relative 
effect 
(95% 
CI) 
Participa
nts  
(studies) 
Quality of 
the evidence 
(GRADE) 
Comments Risk with 
control 
Risk with 
OPC 
Incidence of 
necrotising 
enterocolitis (NEC) 
3 per 100 4 per 100 
(2 to 12) 
RR 1.42 
(0.50 to 
4.02) 
335 
(6 RCTs) 
⨁◯◯◯ 
VERY LOW 
The quality of evidence was downgraded 
to very low due to very serious risk of 
bias (four out of six studies were not 
blinded, and two studies had unclear 
randomisation). Very serious impression 
(small sample size and wide CI) 
Incidence of late-
onset sepsis 
20 per 100 17 per 100 
(11 to 26) 
RR 0.86 
(0.56 to 
1.33) 
335 
(6 RCTs) 
⨁◯◯◯ 
VERY LOW 
The quality of evidence was downgraded 
to very low due to very serious risk of 
bias (four out of six studies were not 
blinded, and two studies had unclear 
randomisation). Very serious impression 
(small sample size and CI crossed the 
line of no effect). 
Death before 
discharge to home 
6 per 100 5 per 100 
(2 to 11) 
RR 0.76 
(0.34 to 
1.71) 
355 
(6 RCTs) 
⨁◯◯◯ 
VERY LOW 
The quality of evidence was downgraded 
to very low due to very serious risk of 
bias (75% of the included studies were 
not blinded, and two studies had unclear 
randomisation). Very serious impression 
(small sample size and wide CI) 
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Outcomes 
Absolute effects* (95% CI) Relative 
effect 
(95% 
CI) 
Participa
nts  
(studies) 
Quality of 
the evidence 
(GRADE) 
Comments Risk with 
control 
Risk with 
OPC 
Days to full enteral 
feed 
Mean =10-25 
days 
MD -2.58 
lower  
(-4.01 
lower to     
-1.14 
lower) 
- 355 
(6 RCTs) 
⨁◯◯◯ 
VERY LOW 
The quality of evidence was downgraded 
to very low due to very serious risk of 
bias (75% of the included studies were 
not blinded, and two had concerns about 
allocation concealment and unclear 
randomisation). Serious impression 
(small sample size and CI crossed the 
line of no effect in three trials). 
Length of hospital 
stay 
Mean = 47-86 
days 
MD 0.81 
days 
higher  
(-5.87 
lower to 
7.5 higher) 
 
- 293 
(4 RCTs) 
⨁◯◯◯ 
VERY LOW 
The quality of evidence was downgraded 
to very low due to very serious risk of 
bias (50% of the included studies were 
not blinded and had concerns about 
allocation concealment. One study had 
unclear randomisation). Serious 
impression (small sample size and CI 
crossed the line of no effect).  
Pneumonia 
 
 
 
6 per 100 
(3 to 52) 
7 per 100 
(1 to 45) 
RR 2.08 
(0.54 to 
8.06) 
57 
(3 RCTs) 
⨁⨁◯◯ 
LOW 
The quality of evidence was downgraded 
to low due to very serious risk of bias 
(75% of the included studies were not 
blinded, and had concerns about 
randomisation). Serious impression (very 
small sample size, variable effect size 
and very wide CI). 
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Outcomes 
Absolute effects* (95% CI) Relative 
effect 
(95% 
CI) 
Participa
nts  
(studies) 
Quality of 
the evidence 
(GRADE) 
Comments Risk with 
control 
Risk with 
OPC 
Reported adverse 
effects 
No pre-defined adverse effects have 
been described by all the studies. 
Adverse effects were narratively 
reported as no adverse effects with the 
intervention. No numerical data were 
provided. One study reported ‘‘no 
recorded episodes of apnoea, 
bradycardia, desaturation or other 
adverse effects’’ but without defining the 
adverse effects. A second study stated 
that ‘‘no adverse events were noted’’, 
and another mentioned in the method 
section that ‘‘apnoea, bradycardia 
events and aspiration pneumonia were 
charted according to unit policy.’’ 
335 
(6 RCTs) 
⨁◯◯◯ 
VERY LOW 
The quality of evidence was downgraded 
to very low due to very serious risk of 
bias (75% of the included studies were 
not blinded, and two contained concerns 
about randomisation and allocation 
concealment). Neither definitions of 
adverse effects nor the methods used for 
monitoring were reported. A narrative 
report was conducted without a clear 
statement of adverse effect, and 
estimates were not precise. 
* The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the 
relative effect of the intervention (and its 95% CI).   
“GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, 
but there is a possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the 
effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the 
estimate of effect.” 
CI: Confidence interval; RR: Risk ratio; MD: Mean difference; RCT: randomised controlled trials; GRADE: Grading of 
Recommendations Assessment, Development and Evaluation 
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3.5 Discussion  
3.5.1 Key findings  
Based on predefined eligibility criteria, this review included six RCTs that considered the 
effects of using OPC in preventing mortality and other morbidities in preterm infants (357, 
358, 417, 502, 505, 506). These trials were recent; conducted between 2010 and 2016 and 
therefore, the results are relevant to the current practice of the care for preterm infants. All of 
these studies were small and from single centres, involving 335 infants with sample sizes of 
between 12 and 149 patients. Participants had gestational ages ranging from 25 to 32 
weeks’ gestation and birth weights between 410 to 2500g (Table 3.2).  
As no other comparisons have been studied by RCTs, this review focussed on only one 
comparison; namely the early use of OPC versus control in preterm infants. All the included 
studies administered OPC within 48 hours of birth, and own mother’s colostrum was used 
except for one trial. Mota-Ferriera 2016 (505) used human donor milk for infants assigned to 
the colostrum group if mother’s colostrum was not available, this could introduce bias into the 
results as preterm infants fed with own mother’s milk have a better outcome than those who 
fed donor milk (507, 508); which could partly be explained by the effect of pasteurisation on 
the bioactive factors and nutrients of the milk (509). 
Generally, the included studies were of low methodological quality (high to unclear risk of 
bias). Most of the included studies were not blinded and contained concerns about allocation 
concealment, and one study, Mota Ferreira 2016 (505), was unpublished data. The overall 
quality of evidence ranges from low to very low across almost all the outcomes of interest for 
this review.    
3.5.2 Primary outcomes 
All the included trials reported the primary outcomes of the review; ‘incidence of NEC’, 
‘incidence of LOI and ‘death before discharge home’. Meta-analyses of the available trial 
data for these outcomes showed no significant differences between OPC and controls in the 
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‘incidence of NEC’ (p = 0.51), ‘incidence of LOI’ (p = 0.43) and ‘death before discharge 
home’ (p = 0.51) in preterm infants <37 weeks’ gestation. These are expected findings as all 
the included studies were small trials with insufficient power to detect statistically significant 
differences but clinically important effects in the incidence of NEC, LOI, nor death. These 
results are however consistent with the biological plausibility of OPC administration 
improving outcomes as suggested by previous studies (353, 355, 377). There is an ongoing 
trial (352) that aims to recruit 489 extremely preterm infants with birth weight <1250 grams, 
during the first 96 hours of life. Once available, including the results of this trial in the meta-
analysis might modify the overall estimates of effects and the conclusions.  
3.5.3 Secondary outcomes 
Several secondary outcomes were considered in this review including, days to full enteral 
feeds, length of hospital stay, pneumonia, CLD, days of antibiotic therapy, days of parenteral 
nutrition, weight gain at discharge home, ROP, receiving any breast milk at discharge home. 
There were no differences between OPC and the controls for the secondary outcomes 
except for the outcome; ‘days to full enteral feeds’. Six trials reported on days to full enteral 
feeds and found that infants who received oropharyngeal colostrum established full enteral 
feeding faster compared with those who received the control (Figure 3.9). However, at the 
study level, only two trials (Rodriguez 2011 (417) and Mota-Ferreira 2016 (505)) 
demonstrated a reduction in time to full enteral feeds in the OPC group compared to the 
control. There was some variability across the trials as indicated by the statistical test of 
heterogeneity (I2=53%); albeit heterogeneity, it could be explained by variability in defining 
time to full enteral feeds between the included studies (100-150 ml/kg/day). Although there 
was a moderate heterogeneity, a fixed-effect model was used for analysing this outcome 
because it is more powerful and estimates the best effect, which is needed for best practice, 
for an intervention. Furthermore, two studies reported the data as median and interquartile 
range; hence, the means and SD were estimated; therefore, the observed variation in the 
standard deviations between the included studies can reflect the difference in the reliability of 
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outcome measurements; therefore, using fixed-effect model was appropriate (453). Also, 
using a random-effects model is primarily intended for unexplained heterogeneity. Moreover, 
there is more uncertainty in the I2 when there are few studies, such as in this review (453).   
This result supports the findings of previous studies in very low birth weight infants (VLBW) 
which reported earlier attainment of full enteral feeding with OPC use (353, 377, 419). 
However, these studies were small, observational studies. Another study found no difference 
in time to reach full enteral feeds between OPC and control (366), but this was also an 
observational study (before and after the adoption of OPC in a neonatal unit) that included 
only a total of 218 preterm infants. This reduction in time to attain full enteral feeds indicates 
the potential benefits of the use of OPC in preterm infants as achieving full enteral feeding 
earlier may have positive impacts on the incidence of NEC and infection, the leading causes 
of death in preterm infants (133). 
Furthermore, attainment of full enteral feeding promotes the growth of the infant and may 
consequently improve long-term outcomes for preterm infants such as neurodevelopmental 
outcomes. Earlier attainment of full enteral feeding is also associated with cost-saving by 
minimising the use of parenteral nutrition, reducing stay in the intensive care unit, and 
shorten hospital stay (47, 67). Therefore, even a small effect would reduce the burden for the 
health services and society. As the included trials did not provide information concerning the 
feeding status of the participating infants during OPC administration, it is possible that a 
confounder effect could be created by the strategy of infant's feeding. Of note, the included 
trials did not show consistent evidence of an effect on length of hospital stay. The findings 
should be cautiously interpreted with consideration of the low quality of the evidence 
because the included trials had a high risk of bias, and serious impression due to small 
sample sizes with few events and a wide confidence interval.   
Although the included studies in this review stated that, no reported adverse effects related 
to the procedures of OPC administration to preterm infants in the first few days after birth, 
selective reporting bias (an outcome non-reporting bias (490)) is a potential concern. As all 
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the studies had no pre-defined adverse effects and described adverse events narratively 
such as no adverse events with the intervention and no numerical data were provided, 
therefore, the estimates are not precise, and meta-analysis was not conducted. Additionally, 
the methods used in monitoring adverse effects, and the duration and frequency of 
monitoring were not detailed by the authors. However, the lack of data does not necessarily 
indicate that the intervention is safe. Furthermore, the studies were not blinded, have small 
sample sizes, and OPC was provided by different procedures. Some methods could be 
associated with a higher risk of adverse effects, such as using a syringe to provide fluid to an 
infant may increase the risk of aspiration compared to using a swab (510). Previous studies 
have suggested the safety of OPC but so far studies were not powered or designed to 
assess adverse effects (353-355, 422).   
All the included trials were able to administer OPC within the first 48 hours of life; this is 
indicating that collection of sufficient volume of colostrum within the first 48 hours of life is 
possible which support the feasibility of OPC. Likewise, previous studies also have reported 
the feasibility of OPC (354, 366, 422).  
3.5.4 Agreements and disagreements with other reviews 
Based on a comprehensive search strategy, this is the first Cochrane review addressing the 
use of OPC in preterm infants. This review focuses on OPC administration within the first 48 
hours of life. There is a previous systematic review (413) published in 2014 that assessed 
the effect of oral therapy with colostrum compared with no colostrum in ill newborn infants. 
The authors concluded that there was no strong evidence for supporting the efficacy of 
colostrum oral care in reducing morbidity and mortality for sick neonates. Although the 
previous review included different study designs (observational, retrospective, RCTs, non-
randomised studies) without meta-analysis unlike this review which only included RCTs and 
undertook meta-analysis, the findings were generally consistent with this Cochrane review.  
Of note, a recent systematic review was published in July 2018 while this Cochrane review 
was in the process of publication. The recent review (511), was a narrative review conducted 
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to address the impact of OPC on the health of preterm infants; similarly, the authors’ s 
conclusion was generally consistent with this Cochrane review; however, it included studies 
with variable methodology; RCTs, non-RCTs and observational studies. This narrative review 
had some drawbacks such as failure to retrieve many studies (355, 358, 366, 419, 422) 
which were potentially relevant to its criteria.  
3.5.5 Overall completeness and applicability of evidence 
Participants in the included trials were very or extremely preterm infants with very low birth 
weight. One study reported that five of 30 participants were small for gestational age (Glass 
2017) while all the included trials did not indicate small for gestational age or compromised in 
utero such as abnormal maternal Doppler as exclusion criteria. The majority of the trials 
included ventilated infants, and only Rodriguez 2011 included the need for “vasopressor 
medications at a dosage of > 10microg/kg/min” as an exclusion criterion. Therefore, the 
review findings should apply to most preterm and very low birth weight babies. Additionally, 
all the included trials were conducted in high-income countries. Therefore, studies from low-
income countries would improve the generalisability of future studies. 
3.5.6 Potential bias and limitations 
Potential publication bias was the main concern with this review. An extensive search with no 
language and regional restrictions was conducted including reference lists of the included 
trials and relevant studies. Proceedings and abstracts of major perinatal conferences were 
also searched for any unpublished study, an attempt to minimise any publication bias. 
However, it is possible that some relevant studies may still have been missed. There were 
insufficient studies to perform a funnel plot analysis to explore possible publication or 
reporting bias (495). However, for this review publication bias could not be assessed as all of 
the included studies are small, and most of the trials have been registered in a clinical trials 
registry. Moreover, that these studies reported insignificant results makes it less of likely as 
publication bias arises when there is a tendency for the publication of large trials and 
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acceptance and publication of manuscripts based on positive results rather than negative or 
null results (512, 513).   
Reporting bias was another concern; incomplete reporting of the results by some of the 
included trials. To minimise this bias trials authors were contacted for additional information 
when needed, many of them provided missing data which were reported in the review. The 
majority of data included in the analyses were obtained from study reports (published or 
unpublished), and additional information was provided by study authors. Mota Ferreira 2016 
reported continuous outcomes as a median (IQR), and mean (standard deviation (SD)) was 
not available on request. Therefore, a normal distribution was assumed and mean ± SD was 
estimated (494). Moreover, intention-to-treat analysis (ITT) was not conducted by some 
studies. ITT analysis, which is highly endorsed to estimate the unbiased effect of an 
intervention in RCTs (514, 515), was applied when missing or unclear data were provided by 
the study authors.  
Furthermore, to ensure that any bias in the review is avoided, all the stages (study search, 
screening of search result, data extraction and analysis and assessment of the risk of bias 
and quality of studies) of the review were conducted independently by the review authors.  
The review results were limited by lack of participants with just of few eligible small trials 
enrolling a low number of participants and events and some outcomes being reported only by 
one trial.  
3.6 Conclusion 
Despite the risk of bias and the low quality of the studies, this systematic review presents 
updated information regarding the available evidence on the use of OPC in preterm infants 
and provides data for designing future clinical trials, which are still needed. 
3.6.1 Implications for practice 
Based on the currently available studies, there was insufficient quality evidence to ascertain 
if oropharyngeal administration of colostrum to preterm infants during the first 48 hours of life 
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can reduce the risk of NEC, late-onset infection, or death until discharge in preterm infants. 
There was a trend towards earlier attainment of full enteral feeding with OPC but no impact 
on the length of hospital stay. Results from an ongoing study may alter these conclusions.  
3.6.2 Implications for research 
Does OPC prevent mortality and morbidities in preterm infants? Could OPC be implemented 
as a part of the standard care for preterm infants?  There appears that no high-quality 
evidence to answer those questions and additional, larger RCTs are required to answer 
these questions conclusively and assess the efficacy and safety of OPC in the care of 
preterm infants. Therefore, large well-designed randomised controlled trials are needed to 
assess the efficacy and safety of OPC in the care of preterm infants.  
Future trials should be powered to assess the effects of OPC on clinically critical and 
important outcomes such as NEC and LOI. A preceding consensus on dose and procedure 
of OPC administration, inclusion of the most immature and smallest (including growth-
restricted) infants with other intensive care needs (such as mechanical ventilation and 
inotropic support) will enable broader application of the evidence to groups at highest risk. 
Trials should also aim to evaluate the impact of OPC on prematurity-related long-term 
morbidities such as neurodevelopmental outcomes and chronic lung disease. Large, 
observational, prospectively designed studies can be undertaken to address adverse effects 
and long-term outcomes.  As OPC can be provided by parents and caregivers, the 
involvement of parents and infants carers in designing trials may highlight important 
outcomes especially those related to the satisfaction of the parents.  
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Chapter 4. The impact of oropharyngeal administration 
of mother’s colostrum on the clinical outcomes of 
preterm infants: a case-control study 
 
4.1 Chapter overview  
Chapter 2, showed that the UK neonatal units have adopted the use of OPC despite lack of 
evidence and recommended by the neonatal professionals. The Cochrane systematic review 
(Chapter 3) also showed that no published randomised controlled trial (RCT) investigated the 
effects of OPC in preterm infants in the UK. The study described in this chapter was then 
designed to investigate whether there is an association between OPC and clinical outcomes 
of preterm infants in the UK. It was prospectively designed and utilised data collected from 
patient medical records (medical notes and electronic patient records) using the UK National 
Neonatal Database (BadgerNet Neonatal) and the UK National Health Services (NHS) 
Trust’s Digital Health Records (DHR)). This study had a favourable opinion from the Faculty 
of Medicine & Health Sciences Research Ethics Committee, University of Nottingham (UoN): 
A09102016 Audit 16-086C (Appendix 6).                             
4.2 Background  
Preterm infants (born before completed 37 weeks of gestation) are a population at high risk 
of morbidity and mortality.  Although advances in neonatal care have led to increases in 
survival rates, premature infants carry a high burden of short and long-term morbidities. 
Further discussion of prematurity-associated complications is described in Section 1.1.8.     
OPC is a new practice introduced to deliver colostrum to preterm infants. It was postulated 
that early OPC (i.e. during the first week of life) could stimulate the immune system and 
protect the infant from infections and other conditions such as necrotising enterocolitis (NEC) 
(353, 356, 358, 516). More details about the compositions and benefits of colostrum and 
OPC were given in sections 1.1 1 and 1.16.  
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4.2.1 Case-control study 
A case-control design is a category of observational studies. Observational studies are 
classified under analytical designs and subdivided into cohort, case-control and cross-
sectional studies. In observational studies, there is no intervention conducted by the 
investigators; the researchers observe and assess the association between exposure and 
outcomes or disease (517).     
The case-control study was first recognisably used in 1926 in a study, evaluating risk factors 
for breast cancer (518) and it became more famous in the biomedical research after the 
publication of a study that reported the association of smoking and lung cancer in 1950 
(519).  
In a case-control study, cases are identified by a predefined exposure, treatment or outcome 
which could be an intervention such as drug treatment or a surgical procedure, faced an 
adverse effect or suffered from a disease. Data from these cases are then compared with 
those of selected controls from the same population as the cases but without the exposure, 
treatment or outcome. Data are usually collected retrospectively.  A case-control study is a 
useful design for evaluating associations between diseases and risk factors, and 
investigating rare diseases and outcomes (520); however, unrecognised confounders may 
bias the findings. RCTs are the gold-standard design for evidence-based medicine and 
classified as Level-I evidence (521). RCTs could bridge the gap regarding efficacy, safety 
and feasibility for interventions, however, the generalisation and implementations of the 
intervention in the standard care remain under the health services and in certain situations, 
RCTs might be questioning to conduct (522). As health services focus on more broad 
populations, they still depend on observational studies especially in evaluating practices, 
regional variations and national health outcomes (523).  
Although observational studies (classified as Level-II and III evidence (521)) such as case-
control studies can be especially useful when RCTs would be unethical, but they may also be 
used to generate hypotheses and data for future studies (442, 520). Moreover, they have the 
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advantages of being less expensive, quicker to conduct and usually need fewer cases in 
comparison to cohort and cross-sectional studies. However, case-control studies have been 
criticised because of the potential risk of selection and recall bias (517) and the inability to 
determine causal relationships.  
4.2.2 Use of secondary data in research 
Secondary data was defined as data that are collected for purposes other than the research 
for which they have been used and originally were collected by other individuals (such as 
universities, governments, institutions and hospitals) who were not involved in the research 
(524). Whilst collecting data by the researcher is more useful to answer a specific research 
question; however, it is not possible nor feasible to obtain all the required data, especially in 
longitudinal observational studies. Therefore, using secondary data is a practical tool for data 
collection and usually represents larger population or all population of a country and provide 
more comprehensive data sets (524); these may broaden the external validity of the 
research. 
Using secondary data is cost-effective and saves time as most of the secondary data have 
pre-set statistical software that could provide the researcher with ready coded data in 
downloadable files for analysis (525).  The breadth and the depth of secondary data 
strengthen the quality of the data especially governmental and national data sets (526); this 
advantage may power the quality of the research which, used those secondary data 
especially retrospective studies.  
Secondary dataset usually designed and weighted by individuals who are specialised and 
experienced in the topic of the data set (524). For instance, data representing a subgroup of 
a population, such as the National Neonatal and Statistics Database, and specific disease 
registries, may provide the researchers with data that are more detailed and a larger sample 
regarding their target population especially if the target sample of low prevalence. Moreover, 
using secondary data might assist the researchers with long-term follow up as some of them 
are longitudinal data that have been collected over a long period (524). Secondary data also 
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offers the researchers with opportunities to compare their results with others who used the 
primary and secondary data. Therefore, secondary data analysis has been used in this 
study.  
However, using secondary data has some disadvantages; lack of data related to the 
research questions and how the data was collected or the data may have different definitions 
for research specific variables (525). Therefore, it is important to know what the primary 
objective of the secondary data was. In contrast to primary data, requesting additional data, 
or follow-up data could not be conducted when using secondary data (526) and it may not 
provide information regarding a very recently adopted guidelines or policies.     
4.2.3 Electronic Health Records (EHRs) 
Information technology (IT) has been identified as an important empower to improve health 
care services. Electronic health record was defined as a digital recording of patients and 
population health information on a longitudinal pattern. It was emerged after an initiative from 
the Institute of Medicine’s Quality of Health Care in America to improve and innovate the 
health care delivery system in 2001 (527).  EHRs is patient-centred records that allow secure 
and instant availability of patient’s information for authorised peoples. EHRs comprise very 
comprehensive information about patients’ medical histories, laboratory tests, diagnostic 
images, medications and progress reports from all clinical specialities that involved in the 
care of a patient (528, 529). A patient EHR is a real-time record that collates the patient’s 
current and past health information in one record, available anytime and anywhere; hence; 
the researchers could study health issues and interventions as occur in actual practice that 
may facilitate clinical implication of the findings (530). 
Furthermore, EHRs could be managed and assessed by multiple organisations and health 
providers; helping coordination between health services and institutions. Therefore, EHRs 
are useful tools for improving the availability and security of information and promising 
methods for national and international comparisons that would lead to improved health care 
(531). EHRs have many advantages such as  (529): 
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- easy and quick access to a patient’s records 
- reduction of medical errors and empowering a safer and reliable prescription 
- cost-effective by reducing paperwork, repetitions of laboratory tests and diagnostics 
images 
- improved decision making by incorporating the patient’s data from various sources 
- provide updated patient’s information 
- allow better communications between different health care services    
- save time by easier centralised patient management and provide specific-topic 
queries 
- enhance organisations and accuracy of health information 
- facilitate clinical audits, quality improvement and support research 
The use of EHRs also has some limitations such as (524, 532):  
- different primary purposes from the research questions  
- variability in the recorded patient’s data 
- design of the EHRs might have an impact on data extraction especially if the data 
entered in a text-free format 
- missing or insufficient data or both 
- accessibility to specific databases as authorisation is usually required.  
4.2.4 Neonatal databases in the UK 
Neonatal networks approach improves the quality of neonatal care (533), in 2003, the UK 
Department of Health highly recommended that neonatal units collaborate in the form of 
formally structured clinical, networks to provide safe and efficient maternal and neonatal care 
(403). Since 2004, neonatal data have been shared across neonatal units through EHRs 
(534). Initially started regionally and subsequently extended nationally in BadgerNet neonatal 
database. In 2007, the National Neonatal Research Database (NNRD) was established with 
the aims of improving clinical data records and neonatal services and assisting research, and 
currently, approximately 190 UK (England, Wales and Scotland) neonatal units contribute 
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data to NNRD (531, 535). The NNRD includes very comprehensive and precise data on 
every neonatal admission across the UK and covers all episodes of hospital stay for every 
newborn infant (Neonatal dataset, is an NHS approved Information Standard (535)). The 
BadgerNet neonatal is the primary source of data within the NNRD. The NNRD is approved 
by the National Research Ethics Committee; hence, for this study, the BadgerNet neonatal 
database was used as a source for data collection. 
4.2.4.1 BadgerNet neonatal database  
BadgerNet Neonatal Electronic Patient Record is a national database that provides an 
electronic recording of patient data in neonatal units throughout the UK (536). It was 
designed to assist the paperless recording of patient’s information within a neonatal unit and 
connect to BadgerNet data from other neonatal units; also permits daily recording of events 
occurring during the same period. BadgerNet Platform is produced and managed by a 
commercial medical software company; Clevermed Limited  (537), which has an agreement 
with the UK Trust to provide perinatal data management services for the BadgerNet platform 
(536). Clevermed provides secure data, live reporting of data and connects health networks 
in the UK. Moreover, it regularly updates the software according to the latest IT technology.  
BadgerNet neonatal offers comprehensive, detailed records for neonatal units; including 
detailed clinical and nursing notes, charting and handover, fluids management, procedures, 
medications, trend monitoring and clinical reviews. It also provides clinical summary reports 
such as admission, pregnancy and labour details and detailed discharge letters from 
recorded data during the stay at the neonatal unit (531).  
BadgerNet is a useful tool for data collection in clinical research, and most of the recorded 
items are similar to those required for research purposes and expected to be more valid than 
administrative data (538, 539). Furthermore, BadgerNet neonatal has been designed to offer 
easily searchable and extractable data for the researchers. However, missing data, lack of 
standardisation for some clinical variables could be significant limitations. In BadgerNet 
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neonatal, this issue has been minimised by using a structured list of items (540) and 
providing a descriptive dictionary for the data.  
Of note, data within the Badger Neonatal database are regularly assessed by the National 
Neonatal Audit Programme (NNAP), a project carried out by the Royal College of Paediatrics 
and Child Health (RCPCH) to assess and monitor the quality of care provided by the 
neonatal units in England, Scotland and Wales (414). The quality of the data is also 
monitored by the performing and publications of studies that evaluate the accuracy, validity 
and quality of  the recorded data (541). Therefore, BadgerNet neonatal has been recognised 
to be an appropriate, accessible and cost-effective source of data.  
4.2.5 Rationale of the study  
According to a survey of neonatal professionals presented in Chapter 2, OPC use is 
progressively increasing among UK neonatal units with variable practice between the units. 
However, to the best of my knowledge, no previous studies have explored the clinical impact 
or feasibility of using OPC in preterm infants in the UK.  In this chapter, I evaluate the effects 
of OPC administration on the health outcomes of preterm infants and assess the feasibility of 
performing this practice in the UK neonatal units.  
4.2.6 Hypothesis and aim 
This study hypothesised that administrating mother’s colostrum by the oropharyngeal route 
to preterm infants during the early neonatal period would lead to improved feeding tolerance 
of preterm infants, shorten hospital stay and improve nutritional outcomes while decreasing 
the incidence of prematurity-related morbidities.  
This study aimed to evaluate the impact of OPC during the early neonatal period on the 
short-term clinical outcomes of preterm infants and to generate pilot data to guide potential 
future research. 
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4.2.7 Objectives  
4.2.7.1 Primary objectives  
The primary objectives of the study were:   
- to assess the hypothesis that oropharyngeal administration of mother’s own 
colostrum is associated with improved feeding tolerance in preterm infants and 
shorter time to full enteral feeds 
- to evaluate the feasibility of assessing the efficacy in preterm infants. 
4.2.7.2 Secondary objective  
The secondary objective of this study was: 
- to determine if there are relationships between OPC administration and short-term 
clinical outcomes of preterm infants such as NEC, sepsis and nutritional outcomes. 
4.3 Methods  
In February 2017, in the UK, the Nottingham Neonatal Service (i.e. the Neonatal Units of the 
Queen Medical Centre (QMC) & City Hospital (CH) Campuses of Nottingham University 
Hospitals NHS Trust (NUH)), adopted OPC for the care of preterm infants as a quality 
improvement project supported by a guideline (396); Appendix 7). The two Nottingham 
neonatal units are neonatal intensive care units (NICUs), specialised in the management and 
care of preterm and sick newborn infants. They are the neonatal lead units for the Trent 
Perinatal Network; one of the clinically managed Operational Delivery Networks for the UK 
neonatal services (401). Together, the two neonatal units provide neonatal intensive care, 
high dependency care (24 beds) and special care (14 beds). The average annual admission 
of babies to the units is approximately 1500 babies with preterm infants (less than 37 weeks 
gestation) constituting about 45% of the total yearly admissions.      
4.3.1 Study design 
The study design was an observational, historical case-control study that compared preterm 
infants before, and after, the implementation of oropharyngeal colostrum guideline in the care 
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of preterm infants. It was a single centre study conducted at the two Nottingham neonatal 
units (QMC and CH) in the UK.  
A matched case-control design was chosen to minimise potential confounding by reducing 
baseline differences between the two groups. Controls were matched for the well-known risk 
factors that influence the outcomes of preterm infants (151, 542). The controls were matched 
to OPC cases by sex, gestational age and the closet birth weight, in a ratio of 2:1 to increase 
the power of the study and ensure comparability between the study groups (543). Pre-
defined inclusion and exclusion criteria were used to avoid possible selection bias that can 
limit the validity of research using this type of study design (517). 
The study compared two groups: an intervention group (OPC) and a control group (Pre-
OPC). The OPC cohort included preterm infants admitted to the neonatal units after the 
adoption of OPC (February, 2017) and received OPC by the unit guideline. The control group 
(Pre-OPC) was identified from preterm infants admitted to Nottingham neonatal units before 
the adoption of OPC use.  
4.3.2 Participants 
Participants were preterm infants < 32 weeks’ gestation or/ and ≤1500g birth weight. For the 
intervention (OPC group), eligible infants were identified from the neonatal units at the QMC 
and City hospitals. For the control (Pre-OPC) group, participants were identified from the list 
of preterm infants admitted to the two Nottingham neonatal units before the adoption of OPC 
using the BadgerNet Neonatal for the Nottingham neonatal service.   
4.3.2.1 Inclusion criteria  
- Gestational age less 32 weeks. 
- Birth weight of 1500g or less. 
- Admission to neonatal units within 96 hours of birth. 
4.3.2.2 Exclusion criteria 
- Major congenital anomalies. 
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- Maternal HIV infection. 
- Maternal drug use as a known contraindication to breastfeeding. 
Other exclusion criteria for enteral feeding in the neonatal units, such as inotrope use did not 
constitute exclusion criteria for this study.  
4.3.3 Data collection 
4.3.3.1 Source of data  
Data were collected from the infants’ medical records. For the OPC group, the data were 
collected prospectively from the infant’s medical notes, nursing charts and records. Badger 
Neonatal database and the NHS Trust’s DHR were also used as needed such as when the 
infant discharged to a postnatal or paediatric ward. For the Pre-OPC group, all data were 
primarily extracted from the Badger Neonatal database. The NHS Trust’s DHR has also been 
used if data were missed or unavailable in the Badger database.   
4.3.3.2 Types of data  
The following demographic and clinical data of the participants were collected: 
- Date of birth, date & time of admission to the neonatal unit, gestational age, sex, birth 
weight, date of hospital discharge. 
- Clinical characteristics of each infant such as: 
o mode of delivery, multiple gestations, delivery room resuscitation, 1 & 5-min 
Apgar score, non-invasive ventilation, mechanical ventilation, central line 
placement, nasogastric tube, use of parenteral nutrition and medications 
o detailed feeding history, including; type of milk, mode of feeding, date of 
commencement, volume received during the intervention, date of attainment of 
full enteral feeding and discharge feeding 
o morbidities during the hospital stay, including; NEC defined as Bell’s criteria 
stage II or more, clinical or culture-proven late-onset sepsis, pneumonia and 
any serious complications 
o death 
o weight and clinical status on discharge home. 
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- Administration of oropharyngeal colostrum included; time of starting, the frequency of 
OPC, the number of doses and total volume received by an infant, days of receiving 
OPC and adverse effects related to the OPC procedure. 
- Maternal history, depending on data that were available from the infant’s record and 
included; age, multiple pregnancies, pre-eclampsia, premature rupture of membrane, 
prolonged rupture of membranes (>12hours), antibiotic therapy, antenatal steroid 
administration, antenatal infection, other medical illness.  
4.3.4 Outcome measures 
4.3.4.1 Primary outcomes  
- Days to attain full enteral feeding defined as (150 ml/kg/day) sustained for 72 hours.  
- Feasibility of OPC administration defined as an infant received OPC within 96 hours 
of life and received 50% or more of the planned doses.   
4.3.4.2 Secondary outcomes  
- Length of hospital stays to discharge home (days). 
- Days to start enteral feeds (gavage, oral feeding or both). 
- Days of parenteral nutrition received by the infant. 
- Days of mechanical ventilation the infant had.   
- Incidence of NEC (defined as modified Bell’s criteria ≥ II (167). 
- Late-onset sepsis (LOS): clinically suspected and culture confirmed after 72 hours of 
life. 
- Adverse events within 60 minutes of OPC administration:  
o bradycardia - decrease in heart rate to <100/min 
o tachycardia - increase in heart rate to >200/min 
o tachypnea - increase in respiratory rate to >80/min 
o apnoea - cessation of breathing for >20 seconds 
o decrease in oxygen saturation (SpO2 %) to <80%  
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o milk aspiration (an episode of choking/milk in the mouth with consistent chest 
X-ray changes).   
Data related to OPC administration was not available in the electronic databases (Badger 
and Trust DHRs), data for adverse events were exclusively and prospectively collected 
from the infants’ record charts at the neonatal units. Nursing reports and medical notes 
were also used for collecting these data. A study-specific form was created for collecting 
data for OPC administration, including the adverse events (Appendix 8). 
- Incidence of death before discharge to home. 
- Rates of breastfeeding at hospital discharge to home (exclusive/mixed/none). 
- Weight at hospital discharge. Weight-for-age Z (WAZ) score was used to assess 
weight against weight for age percentiles.  WAZ score was calculated using clinical 
actual age percentile Z-score calculator (544).  
Weight-for-age, height-for-age and weight-for-height, Z-scores are widely recognised as 
the best approach to analyse and present anthropometric data (545). The Z-score is the 
number of standard deviations (SD) above or below the reference mean or median of a 
dataset (545). It can compare results across age groups. Z-score allows combining sex 
and age groups and can be computed as summary statistics such as means and SD that 
can be used to describe nutritional status for population (545). The cut-off point of <-2 SD 
to >+2 SD was used by the World Health Organization (WHO) to classify nutritional 
status child growth and malnutrition (546).  
4.3.5 Blinded Endpoint Reviews (BERs)  
BERs were performed for the outcome incidence of NEC during the hospital stay to 
determine definite NEC cases and ensure they have met the pre-specified criteria. Endpoint 
refers to a targeted outcome of a clinical study that can be measured objectively to 
investigate if the studied intervention has effects, such as survival, the incidence of disease, 
and quality of life (547). BERs are used to reduce the risk of variation in important clinical 
outcomes. 
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NEC is a critical clinical outcome with significant short and long-term sequelae in preterm 
infants. Lack of consistent case-definition may potentially lead to difficulty deciding if an 
infant had NEC (548), and may also lead to variation in reporting NEC cases in the Badger 
neonatal database where data are documented as part of routine clinical care.  
Two clinicians (subspecialist neonatal registrars) independently reviewed the information of 
all cases of a possible diagnosis of NEC among the study cohort. The reviewers were also 
masked/blind to the study groups. The two reviewers were independent of the study to avoid 
any possible perception bias. If a consensus could not be reached, cases would be 
discussed with a third reviewer (consultant neonatologist). Based on the final decisions of the 
reviewers, NEC has been recorded as confirmed or not occurring.  
A BERs form (Appendix 9), containing data on all cases potentially diagnosed with NEC, was 
prepared and submitted to the reviewers as either as a paper or electronic copy based on 
reviewer preference. Every reviewer assessed each case and completed the form and 
returned it to the study investigator. The two independent reviews were compared for each 
case, and whenever the reviews did not agree, this was clarified by discussion between the 
two reviewers.  
4.3.6 Statistics  
4.3.6.1 Sample size 
This study was originally powered to demonstrate a likely difference in the primary outcome 
(time to full enteral feeds). The sample size was based on the results of previous studies 
[estimated mean ± SD, Pre-colostrum: 29.3 ± 15.6; Colostrum: 25.3 ± 12.8 days); p = 0.02 
(353)] and [mean ± SD, Placebo: 24.17 ± 8.66; colostrum: 14.29 ± 5.74); p = 0.03 (417)], 
assuming a mean difference in the time for attainment of full (150ml/kg/day) enteral feeds of 
four days between the two groups. With a significance level of 0.05 and power of 80%, 111 
infants would be needed to detect a clinical difference of four days in the primary outcome 
(days to full enteral feeds). It was also based on the cases being matched by a 1:2 ratio with 
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controls (2 controls per 1 OPC case; 37 for the OPC group and 74 for the pre-OPC group) to 
increase the strength of the study. 
After the study commenced, it became apparent that hazard ratio analysis was a more 
appropriate and powerful way to analyse these data. A post hoc power calculation was 
therefore; performed before assessing the data using this method. Based on two to one 
allocation ratio, an alpha of 5% (nQuery software power calculation (46)), found that the 
study sample size of 111 infants provided approximately 80% power to detect a hazard ratio 
of 0.5 or 90% power to detect an HR of 0.45, assuming minimal drop-outs. 
4.3.6.2 Statistical analysis  
Statistical analysis was conducted using the Statistical Package of the Social Science 
version 23 (IBM 2013, (549)) for Windows and statistical significance described with a p-
value of <0.05.  
Continuous variables were tested for normality using histograms. Data were described 
according to the data distribution as a mean ± standard deviation (SD) for normal distribution 
and median (interquartile range (IQR)) for skewed data. Comparisons between the study 
groups, for continuous variables, and differences in outcomes were summarised using 
independent t-tests for parametric data and Mann Whitney U tests for non-parametric data.   
Categorical data were presented using descriptive analysis (frequencies and percentages), 
and the Pearson Chi-Square test or Fishers’ exact tests were used for comparison between 
the two groups.  
Survival analysis was used to analyse time to event variables such as time to reach full 
enteral feeds, length of hospital stay, days of parenteral nutrition and days of mechanical 
ventilation.  Multivariate analysis was conducted to address potential confounding when 
there were statistically significant differences between the study groups. 
Reliability analysis, using Krippendorff alpha (Kalpha), was conducted to evaluate agreement 
between the reviewers of the BERs and the study investigator. Kalpha (550) is a reliability 
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coefficient that used in content analysis to determine agreement among independent raters, 
observers or measuring instruments; however, it is applicable where two or more approaches 
are performed to the same unit of analysis. Kalpha differs from other reliability coefficients, 
such as Cohen’s Kappa, in that it can be applied to a various number of observers, 
categories and sample sizes. It also applies to any scale or measurement levels such as 
nominal, ordinal, interval or ratio and allows for reliability with missing data (550). Kalpha’ s 
range is 1 ≥ α ≥ 0, Kalpha > 0.8 indicates strong inter-rater reliability (551).    
4.3.6.3 Dealing with missing data 
As this study was a single centre, matched case-control study, participants were similar for 
most of the baseline characteristics. Therefore, data were analysed by the complete case 
basis; for each variable; only those infants with complete data are included in the final 
analysis. 
Sensitivity analyses were also performed for missing data. A variable was considered 
incomplete if ≥ 5% was missing. Sensitivity analysis is another approach to assess the effect 
of missing data on the final analysis.  In this analysis, possible values are imputed for the 
missing data using different scenarios such as worst-case and best-case scenarios and hot 
deck imputation (552, 553). Worst and best case scenarios involve replacing missed values 
with favourable outcomes in one group and poor outcomes in the comparison group.  Hot-
deck imputation is a method (552) that involves replacing the missed data with a value from 
a similar available case within the same study. In this study, I used the data of the 
corresponding matched case for every missing value. If the results are consistent with each 
scenario, the results should be more robust.  
4.3.7 Ethical considerations  
4.3.7.1 Ethical approval 
The study was conducted as a clinical audit of practice against the current, Nottingham 
Neonatal Service Guideline (396), for the administration of OPC to infants in the NICUs 
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within the Nottingham University Hospitals NHS Trust (Audit number: ID 16-086C). According 
to the Health Research Authority (HRA) decision-tool (554), this study did not require the full 
Ethics Committee review. A favourable opinion was also received from the Faculty of 
Medicine & Health Sciences Research Ethics Committee, UoN (reference No: A09102016 
Audit 16-086C (Appendix 6)). The research was conducted according to the laws and 
regulations of the UK and the HRA (373).   
4.3.7.2 Data management and confidentiality   
The policy regarding the data of the study was as follows: 
-  ensure the confidentiality of participants 
-  ensure the secure storage of data. 
Each participant was allocated a study identity number (ID), for use on data collection 
sheets, and in the study electronic records, which also included a second anonymous 
identifier (Badger ID) as is considered best practice. A separate confidential record of the 
participant’s name, date of birth, Badger ID, local hospital number or NHS number, and the 
study ID was made to permit identification of all participants enrolled in the study in case 
additional follow-up was required. The master file linking the study ID with the infants’ 
identifiable information was kept securely and separately at the Division of Child Health, 
Obstetrics & Gynaecology (COG) of the UoN. 
The data collection sheets were handled securely according to ethical regulations and best 
practice.  The sheet was filled by hand using a black pen. Data were imported anonymously 
to electronic records, and all paper forms were stored in a locked cabinet in an authorised 
access restricted area in the Division of COG, UoN, according to the University of 
Nottingham Code of Research Conduct and Research Ethics (372).  Only members of the 
study team have access to this cabinet.  
The electronic data collection file was password-protected and stored in a secure dedicated 
web server (Z-drive, UoN) and a password-protected computer provided by the UoN. All 
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study documents were updated on 21. 05. 2018 according to the UK new General Data 
Protection Regulation (GDPR) (55) and Data Protection Act 2018 (56). 
4.3.7.3 Safety considerations 
The intervention was part of the care of preterm infants in Nottingham neonatal units. The 
study did not include samples or investigations beyond those considered as standard care in 
the neonatal units. All study data were routinely recorded clinical items that can be collected 
from infant health records. There was no direct contact with the participants’ families nor 
carers.  
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4.4 Results 
From March 1st 2017 to February 6th 2018, 1481 babies were admitted to Nottingham 
neonatal units at the Nottingham University Hospitals NHS Trust; QMC and City Hospital, UK 
of whom 593 infants were born before a gestational age of 37 weeks. One hundred sixty-
three infants were born < 32 weeks of gestation, and these infants were expected to receive 
OPC according to the unit guidelines. Infants were included in the study as soon as the infant 
received OPC.  
Based on the infant’s records, fifty-two infants who received OPC were identified, of these, 
15 infants were excluded (Figure 4.1). Thirty-seven infants who received OPC were therefore 
included in the study as the OPC group. The control (Pre-OPC) group consisted of 74 
matched preterm infants who were admitted before the implementation of OPC in the 
neonatal units; from December 2012 to December 2016 (Figure 4.1). 
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Figure 4.1 Study flow chart 
Selection of participant infants. n: number of infants; OPC (oropharyngeal colostrum) group; 
the intervention; Pre-OPC group: the control 
15 infants were 
excluded: 
- 5 infants were >32 
weeks’ gestation 
- 9 infants received 
only one dose of OPC 
- One received OPC 
after 96 hours 
postnatal age  
74 infants were matched 
based on; sex, gestational 
age and closet birth 
111 babies included in the 
study and final analysis 
- OPC group (n = 37) 
- Pre-OPC group (n = 74) 
Retrospective Pre-OPC cohort 
Selected infants were born between   
December 2012-December 2016 
52 infants received OPC 
per the unit’s guideline 
37 infants fulfilled the 
study inclusion criteria 
163 were preterm < 32 
weeks’ gestation 
593 were preterm < 37 
weeks’ gestation 
OPC was adopted by the Nottingham 
neonatal units, February 2017 
Prospective OPC cohort 
1481 babies were admitted between 
March 1st 2017-February 7th 2018 
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4.4.1 Baseline characteristics 
4.4.1.1 Infants’ characteristics   
The study sample was predominately male (64.9%). The mean ± SD gestation age was 27.6 
± 2.37 weeks, and the mean ± SD birth weight was 1042.5 ± 343.51 g. As matched groups, 
gestational age, gender and birth weight were similar between Pre-OPC and OPC groups 
(Table 4.1). There were no statistically significant differences in the baseline characteristics 
of the infants between the Pre-OPC group and the OPC group. Table 4.1 compares the 
infants’ baseline characteristics by study group.  
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Table 4.1  Infants baseline Characteristics 
Characteristic 
Pre-OPC  
(n = 74) 
Post-OPC  
(n = 37) 
p value 
Male*, n (%) 50 (67.6%) 25 (67.6%) 1.0f 
Gestational age*, week Mean± SD 27.6±2.37 27.5±2.41 0.98t 
Birth weight* g,  Mean ± SD 1041.2 ± 337.98 1045.6 ± 359.04 0.95t 
Weight/GA, n (%) 
AGA 
SGA 
 
70 (94.6) 
3 (4.1%) 
 
34 (91.9%) 
2 (5.4%) 
1.0f  
Weight Z score at birth, Mean± SD 0.039 ± 0.70 0.035 ± 0.76 0.97t 
Agar at 1 min, Median (IQR) 6 (4, 8) 6 (4, 8) 1.0 U  
Apgar at 5 min, Median (IQR) 8 (7, 9) 8 (6.75, 9)   0.71U 
First Admission temperature Mean ± SD 36.59 ± 0.56 36.52 ± 0.30 0.69t 
Inotropes, n (%) 30 (40.5%) 14 (37.85%) 0.83f 
IUGR, n (%) 9 (12.2%) 4 (10.8%) 0.87f 
Major congenital anomalies, n (%) 5 (6.8%) 3 (8.1%) 1.0f 
Postnatal steroid therapy, n (%) 14 (18.9%) 6 (17.6%) 1.0f 
CLD 39 (52.7%) 12 (35.3%) 0.12f 
Received EBM during stay in neonatal 
unit 
72(97%) 37 (100%) 0.55 f 
OPC: oropharyngeal colostrum; n: number; SD: standard deviation; AGA: appropriate for 
gestational age; SGA: small for gestational age; LGA: large for gestational age; IQR; 
interquartile range; IUGR: intrauterine growth restriction; CLD: chronic lung disease; EBM: 
expressed breast milk; t: independent t-test; U: Mann-Witney test; f: Fischer’s Exact test.             
*: Matching criteria 
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4.4.1.2 Maternal baseline characteristics  
Most maternal characteristics recorded were also similar between the two groups, Table 4.2.  
Table 4.2  Maternal baseline characteristics 
 
There was a statistically significant difference between the two groups for the incidence of 
chorioamnionitis (p = 0.02). However, there were missing data for 9.9% (where data were not 
Characteristic 
Pre-OPC,  
(n = 74) 
Post-OPC  
(n = 37) 
P value f 
Missing 
data 
Multiple pregnancies, n (%) 
    Singleton 
    Twins,  
    Triplets 
 
53 (71.6%) 
20 (27%) 
1 (1.4%) 
 
28 (75.7%) 
9 (24.3%) 
0 (0%) 
0.88 0% 
Fetal presentation 
   Cephalic, n (%) 
   Breech, n (%) 
 
38 (52.1%) 
29 (39.7%) 
 
23 (62.2%) 
13 (35.1%) 
0.55 6.4% 
Mode of delivery 
   SVD, n (%) 
   CS, n (%) 
 
34 (45.9%) 
38 (51.4%) 
 
20 (54.1%) 
18 (48.6%) 
0.48 1.8% 
Antenatal steroid, n (%) 64 (86.5%) 35 (94.6%) 0.47 0.9% 
Prolonged rupture of membrane, 
n (%)  
29 (39.2%) 8 (21.6%) 0.16 6.3% 
Chorioamnionitis, n (%)  6 (8.1%) 2 (5.4%) 0.02 9.9% 
Preeclampsia, n (%) 9 (12.2%) 5 (13.5%) 0.08 4.5% 
Smoking during pregnancy, n 
(%) 
14 (18.9%) 4 (10.8%) 0.29  9.9% 
Abnormal antenatal Doppler  
    AREDF, n (%) 
5 (6.8%) 
42% 
3 (8.1%) 
47% 
0.26  49% 
Intrapartum pyrexia, n (%) 13 (17.6%) 1 (2.7%) 0.01 8.1% 
OPC: oropharyngeal colostrum; n: number; SVD: spontaneous vaginal 
delivery; CS: Caesarean section; AREDF: Absent or reverse end diastolic flow; 
f: Fischer’s Exact test. Values: frequencies (%) 
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recorded in the Badger database nor in the infants’ medical notes) unbalanced between the 
groups for these variables. Therefore, a sensitivity analysis was conducted to evaluate the 
effect of the missing data. Assuming the data were missing at random, using complete-case 
analysis yielded different results for the variable chorioamnionitis (from p = 0.02 to 1.0). I 
imputed the missing values using different scenarios; worst case (had chorioamnionitis and 
coded as yes) and best case (did not have chorioamnionitis and coded as no) as shown in 
Table 4.3.  
Table 4.3  Sensitivity analysis for chorioamnionitis 
 
Similarly, there was a statistically significant difference between the two groups for the 
incidence of intrapartum pyrexia (p = 0.01). However, there were missing data for 8.1%. The 
complete-case analysis yielded different results; the p value changed from 0.01 to 0.06. 
Missing data were also imputed; worst case (had intrapartum pyrexia and coded as yes) and 
best case (did not have intrapartum pyrexia and coded as no) as shown in Table 4.4. This 
indicates that the missing data may have an impact on the significant differences for these 
two variables.  
Assumption  
Pre-OPC with 
missing data 
(n=3) 
OPC with 
missing data 
(n=8) 
Chorioamnionitis P 
value f 
Pre-OPC OPC 
Worst Case Analysis Yes Yes 9 (12%) 10 (27%) 0.06  
Best Case Analysis No No 6 (8.1%) 2 (5.4%) 1.0  
Best-Worst Imputation  No Yes 6 (8.1%) 10 (27%) 0.01  
Worst-Best Imputation  Yes No 9 (12%) 2 (5.4%) 0.33f 
Hot Deck Imputation m NO/Yes NO/Yes 6 (8.1%) 5 (13.5%) 0.72  
OPC: oropharyngeal colostrum; n: number; Yes: Worst (had chorioamnionitis); No: Best (did not 
have chorioamnionitis); f:  Fischer’s Exact test; m: missed values are imputed based on values of 
the matched cases. 
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Table 4.4  Sensitivity analysis for Intrapartum pyrexia 
Assumption  
Pre-OPC with 
missing data 
(n=3) 
OPC with 
missing data 
(n=6) 
Intrapartum pyrexia P value 
f 
Pre-OPC OPC 
Worst Case Analysis Yes Yes 16 (21.6%) 8 (21.6%) 1.0  
Best Case Analysis No No 13 (17.6%) 2 (5.4%) 0.13  
Best-Worst Imputation  No Yes 13 (17.6%) 8 (21.6%) 0.61  
Worst-Best Imputation  Yes No 16 (21.6%) 2 (5.4%) 0.03  
Hot Deck Imputation m NO/Yes NO/Yes 13 (17.6%) 2 (13.5%) 0.13  
OPC; oropharyngeal colostrum; n: number; Yes: Worst (had Intrapartum pyrexia); No: Best (did 
not have Intrapartum pyrexia); f: Fisher’s Exact Test; m: missed values are imputed based on 
values of the matched cases. 
 
There were also missing data (per the study protocol, > 5%) for other maternal 
characteristics namely, fetal presentation, prolonged rupture of membrane, smoking during 
pregnancy and abnormal antenatal Doppler. There were no significant differences between 
the study groups for these variables (Table 4.2). However, a sensitivity analysis was 
conducted using complete-case analysis, which did not change the significant differences 
between the two groups for these variables. Therefore, further sensitivity analyses were not 
conducted.  
4.4.2 Administration of OPC 
The OPC group included 37 infants. OPC administration was started within the first 48 hours 
of life in 62 % of the participant infants (Figure 4.2).  
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Figure 4.2  Postnatal age of receiving OPC 
Postnatal age (hours) when preterm infants (<32 weeks) started OPC. Bar: percentage of 
infants; <24: (n=4); 24-48: (n=19); 48-72: (n=12); 72-96: (n=1); 96-120: 9n=1).                
OPC: oropharyngeal colostrum 
 
Based on the Nottingham Neonatal Service’s guideline for OPC, each infant would be 
expected to receive a total of 3.6 ml of colostrum divided into18 doses over 3 days. The median 
(IQR) volume of colostrum received by an infant was 2 (1.3, 2.8) ml. The Median (IQR) of OPC 
doses received was 10 (6, 12) doses (10/37 (27%) infants received <50% of the planned 
doses; 14/37 (38%) received 50-70% and 13/37 (35%) >70% doses).  
The mean ± SD duration of receiving OPC by an infant was 2.6 ± 0.7 days (Figure 4.3). During 
the period when OPC has been provided, only 7/37 (19%) infants received trophic feeding by 
nasogastric tube along with OPC administration. 
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Figure 4.3  Duration of receiving OPC 
Period (days) during which preterm infants (<32 weeks) received OPC; Bars: percentage of 
infants; one day: (n=3); 2 days; (n=12); 3 days: (n=20); 4 days: (n=2).                               
OPC: oropharyngeal colostrum 
 
4.4.2.1 Adverse effects with the OPC procedure  
Adverse events defined per the study protocol (section 4.3.4.2) and recorded within 60 minutes 
of OPC administration were reported. 
Based on the infants’ clinical records and using the adverse effects study-specific form, there 
were no adverse effects reported during the administration of OPC. Specifically, there were no 
bradycardia, tachycardia, tachypnea, hypotension, oxygen saturation decreases, and choking 
or aspiration events during or soon after, the OPC administration procedure.  
4.4.3 Primary outcomes  
4.4.3.1 Days to full enteral feeds 
Infants who received OPC achieved full enteral feeds faster compared to those who did not 
receive OPC. There was a statistically significant difference between the study groups in days 
to full enteral feeds, the median (95% confidence interval (CI)); (Pre-OPC: 18 (95% CI; 13.49 
to 22.50); OPC: 14 (95% CI; 9.61 to 18.38); p=0.004) Figure 4.4. 
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Figure 4.4  Days to full enteral feeding 
Kaplan-Meier plot demonstrating the probability of days to attain full enteral feeds among 
preterm infants (<32 weeks) who received OPC and those who did not receive OPC. The 
median for each group corresponds to the probability of 0.5. Green line: Pre-OPC group 
(n=74); Blue line: OPC group (n=37); Circle marker on each line: censored (died); p= 0.004 
(Log-rank test); OPC: oropharyngeal colostrum. 
 
Most infant and maternal characteristics were similar between the two groups except for 
maternal chorioamnionitis and intrapartum pyrexia. Therefore, Cox regression analysis was 
conducted to investigate the effect of maternal chorioamnionitis and intrapartum pyrexia on 
days to full enteral feeds. Cox regression showed that the effect of OPC did not change by 
adjusting for maternal chorioamnionitis (adjusted p = 0.004) and intrapartum pyrexia 
(adjusted p = 0.005), Table 4.5. However, the variables maternal chorioamnionitis and 
intrapartum pyrexia had significant numbers of missing data (9.9% and 8.8% respectively), 
which were unbalanced between the two groups (Table 4.3, Table 4.4). Regression analysis 
for maternal chorioamnionitis, using complete case analysis, did not change the estimate of 
the OPC effect (unadjusted Hazard ratio (HR): 1.83 (p = 0.01); adjusted HR: 1.81 (p = 0.01)).  
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NEC is a critical clinical outcome for preterm infants, and the study cohort had a high NEC 
rate that was reported more often in the Pre-OPC group. In univariate analysis, NEC was a 
significant predictor of days to full enteral feeds. There was a statistically significant 
difference for the days to full feeds between infants with NEC (median (95% CI): 37 (95% CI; 
15.8 to 58.2) and infants without NEC: 13 (95% CI; 11.6 to 14.4) days; p = 0.001), Figure 4.5. 
 
Figure 4.5  Days to full enteral feeding and NEC 
Kaplan-Meier plot demonstrating the probability of days to attain full enteral feeds among 
preterm infants (<32 weeks) who had NEC and those who did not have NEC. The median for 
each group corresponds to the probability of 0.5. Green line: NEC (n=18); Blue line: no NEC 
(n=93); p= 0.001(Log-rank test); Circle marker on each line: censored (died); NEC: 
necrotising enterocolitis 
 
Although there was no statistically significant difference in the incidence of NEC between the 
study groups, another model was undertaken to investigate whether NEC might confound the 
effect of OPC on days to full enteral feeds. In a multivariate Cox regression, adjusting for 
NEC slightly decreased the effect of OPC (adjusted p = 0.02). OPC remained a significant 
dependent predictor for days to full feeds; however, NEC was a weak confounder effect on 
this association. In a multiple regression model to further control for the covariates; confirmed 
NEC, maternal chorioamnionitis and intrapartum pyrexia made a slight difference to the 
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effect estimate (unadjusted HR: 1.90; adjusted HR: 1.71; adjusted p=0.02), OPC remained a 
significant factor (Table 4.5). 
Table 4.5  Cox regression for the effect of OPC on days to full enteral feeds in preterm 
infants (<32 weeks gestation) 
 HR (95% CI) P value 
Unadjusted analysis 1.90 (1.22, 2.96) 0.004 
Adjusted for NEC 1.74 (1.12, 3.15) 0.022 
Adjusted for Maternal chorioamnionitis  1.99 (1.26, 3.06) 0.004 
Adjusted for maternal intrapartum-pyrexia  1.98 (1.25, 3.14) 0.005 
Fully* adjusted analysis 1.71 (1.06, 2.74) 0.026 
HR: hazard ratio; CI: confidence interval; OPC: dependent variable 
*: multiple regression model adjusted for confounders NEC, maternal chorioamnionitis 
and intra-partum pyrexia; NEC: necrotising enterocolitis 
 
4.4.4 Secondary outcomes 
4.4.4.1 Length of hospital stay  
The mean ± SD of the length of hospital stay for the study population was 67.6 ± 34.54 days. 
Survival analysis showed no significant difference between the two groups in the length of 
hospital stay, median (95% CI); (Pre-OPC: 73 (95% CI; 61.5 to 84; OPC: 62 (95% CI; 58.4 to 
65.5); p = 0.84). The Kaplan-Meier graph also showed close approximation and crossing of 
the two curves (Figure 4.6). Therefore, Cox regression analysis to explore potential 
confounders could not be performed.  
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Figure 4.6  Length of hospital stay 
Kaplan-Meier plot demonstrating probability of the length of hospital among preterm infants 
(<32 weeks) who received OPC and those who did not receive OPC. The median for each 
group corresponds to the probability of 0.5. Green line: Pre-OPC group (n=74); Blue line: 
OPC group (n=37); p = 0.84 (Log-rank test); Circle marker on each line: censored (died); 
OPC: oropharyngeal colostrum. 
 
4.4.4.2 Postnatal day of starting enteral feeding 
The number of infants available for this analysis was 109/111 (98%) infants; (Pre-OPC: 
73/74; OPC: 36/37 infants) as two infants died before receiving any enteral feeds. There was 
a statistically significant difference between the two groups for postnatal days of starting 
enteral feed, median (IQR) (Pre-OPC: 5 (3,10) days; OPC: 4 (2, 5) days; p = 0.006), Figure 
4.7.    
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Figure 4.7  Days of starting enteral feeding 
Box & whisker plot displaying, the median days of starting enteral feeding for the Pre-OPC 
and OPC groups. The top and bottom sides of the box represent IQR. The horizontal line 
inside the box is the median. Green box: Pre-OPC (n = 73); Blue box: OPC group (n =36); P 
= 0.006 (Mann-Whitney U test); Asterisks and circles: extreme values (outliers). OPC: 
oropharyngeal colostrum; IQR: interquartile range  
  
4.4.4.3 Days of parenteral nutrition  
There was no difference between the study groups in days of parenteral nutrition, median 
(95% CI) (Pre-OPC: 15 (95% CI; 10.77 to 19.22) days; OPC: 15 (95% CI; 10.34 to 19.65) 
days; p = 0.30). The Kaplan-Meier graph showed partial overlapping and crossing of the two 
curves, which may point to an inconstant hazard ratio over time (Figure 4.8). Therefore, Cox 
regression analysis could not be conducted. 
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Figure 4.8  Days of parenteral nutrition therapy 
Kaplan-Meier plot demonstrating probability of days of parenteral nutrition (PN) among 
preterm infants (<32 weeks) who received OPC and those who did not receive OPC. The 
median for each group corresponds to the probability of 0.5. Green line: Pre-OPC group (n = 
74); Blue line: OPC group (n = 37); p = 0.30 (Log Rank test); Circle marker on each line: 
censored (died); OPC: oropharyngeal colostrum. 
   
4.4.4.4 Days of mechanical ventilation 
There was no statistically significant difference between the two groups in days of 
mechanical ventilation, the median (95% CI); (Pre-OPC group: 8 (95% CI, 3.91 to 12.08 
days; OPC; 5 (95% CI, 0.43 to 9.56 days); p = 0.22). Although there was a separation of the 
two curves between 5 to 40 days that indicating fewer days of mechanical ventilation in the 
OPC group, there was a close approximation in the extremes, which may point to an 
inconstant hazard ratio over time (Figure 4.9). 
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Figure 4.9 Duration of mechanical ventilation 
Kaplan-Meier plot; demonstrating probability of days of mechanical ventilation (MV) among 
preterm infants (<32 weeks) who received OPC and those who did not receive OPC. The 
median for each group corresponds to the probability of 0.5. Green line: Pre-OPC group 
(n=74); Blue line: OPC group (n=37); p =0.22 (Log Rank test); Circle marker on each line: 
censored (died); OPC, oropharyngeal colostrum.  
 
Further comparison showed no significant difference in days of mechanical ventilation 
between 5-40 days of age, median (IQR); (Pre-OPC: 17.5 (9, 30); OPC: 17 (7.5, 27.7) days; 
p = 0.58). Gestational age, birth weight and sex were similar between the two groups for 
those infants (Table 4. 6).  
Table 4.6  Characteristics of infants received mechanical ventilation for 5-40 days 
Characteristic 
Pre-OPC 
(n = 35) 
Post-OPC  
(n = 14) 
p 
value 
Male, n (%) 25 (71%) 9 (64%) 0.73f 
Gestational age, weeks median (IQR) 25.5 (25. 27.5) 25.2 (24.6, 27.2) 0.40U 
Birth weight, g  median (IQR) 800 (720, 995) 795 (724, 1000) 0.91U 
OPC: oropharyngeal colostrum; n: number; IQR: interquartile range; f: Fischer’s Exact test; 
U: Mann-Whitney U test; statistical significant: p<0.05 
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4.4.4.5 Incidences of NEC and LOS 
The incidences of suspected NEC and clinically suspected LOS in the study population were 
53.2% and 96.4% respectively. There were no statistically significant differences between the 
study groups in the incidences of clinically suspected, NEC and LOS (p =0.84; p =0.6 
respectively). 
The incidences of confirmed NEC and culture proved LOS in the study cohort were 16.2% 
and 33.3% respectively. There were no statistically significant differences in the incidence of 
confirmed NEC and confirmed LOS between the study groups as demonstrated in Table 4.7.  
Table 4.7  Incidences of NEC and LOS 
Outcome 
Pre-OPC group 
n= 74 
OPC group 
n=37 
P value (f) 
Clinically Suspected NEC  40 (54%) 18 (51%) 0.84 
Clinically Suspected Sepsis 72 (97%) 35 (95%) 0.60 
Confirmed NEC 15 (20.3%) 3 (8%) 0.08 
Culture proved LOS 27 (36%) 10 (27%) 0.39 
OPC: oropharyngeal colostrum; n: number of infants; NEC; necrotising enterocolitis; LOS: 
late-onset sepsis; values: frequencies (percentage); f: Fisher’s Exact test; statistical 
significant: p<0.05. 
 
Of note, in the study cohort NEC was commonly seen (18/111 (16.2%); surgical NEC: 11/18 
(61.1%); medical NEC: 7/18 (38.9%)). The Pre-OPC group showed a higher NEC rate than 
the OPC group although this did not reach statistical significance (p = 0.08; Table 4.7). 
Further analysis showed that in the two study groups, infants with NEC were inborn and 
admitted within the first day of life. Table 4.8 demonstrates the criteria of NEC cases by the 
study groups.  
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Table 4.8  Criteria of infants with NEC 
Criteria  Pre-OPC 
(n=15) 
OPC 
(n=3) 
P value f 
Gestational age* 25.9 (25, 28.3) 25 (24.6, 26.7) 0.44U 
Birth weight*  790 (710, 955) 740 (687.5, 770) 0.44U 
IUGR, n (%) 2/15 (13.3%) 1/33 (33.3%) 0.55 
Twins, n (%)  4/15 (26.7%) 0 (0%) 0.55 
Medical NEC, n (%) 7/15 (47.7%) 1/3 (33.3%) 1.0 
Surgical NEC, n (%) 8/15 (53.3%) 2/3 (66.7%) 1.0 
Death, n (%) 3/15 (20%) 1 (33%) 0.55 
*: median (interquartile range); n = number; f: Fisher’s Exact test; U: Mann-Whitney 
test; statistical significant: p<0.05; NEC: necrotising enterocolitis; OPC: 
oropharyngeal colostrum 
 
To identify definite NEC cases, blinded endpoint reviews were conducted to assist in data 
validation. Blinded data for twenty cases with a possible diagnosis of NEC were reviewed by 
two clinicians. The two reviews were matched; two cases were excluded, and further 
information was requested for one case. A consensus was reached and the occurrence of 
NEC was confirmed for 18 infants who were included in the analysis of the outcome 
incidence of NEC during a hospital stay. There was also a strong agreement between the 
study investigator and the two reviewers (Krippendorff α: 0.86 (95% CI: 0.72 to 1.0). 
4.4.4.6 Death before discharge home 
There was no statistically significant difference in mortality before discharge to home 
between the two groups (Pre-OPC: 8/74 (10.8%); OPC: 2/37 (5.4%); p = 0.71).  
4.4.4.7 Weight at discharge to home 
To report on the weight in a standardised mode, the weight-age-Z score was used to 
compare the weight gain between groups.  At birth, the two groups were similar (p = 0.97), 
Table 4.1.  
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At discharge to home, 101 infants who survived were included in the analysis (Pre-OPC: 
66/74 (89%): OPC: 35/37 (95%) infants). There was no statistically significant difference 
between the two groups for WAZ score at discharge to home; median (IQR) WAZ scores 
(Pre-OPC: -1.40 (-2.22, -0.670); OPC: -1.50 (-2.30, -0.90); p = 0.65) Figure 4.10.  
 
Figure 4.10  Median weight Z score at discharge to home 
Box & whisker plot displaying, the median weight Z scores at hospital admission and 
discharge home for the Pre-OPC and OPC groups. The top and bottom sides of the box 
represent interquartile range. The horizontal line inside the box is the median. Green box: 
Pre-OPC; Blue box: OPC group. At Birth: Pre-OPC: n = 74; OPC: n=37 (p = 0.97); At 
discharge: Pre-OPC: n = 66; OPC: n = 35 (p = 0.65) (Mann-Whitney test U); OPC: 
oropharyngeal colostrum.  
 
4.4.4.8 Breastfeeding at hospital discharge 
Ten infants died before hospital discharge, therefore; analysis of this outcome included 
101/111 infants (8 infants from the Pre-OPC group and 2 form the OPC group).  
4.4.4.9 Receiving any breast milk at discharge to home 
There was a statistically significant association between OPC use and receiving any breast 
milk at discharge to home (Pre-OPC: 35/66 (53.0%); OPC: 28/35 (80.0%); p = 0.01 
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(Fischer’s Exact test)), Figure 4.11. There was no significant difference between the study 
groups in receiving expressed breast milk (EBM) during stay in the neonatal unit (p = 0.5; 
Table 4.1). However, the volumes of EBM received by the infants were not analysed as data 
were not available for the Pre-OPC group. 
 
Figure 4.11  Receiving any breast milk at discharge home 
Bar chart comparing receiving any breast milk at discharge home among preterm infants 
(<32 weeks’ gestation) who received OPC and those who did not receive OPC; Bar: 
percentage of cases; Green column: Pre-OPC group (n = 66); Blue column: OPC group (n = 
35); Yes: infants received any breast milk; No: infant did not receive any breast milk;               
* p = 0.01 (Fischer’s Exact test); OPC: oropharyngeal colostrum  
 
4.4.4.9.1 Type of milk and method of feeding at discharge home 
Overall, there was a statistically significant difference between the study groups in the type of 
milk at discharge home (p = 0.04; Figure 4.12). Post hoc pairwise comparisons demonstrated 
that the difference in the proportion of infants in the groups who were discharged to home on 
formula milk and mixed types of milk remained statistically significant (corrected p = 0.02). 
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Figure 4.12  Type of milk at discharge 
Type of milk at discharge home among preterm infants (<32 week’s gestation) who received 
OPC and those who did not receive OPC. Bars: percentage of infants; Green column: Pre-
OPC group (n = 66); Blue column: OPC group (n = 35). Mixed: breast milk and formula;        
*** p = 0.04; **: p = 0.02 (Fisher’s Exact test); OPC: oropharyngeal colostrum 
 
Whilst, there was a significant difference between the two groups for the type of milk being 
used at discharge to home, there was no statistically significant difference (p = 0.17) in the 
method of feeding at discharge home as demonstrated in Table 4.9. 
 
Table 4.9  Methods of feeding at discharge home 
Method 
Pre-OPC group 
(n = 66) 
OPC group 
(n = 35) 
P value 
(f) 
Suckling at breast 9 (13.6%) 4 (11.4%)  
Bottle  38 (57.6%) 21 (60%)  
Multiple  16 (24.2%) 10 (28.6%) 0.17* 
OPC: oropharyngeal colostrum; n: number of infants; Multiple: > one method (breast 
and bottle or breast and cup or nasogastric tube (NGT); f: Fisher’s Exact test; *: overall 
p value. Values: frequencies (percentage). 
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4.5 Discussion  
4.5.1 Key findings  
OPC administration was associated with earlier commencement of enteral feedings and 
faster attainment of full enteral feeds in preterm infants <32 weeks’ gestation. Rates of 
breastfeeding and breast milk use were also higher at discharge to home in those infants 
who received OPC in the first 96 hours after birth. There were no significant differences in 
confirmed NEC, the length of hospital stay, and weight Z score (at discharge home) between 
the study groups. The occurrence of microbiologically proven sepsis and death was similar 
between the OPC and Pre-OPC groups. Infants and maternal characteristics that could be 
anticipated to contribute to the study outcomes revealed no significant differences between 
the study groups except for maternal chorioamnionitis and intrapartum pyrexia (Table 4.2).   
4.5.2 Primary outcomes      
The OPC group achieved full enteral feeds faster than the Pre-OPC group at 14 versus 17 
days respectively and started enteral feeds earlier than the Pre-OPC group. A higher rate of 
maternal chorioamnionitis was found in the Pre-OPC group compared to the OPC group. 
Maternal chorioamnionitis has been recognised as a potential risk factor for NEC (555-557), 
which might be initiated by exposure to infection in the uterus (558), thus, may indirectly 
impact infant feeding as withholding feeds is one of the medical treatment of NEC (146).  
However, in the Cox regression analysis, adjusting for maternal chorioamnionitis, OPC 
remained a significant predictor for time to achieve full enteral feeds. Though, this earlier 
achievement of full enteral feeds associated with the administration of OPC could be 
confounded by other factors such as NEC. Although there was no statistically significant 
difference between the study groups in the incidence of NEC, a higher percentage of NEC 
was noted in the Pre-OPC group. A univariate analysis showed that NEC was a significant 
factor associated with days to full enteral feeds. NEC also remained a significant 
independent predictor after multivariate regression (Table 4.5). 
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Earlier initiation of enteral feeds and quicker achievement of full enteral feeds (defined here 
as 150 ml/kg/day in this study) have also been reported in previous studies conducted to 
assess outcomes of VLBW infants after implementation of a standardised feeding protocol 
including OPC use (353, 377, 417). Nonetheless, other clinical trials that were on-going in 
the period of this study could have affected the results. For instance, the Speed of Increasing 
milk Feeds Trial (SIFT), a multicentre RCT which evaluated the impact of two speeds of 
advancing the rate of milk feeds in preterm infants (<32 weeks gestation) (559). The SIFT 
trial had been conducted and completed enrollment (From June 2013 to June 2015) during 
the Pre-OPC period. The SIFT reported that infants who were fed faster (30ml/kg/day) 
reached full enteral feeds quicker than those infants who were fed 18ml/kg/day (7 versus 10 
days) (conference abstract had been granted by the author) (559). However, the enteral 
feeding guidelines in the NICUs did not change along with the adoption of OPC practice in 
Nottingham neonatal units. Similarly, a meta-analysis from a Cochrane review (560) (Chapter 
3) also showed an association between OPC and faster attainment of full enteral feeds in 
preterm infants (<37 weeks’ gestation); however, the studies included in the review were low-
quality evidence. In contrast, other recent studies reported no difference in the time to start 
enteral feeds or to achieve full enteral feeds between preterm infants who received OPC and 
those who did not (356, 358, 366). However, these previous studies were small unblinded 
RCTs and one was an observational study before and after the introduction of OPC in the 
care of VLBW infants.  
The earlier commencement of enteral feeds and faster achievement of full enteral feeds 
might be related to the exposure of the oropharyngeal mucosa to immune and growth factors 
found in colostrum (236, 238). These bioactive factors are present in higher concentrations in 
colostrum from mothers who deliver preterm infants than mothers who deliver full-term 
infants (192, 274, 275, 561) suggesting the importance of providing mother’s colostrum in the 
early neonatal period.  Although the current study demonstrated a significant difference 
between the Pre-OPC and OPC groups in days to full enteral feeds, the confidence interval 
was wide, indicating that the sample size was small. Studies with larger sample sizes with 
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complete data on variables for risk adjustment could support the association between OPC 
and shortened days to full enteral feeds.  
Despite, faster achievement of enteral feeds was associated with OPC use, there was no 
statistically significant difference in weight Z score at discharge to home between the two 
groups. Likewise, there was no statistically significant difference (p= 0.21) between the study 
groups in the length of hospital stay. Previous studies (353, 417, 506) also reported that OPC 
use was not associated with a reduction in the length of hospital stay. In contrast, a recent 
randomised controlled trial (358) assessed the effects of OPC on the oral immuno-microbial 
environment in preterm infants < 32 weeks of gestation reported a statistically significant 
reduction in the length of hospital stay in infants who received OPC compared to controls (40 
versus 56 days). However, the study did not explain the causality of the reduced hospital 
stay associated with OPC use, but other variables would be expected to be dealt with by the 
randomisation.    
4.5.3 Secondary outcomes    
There was no statistically significant difference in the incidence of confirmed NEC between 
the study groups. Overall, the whole study population had a reasonably high NEC rate of 
16.2 %, which might be in part due to the low gestational age and birth weight (mean 1040g) 
in the study cohort as the incidence of NEC is inversely related to the gestational age (78).  
Approximately 70% of NEC cases in this study were <27 weeks’ gestation with a mean birth 
weight of 750g (Table 4.7). Since infants born <28 weeks or VLBW infants are at a higher 
risk of complications including NEC (164, 170), which was estimated to affect 10-15% of 
those infants (78), this finding is plausible and suggests the likelihood of incorrect attribution 
is low.  
Although there was no statistically significant difference between the study groups, confirmed 
NEC was reported more often in the Pre-OPC group; this could be related to a higher rate of 
maternal chorioamnionitis among this group compared to the OPC group (p=0.02). 
Chorioamnionitis has been indicated as a potential risk factor for developing NEC (556, 557), 
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though a systematic review was inconclusive about the effect of chorioamnionitis on the risk 
of NEC (555). Some previous studies showed high NEC rates in VLBW and ELBW infants. In 
Canada, a prospective cohort study reported that the incidence of NEC was 14% for infants 
22-25 weeks gestation and 10% for 26-28 weeks infants; a 5.9% reduction was associated 
with the use of colostrum and EBM as a part of Quality Improvement Program (562). 
However, the program involved multiple interventions; therefore, reduced NEC rate might be 
attributed to the whole program, as the authors did not adjust for individual intervention. 
Likewise, a retrospective study of quality improvement found a significant reduction in the 
incidence of NEC after the implementation of a standardised feeding protocol, which included 
OPC; NEC was reduced from 18% to 3% in VLBW and from 35% to 8% in ELBW infants 
(377). However, other factors, such as an occurrence of other interventions at the same time, 
may confound this association.  
NEC rate that was reported in this study contrasts to a recent study that including data from 
the UK, reported a very low incidence of NEC (3.15%) in infants < 32 weeks gestation, 
however, the authors reported only on severe cases of NEC that confirmed by surgery or 
autopsy, or death (80).  Conversely, EPICure, a population-based study conducted to 
determine survival and morbidities for extremely preterm infants in England, reported 8% of 
laparotomy confirmed NEC among infants between 22-26 weeks’ gestation (59). However, 
EPICure did not report on medically treated NEC; this may underestimate the incidence of 
NEC in those infants. The NEC (defined as Bell stage 2 or 3) rate was similar at 10% in the 
Probiotics in Preterm Infants Study (PiPS), an RCT, which investigated the effect of probiotic 
on the rate of NEC, sepsis and death in infants <31 weeks of gestation (142). However, the 
incidence of NEC is variable between hospitals, nationally and internationally, a recent 
systematic review reported NEC rates ranging from 5% to 22% in infants with a birth weight 
<1000g among developed countries (365).  
The current study presented NEC episodes documented in electronic patient records 
(BadgerNet Neonatal), which included medical and surgical NEC. Lack of consistent case-
definition may potentially lead to difficulty deciding if an infant had NEC, this may lead to an 
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overestimation/underestimation of NEC rate. For example, diagnosing feeding intolerance as 
a stage of NEC or medically treated spontaneous intestinal perforation might be erroneously 
diagnosed as NEC (548). Similarly, some of the Bell’s staging criteria, such as pneumatosis 
intestinalis and portal vein gas, are less manifested in extremely preterm infants (563). 
However, to minimise variation in reporting NEC case in Badger neonatal database, 
additional sources such as radiology, histopathology reports and death certificates, were 
used to determine definite NEC cases.  
Furthermore, Blinded Endpoint Reviews (547) were performed to determine definite NEC 
cases and ensure they have met the pre-specified criteria. BERs (also referred to as 
Endpoint Adjudication) (547) is an important part of clinical research for validating data, 
especially when the endpoints are subjective and require expertise to assess and apply a 
complex definition. The reviews are conducted by clinicians who have expertise in the 
relevant area for the study (564). These reviewers should also be trained in keeping with the 
principles of Good Clinical Practice (GCP) and compliant with the Data Protection Act. Such 
endpoint assessment can facilitate a study achieving higher scientific quality (564). 
Noteworthy, the sample size of this study was too small to infer the incidence of NEC as 
conclusive.  
OPC use was also associated with a higher rate of feeding any breast milk at discharge to 
home (80% versus 53%) although similar rates of EBM were used during the hospital stay in 
the two groups (Table 4.1). Additional detail on EBM volumes received by infants may have 
provided further information on the effect of OPC administration on the type of milk at 
discharge home. As these data were not available for the Pre-OPC group, such an analysis 
was not possible. This might be important as the benefits of human milk have been shown to 
have a dose-response effect (281, 284).  
Breastfeeding and breast milk use at discharge to home were higher in the OPC group while 
significantly fewer infants in this group were receiving formula alone at discharge. In a recent 
RCT, Romano-Keeler et al. also observed a statistically significant effect of OPC on receiving 
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any breast milk at discharge home in infants <32 weeks GA compared to controls (358). 
However, this was a small unblinded RCT. Similarly, a prospective observational study (565) 
found an association between OPC use and receiving breast milk as the main enteral feed at 
six weeks postnatal age, and at hospital discharge in VLBW infants. Conversely, a recent 
Cochrane review (Chapter 3) did not demonstrate an effect of OPC on receiving any breast 
milk at discharge to home in preterm infants (<37 weeks) (560).  
The rate of breast milk feeding in the Pre-OPC group is comparable to reported UK rates 
(58-60%) of feeding any breast milk at discharge home for infants less than 33 weeks 
gestation from 2012 to 2016 (414). It is also similar to the rates of receiving any breast milk 
at discharge home in the Nottingham population (54%) according to 2016 data from Trent 
Perinatal & Central Newborn Neonatal Networks (414). The observed association of OPC 
with a higher rate of receiving any breast milk might be explained by the encouragement of 
the mothers to express breast milk as early as possible to provide OPC to their infants. 
Interestingly, the Nottingham Neonatal Service’s guidelines to support breastfeeding and 
educate mothers on the benefits of breast milk did not change over the study period, and the 
feeding guideline has not been updated since 2014. This supports the change in the 
breastfeeding at discharge being due to OPC introduction.  
However, breastfeeding and the use of breast milk has risen since the 1990s; the WHO 
reported that globally >80% of newborn infants receive breast milk during the neonatal period 
and exclusive breastfeeding rates were increased by 10% from 1993 to 2013 (566). The UK  
EPICure2 studies also found that in 2006, the use of any breast milk was increased by 10% 
from 1995 in infants < 26 weeks gestation; approximately 96% of those infants received 
some EBM during a stay in the neonatal units, and 43% were receiving breast milk at 
discharge to home (59). Additionally, the UK implemented the Baby Friendly Initiative, a 
global program of the United Nations International Children's Emergency Fund (UNICEF) 
and the World Health organization (WHO) for improving practice to support breastfeeding 
(567). Hence, in this study, the pattern of breast milk feeding that was observed for the OPC 
group might reflect a continuation of an existing trend.  
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There were no statistically significant differences between the two groups in the incidence of 
proven sepsis, death before discharge home, and days of PN or mechanical ventilation.  
While some studies (353, 377) have found that OPC might reduce the risk of these common 
prematurity-related morbidities, other studies have not shown effects on some of these 
morbidities (356, 357, 417, 506). However, these previous studies were not powered to 
detect significant differences in prematurity-related complications such as NEC or sepsis. 
There is an ongoing multicentre RCT to evaluate the impacts of OPC on the incidence of 
NEC, sepsis and death in extremely preterm infants (target sample, n = 498 infants) (352).  
4.5.4 Feasibility of OPC use in neonatal units  
OPC appears to be a safe intervention in the care of preterm infants as no adverse events 
were reported for the infants during the OPC procedure.  
Although data regarding adverse events were collected from routinely reported data on the 
clinical records, every effort was made to minimise this potential reporting bias; by using all 
available clinical records including nursing charts and reports and the medical notes. 
Moreover, a study-specific adverse events form was created to collect these data 
prospectively (Appendix 8).  Nevertheless, this result is in line with growing evidence 
suggesting the safety and feasibility of OPC administration in very low birth weight (VLBW) 
and extremely preterm infants (354, 358, 422, 506).  Despite inconsistencies in methods and 
sample sizes, these studies were consistent in demonstrating that the OPC procedure was 
not associated with adverse effects such as bradycardia, a decrease in O2 saturation or 
aspiration. However, the current study and the previous studies were not powered to 
evaluate the safety of OPC use in preterm infants.  
The practice of OPC administration was feasible, and mothers were able to provide 
colostrum at the planned time, as approximately 60% of the infants who received OPC did so 
within the first 48 hours of life. In previous studies, it was possible to start OPC within the 48 
hours after birth (353, 354, 417, 506, 561) while other researchers were able to administer 
 184 
 
OPC after the second postnatal day and reported that it was impractical to apply OPC within 
the first 24 hours after birth (356, 419).  
OPC feasibility was also determined by the percentage of the planned doses and the 
frequency of administration (352, 356, 422). Completed OPC administration was defined as 
receiving more than 70% of the expected doses. In this study, approximately 73% of the 
infants received 50%-70% of the doses; some of the missing doses could be explained by 
unavailability of the mother's colostrum at the scheduled dose. Nine infants had been 
excluded from the study because they received only one dose of OPC as it was assumed 
that receiving one dose will not provide enough information to conclude. Exclusion of those 
infants may have affected the feasibility result. However, OPC administration was stopped to 
use colostrum for trophic feeding rather than for providing OPC once trophic or enteral 
feeding started. This possible non-feasibility could be attributed to understanding and 
adherence to the clinical guideline for OPC administration and a decision of the treating team 
as OPC administration is still under the discretion of the clinical team of the infant.  Although 
the exclusion of those infants may have influenced the feasibility findings, availability of 
mother’s colostrum and an attempt to provide OPC within 96 hours indicate potential 
feasibility in the excluded infants. 
Of note, in some infants, OPC was discontinued before the completion of the planned period 
for its administration when trophic/enteral tube feeds were started despite guidance to the 
contrary. This could be related to the very recent adoption of OPC practice in Nottingham 
neonatal units, and that the educational and training program supporting staff to implement 
this new guideline, may have been insufficient to ensure consistent adoption of the practice 
across the two Nottingham units.  
Clinical guideline implementation can be hindered by a variety of barriers that may lead to 
failure of adherence to the guidelines (568, 569). However, to enhance the implementation of 
the OPC guideline, reminder letters along with the OPC guideline were sent to the attending 
Nottingham neonatal unit consultant at the time of their service (Appendix 10).  A Nurse 
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Information sheet was also created and distributed (Appendix 11). It is likely that OPC use 
could be further improved by educational or quality improvement strategies that influence the 
attitudes, awareness and understanding of the guideline by relevant professionals. This is 
especially the case for neonatal nurses, as OPC is mainly administrated by nurses.  
4.5.5 Strengths and limitations of the study 
To the best of my knowledge, this is the first study in the UK evaluating the impact of early 
OPC administration on the clinical outcomes of preterm infants from birth to discharge to 
home.  Whilst other studies have assessed the effects of OPC in different settings, almost all 
of these studies evaluated the use of OPC in very low and extremely birth weight infants and 
extremely preterm infants, this study included infants up to 32 weeks of gestation. Moreover, 
the current study included comprehensive data analysis from a single centre limiting 
variations in treatment with just one guideline. Another strength was that most of the data 
were extracted from a neonatal database which uses a national standard coding system and 
predefined data items to enhance the accuracy and comparability of the data (531).  
In order to minimise differences, eliminate bias and ensure comparability between the cases, 
the study was designed as a matched case-control study. Each case was individually paired 
with a control infant relating to sex, gestational age and birth weight; as these criteria are 
well-known factors that influence the outcomes of preterm infants (143, 151, 542); also, the 
matched cases were selected from the closest year to the period of the study. Moreover, two 
controls per case were used to increase the power of the study so that, even though the 
sample size of this study was small, the results may generate hypotheses and preliminary 
data for future studies; particularly for sample size calculations.  
Finally, to enhance transparency, ensure complete reporting and minimise potential reporting 
bias, Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (570) 
recommendation was used in writing up the study findings. STROBE constitutes a checklist 
of 22 items to help improve the appropriate reporting of cohort, case-control and cross-
sectional studies to strengthen completeness and transparency in analysing and reporting of 
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observational studies (571). STROBE statement has been endorsed by many biomedical 
journals and by the International Committee of Medical Journal Editors (572). 
This study had several limitations. It compared two different groups of preterm infants before 
and after the adoption of OPC use. The non-parallel comparison may bias the findings due to 
possible differences in the care of preterm infants between the two study periods (517). 
Therefore, the findings might not be entirely attributable to the OPC use. However, in the 
current study, the feeding protocol, management of NEC and sepsis did not differ between 
the two eras.  
Other research studies that were conducted during the same period of this study might have 
altered the outcome of preterm infants independent of the effect of OPC practice (534). The 
finding of the SIFT trial could have influenced the comparison between the Pre-OPC and 
OPC groups in the current study (559).  Enteral lactoferrin supplementation for very preterm 
infants (ELFIN), a recently published RCT (208) that evaluated the effects of enteral 
lactoferrin supplementation on late-onset sepsis in preterm infants (< 32 weeks gestation), 
was also on-going during period of the present study. ELFIN trial found that enteral 
lactoferrin had no effects on late-onset sepsis and its related complications. It appears that 
ELFIN results were unlikely to affect the results of my study. 
As an observational study, a causal relationship could not be assessed and, as data from the 
Pre-OPC group was collected retrospectively, it was susceptible to information bias (442, 
520).  
OPC use also faced some challenges; such as administration of OPC often being 
discontinued when enteral feeds were started despite guidance to the contrary. The OPC 
protocol used in this study had some differences from the protocol used in previous research 
particularly in the frequency and duration of the OPC administration. These differences might 
have contributed to the disagreement with some of the previous study findings. The OPC 
protocol was chosen to fit in with the nursing practices in the units as there was insufficient 
evidence to determine the optimal regime. Additionally, Nottingham neonatal units adopted 
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OPC shortly before this research study, and although a guideline supported it, the application 
of OPC remained the responsibility of the treating clinical team, providing the opportunity for 
individual decision making and practice. With more education and regular reviewing of the 
OPC guideline along with wider adoption, it is likely that results could be further improved.   
4.6 Conclusion 
OPC appears to be a feasible practice in the care of preterm infants. It was possible to 
collect the mother’s colostrum within the first 48 hours after birth, and approximately 60% of 
the infants (included in the study) received OPC during the first 48 hours of life.  
OPC was associated with significantly reduced days to initiate enteral feeds and days to 
reach full enteral feeds. A higher rate of breastfeeding at hospital discharge was also 
observed. Although this study did not find statistically significant differences in the length of 
hospital stay, days of mechanical ventilation, the incidence of NEC and sepsis, and deaths 
before hospital discharge, with larger sample size, these may have been significant. 
The study provided insight into the implementation of a new guideline and if it was well 
integrated into the standard care. The study found that OPC delivered to the preterm infants 
was often not in keeping with the current OPC guideline. Improvements could likely be 
achieved by more and repeated education of the healthcare professionals to establish a 
better OPC practice in the neonatal service. Furthermore, parents could be encouraged to 
administer OPC to their baby, this practice may offer the parent an active role in providing 
care for their baby and ensuring it is given more often. 
4.6.1 Implications for clinical practice  
It is apparent from the results of this study, and previous studies that using OPC in preterm 
infants appears to have positive impacts on the time to start enteral feeds and achieve full 
enteral feeds. Therefore, despite, high-quality evidence being limited, OPC seems to have a 
promising role in the standard care of preterm infants. Moreover, the well-known benefits of 
mother’s colostrum for preterm infants and the potential safety and low cost of OPC 
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procedure may outweigh the high risks of mortality and morbidities, such as devastating NEC 
and infection, in these infants. 
4.6.2 Implications for future studies 
There is still uncertainty whether OPC administration could improve health outcomes for 
preterm infants. Meta-analysis of available trial data in a Cochrane review including high-
quality studies is a worthwhile venture and is presented in Chapter 3 of this thesis. 
Depending on the findings of the meta-analysis, further research using large, adequately 
powered, randomised controlled trials are required to assess the efficacy of this intervention. 
Such studies also offer the potential to identify and elucidate the mechanisms of the effect of 
OPC.  
Additionally, studies comparing different protocols concerning procedural method, doses, 
frequencies and duration of the intervention are needed to optimise the practice of OPC and 
to set a standard protocol for administration of mother’s colostrum by the oropharyngeal 
route. Of note, as OPC does not require advanced technology, it can be implemented even 
in low- income countries where the rate of preterm birth is high (23, 177). Therefore, it is 
worth obtaining data from middle and low-income countries in future studies and synthesising 
these in meta-analyses to ensure generalisability of the results. 
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Chapter 5. Gut hormone response to oropharyngeal 
administration of mother’s colostrum to infants in 
neonatal intensive care 
5.1 Chapter overview 
In Chapter 3 (Cochrane review) and Chapter 4 (case-control study), it was concluded that 
using oropharyngeal administration of mother’s colostrum (OPC) in preterm infants appears 
to have positive impacts on time to start enteral feeds and to achieve full enteral feeds. With 
the introduction of trophic feeds, there are surges in the circulating gut hormones (306). Gut 
hormones (GutH) have essential role in the postnatal adaptations of the gastrointestinal tract 
(GIT) to prepare the infant for enteral feeding (573).  
In this Chapter, I present a study that was conducted to investigate the effects of OPC 
administration on plasma gut hormone concentrations in preterm and sick infants requiring 
Neonatal Intensive Care (NIC).  
5.2 Background  
Infants admitted to neonatal intensive care units require invasive therapies and the 
consequences of their underlying clinical condition be compounded by additional risks arising 
from the medical and nursing care they require. This research will focus on one aspect of 
preventing the complications which can accompany clinical care, i.e. feeding intolerance and 
the subsequent withholding of oral feeding during the early neonatal period. 
5.2.1 Feeding of newborn infants receiving intensive care 
Feeding is a significant challenge for preterm infants and those with congenital GIT 
conditions and an important factor affecting nutrition, growth, and later outcomes (290, 293). 
Unfortunately, the complex clinical conditions of some infants requiring NIC does not permit 
provision of enteral feeds in the critical days after birth. Withholding enteral feeding, and 
delays in achieving full enteral feeds promote intestinal atrophy and abnormal bacterial 
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colonisation of the bowel, leading to disturbance in gut hormones. This may contribute to the 
pathogenesis of necrotising enterocolitis (NEC) (574).  
Preterm infants especially extremely preterm (EXP) and extremely low birth weight (ELBW) 
infants are prone to poor postnatal growth. These infants are often born in a negative-energy 
balance; therefore, after birth, they have to catch-up a favourable growth, but at discharge 
from NICU, their weights are often below the 10th percentile for their completed weeks of 
gestation (332). In preterm infants, inadequate growth during the postnatal period was 
associated, with long-term consequences such as growth retardation, metabolic bone 
disease, and poor neurodevelopmental outcomes (103, 137). Similarly, rapid postnatal 
growth has been linked to obesity and insulin resistance that increase the risk for chronic 
adverse outcomes such as diabetes and cardiovascular diseases (107, 108). Therefore, 
interventions which have the potential to influence enteral feeding and energy balance that 
may enhance achievement to full enteral feeds, could also promote growth and improve 
outcomes for infants requiring NIC. 
5.2.2 Gut hormones during the neonatal period  
The GIT represents the largest endocrine gland in the body (575) containing many 
specialised cells secreting multiple regulatory peptides in response to nutrients (576). These 
multiple regulatory peptides, known as gut hormones, have important effects on the growth 
and functions of the GIT. The neuroendocrine cells of the gut produce hormones such as 
gastrin, gastric inhibitory polypeptides (GIP), peptide tyrosine tyrosine (PYY), glucagon-like 
peptide (GLP), insulin and pancreatic polypeptide (PP), which regulate gastrointestinal 
functions such as digestion, mucosal growth, blood flow, motility, repair and maintenance of 
mucosal integrity (577).  
After birth, the GIT is still growing and maturing; enteral nutrition is vital for intestinal growth 
and normal GIT function. This effect could be reflected by varying changes in the circulating 
concentrations of GutHs that may play a crucial role in postnatal adaptations of the gut. 
During the neonatal period, with the initiation of enteral feeds, there are significant elevations 
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in some of the plasma concentrations of GutHs (578, 579). This postnatal surge of different 
gut hormones is related to the infant’s feeding status rather than the infant’s gestational or 
postnatal age and occurs even with trophic feeding where a minute volume of milk 
<1ml/kg/hr is given via gastric tube (580). This normal postnatal increase in gut hormones is 
absent in those infants who do not receive enteral feeds (306, 574). High levels of certain 
GutHs have been linked with earlier attainment of full enteral feeds in preterm infants < 33 
weeks of gestation (581). Some gut hormones such as GIP, PYY, GLP and ghrelin have 
been proposed to be potential predictors for feeding intolerance, NEC, and postnatal growth 
of preterm infants (333, 582).  
The physiological and structural changes of the GIT, which occur after birth are complex 
processes. Gut hormone secretion in response to enteral feeds is one of the factors that 
influence these processes and circulating gut hormones might reflect enterocytes’ functions 
and the GutH axes (581). Therefore, understanding these regulatory hormones may 
contribute to improving the feeding strategies for preterm infants.  
5.2.2.1 Gut hormones studied  
5.2.2.1.1 Peptide tyrosine tyrosine (PYY) 
PYY is a peptide hormone secreted by the enteroendocrine cells of the terminal ileum and 
colon in response to ingestion of nutrients. PYY is a potent inhibitor for gastric acid and 
pancreatic secretions and gut motility (583, 584). PYY also has a central action binding to 
receptors in the brain to inhibit appetite (583). In newborn infants with the beginning of 
enteral feeding, there was a profound increase in the circulating PYY that reached higher 
concentrations compared to the adults’ levels, and it is further higher in preterm infants (584). 
The pattern of feeding during the neonatal period might explain these higher levels in PYY. 
Even though PYY has inhibitory effects on gastrointestinal motility, rising plasma PYY 
concentrations during the first week of life were associated with less days to attain full enteral 
feeds in preterm infants (581, 585). The rise in plasma PYY is believed to balance the effects 
of gastrin, which stimulates gastric acid secretion at birth and within the first 48 hours of life 
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(584). The inhibitory action of PYY on gastrointestinal motility could also be an adaptive 
response to allow a longer time for digestion and absorption (584), to prepare the newborn 
infants for enteral feeding. Therefore, PYY may be a potential indicator for the GIT transit 
regulation (581).  
5.2.2.1.2 Glucose-dependent insulinotropic polypeptide (GIP) 
GIP is also known as ‘Gastric inhibitory polypeptide’. GIP is one of the essential incretins, a 
peptide secreted by the small intestine (duodenum and jejunum) in response to ingestion of 
nutrients. It stimulates insulin secretion in response to the intake of food, particularly 
carbohydrates. It also enhances the generation of beta-cells of the pancreas (586). GIP is 
present in the brain, bone and adipose tissue, where it has trophic effects on the cells. 
Lucas et al. in a study of 100 preterm infants demonstrated that postnatal insulin response to 
enteral feeding might be related to the onset of GIP release. GIP was indicated as the 
primary effector of the enteroinsular axis (587) and its plasma concentrations during the 
neonatal period had a positive relationship with days to achieve full enteral feeds in preterm 
infants (581). Therefore, plasma GIP could be a potential marker for the integrity of the GutH 
axes and gut maturation to accept enteral feeds (581).  
5.2.2.1.3 Glucagon-like peptide 1 (GLP-1) 
GLP-1 is also an incretin hormone and is mainly secreted by the mucosa of the small 
intestine (terminal ileum) and the colon in response to nutrient intake. It is also secreted by 
the pancreas and the brain. GLP-1 stimulates glucose-dependent insulin secretion from the 
pancreas (588) and promotes proliferation of the pancreatic β-cells (589). GLP-1 has potent 
anabolic effects through its stimulation of insulin secretion; hence higher plasma 
concentrations may be beneficial for the metabolism and energy storage (590). Other 
functions of GLP-1 include inhibitions of glucagon secretion, gastrointestinal secretions and 
motility (588) and food intake (583), and it has neurotrophic effects on the brain (591).  
Preterm infants have higher fasting concentrations of GLP-1 than full-term infants (592). This 
higher GLP-1 concentrations in preterm infants could be attributed to the immaturity of 
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dipeptidyl peptidase (DPP)-IV; an enzyme degrades the active GLP-1 in the blood (593). 
GLP-1 is inversely related to the gestational age, and its concentrations increase in response 
to enteral feeding during the first few weeks of life reaching a peak higher than the adults 
(584, 590). Therefore, it was suggested that GLP-1 is an important peptide in the postnatal 
development and adaptation of the GIT (593). 
5.2.2.1.4 Ghrelin 
Ghrelin is a peptide hormone which is mainly secreted by the gastric mucosa with a small 
fraction produced by other organs such as the small intestine, pancreas, brain, heart, kidney 
and placenta (594). Ghrelin is a potent stimulant for growth hormone secretion. The 
widespread presence of ghrelin in many organs indicates that it has broad effects. Ghrelin is 
also an orexigenic hormone; it acts centrally at the hypothalamus to stimulate appetite, and 
high circulating ghrelin was found during fasting statuses (583).  Ghrelin contributes to the 
regulation of diverse processes including control of energy balance and body weight, 
metabolisms of glucose and fat, and modulation of GIT, and some cardiovascular, pulmonary 
and immune functions (595).  
After birth, the circulating ghrelin was low or even undetectable (581, 590); however, higher 
ghrelin concentrations were detected in the cord blood of small for gestational age (SGA) 
infants compared to appropriate for gestational age (AGA) infants (596). During the postnatal 
period, ghrelin release starts to increase at 2 to 3 weeks, and it is not correlated to enteral 
feeding (597, 598) but is inversely related to the anthropometric parameters of the infants 
(599, 600). The late increase of ghrelin in comparison to other hormones might be related to 
the requirement of ghrelin, as a potent growth hormone stimulant (335), during this stage of 
life when growth hormone starts to exert its actions. This pattern of ghrelin secretion could 
indicate that Ghrelin may play a role in intrauterine and postnatal growth (599), and its 
plasma concentrations might reflect the energy balance and postnatal catch-up growth of the 
infants (596, 601).  
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5.2.2.1.5 Insulin  
Insulin is a peptide secreted by the beta-cells of the pancreas in response to the blood 
glucose levels. It is the principal anabolic hormone and plays a fundamental role in metabolic 
regulation of the body. Insulin enhances cellular transport of glucose and stimulates glycogen 
synthesis and storage in the tissues (602). It also stimulates lipogenesis and protein 
synthesis. Insulin has inhibitory effects on the breakdown of glycogen in the liver and 
muscles and decreases fatty acid oxidation (603).  
Newborn infants have inefficient insulin secretion in response to changes in the 
concentration of blood glucose compared to older children and adults; this insufficient 
response is more manifested in preterm infants (604). In preterm infants, blood glucose 
concentrations are influenced by the administration of glucose rather to plasma insulin nor 
glucagon. Therefore, preterm infants are at higher risk for hypoglycaemia and 
hyperglycaemia at the neonatal period (605). The incretins, such as GLP-1 and GIP, 
stimulate insulin secretion through direct action on the β-cells of the pancreas; consequently, 
factors which influence GLP-1 and GIP secretion, promote insulin release (605). As, the 
patterns of insulin secretion during the neonatal period may programme the consequent later 
metabolic regulations (579, 606), the extent of insulin sensitivity of preterm infants during the 
neonatal period has been proposed as a potential indicator for long-term insulin-resistance 
(607).   
5.2.3 Immunoassay  
Immunoassay is a technique that involves the use of specific antibodies for identification and 
quantification of particular molecules in a sample. Immunoassays enable specific and 
sensitive detection of biomolecules in biological samples for research and clinical 
diagnostics. Traditional enzyme-linked immunosorbent assays (ELISA) was the most popular 
immunoassay procedure since the 1970s and is widely used in diagnostic medicine, quality 
control and research (608). ELISA is easy to perform, a very sensitive and specific technique 
for detecting and quantifying molecules and could be run at high throughput (609). Whilst 
 195 
 
ELISA has been the standard method, it identifies and quantifies only a single marker per 
assay and to identify several molecules, multiple analyses result in longer time and requires 
a larger sample volume (610).  
In certain clinical situations, quick analyses of multiple biomarkers are highly demanded, 
which may assist clinicians in earlier diagnosis and decision-making regarding treatment of a 
patient’s conditions. For example, advances in oncology led to the discovery of varieties of 
biomarkers for different cancers. Detection of those markers facilitated early pre-clinical 
diagnosis and had a remarkable impact on clinical management and prediction of outcomes 
(611). Moreover, in epidemic incidents such as cholera, identification of the bacteria and 
toxins early is exceptionally vital to protect the population (612). The need for fast 
simultaneous analysis of multiple markers, with high sensitivity, requires further methods 
being investigated to conduct immunoassays. Therefore, the multiplexed assay was 
developed as another method for immunoassays.  
5.2.3.1 Multiplexing technology 
Multiplex technology allows simultaneous analysis of multiple different molecules in a single 
sample. There are two approaches available to perform multiplex analysis namely, 
microarray-based technology, and bead-based, which utilising micro-carriers, such as 
microbeads. (613), For the study presented in this chapter, I focus on the microbeads’ 
approach.    
Microbeads-based multiplex assays enable simultaneous identification and quantification of 
different molecules in one sample and process several samples at the same time (610). 
Microbeads immunoassays have been used to analyse cytokines, hormones and growth 
factors in various samples (plasma, serum and tissue culture) acting as a direct approach for 
detecting biomarkers and currently being the most advanced multiplex immunoassay (614, 
615). 
As this study was included neonates (preterm and term infants) and investigated five GutHs, 
a method that can assay multiple hormones in a single small sample is worthy of use; 
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therefore, the magnetic-beads multiplex technique has been used for analysing the targeted 
GutHs. This method has been used in previous research that investigated gut hormones and 
biochemical metabolites in preterm infants (581, 590, 616, 617). Moreover, some of the 
different gut hormones have direct relationships with each other (585, 598); it would be 
advantageous to measure such hormones simultaneously from the same sample. The 
magnetic-beads multiplex assay will be further described in Section 5.3.8.3 and Section 
5.3.8.4. 
5.2.4 Rationale for the study  
As described in Section 1.9.2, colostrum contains many trophic factors such as epidermal 
growth factor, insulin-like growth factor and transforming factor, which have trophic effects on 
the growth and maturation of the GIT (234-236), potentially leading to the earlier 
establishment of enteral feeding (618). Colostrum growth factors may also exert indirect 
trophic effects by increasing the concentrations of some of the circulating gut hormones 
(580); these trophic factors are present in colostrum expressed by mothers of full-term 
infants as well as and preterm infants, and are further higher in colostrum of those who have 
delivered preterm infants (195, 201, 274).  
Using the oropharyngeal route to coat the oropharynx with a small volume of colostrum could 
continue the effects of the amniotic fluid in utero, as described in Section 1.11 (158, 277). 
Furthermore, OPC administration can be used to provide the benefits of mother's colostrum 
to all infants whose care requires that they do not receive milk enterally such as infants with 
GIT immaturity or anomalies (oesophageal atresia, gastroschisis) and those requiring 
mechanical ventilation. Although, research investigating the effects of using OPC on 
outcomes of preterm infants are progressing (359, 503, 619, 620), to the best of my 
knowledge, no ongoing or published study has investigated gut hormone secretion in 
response to OPC administration. Moreover, most of the previous research has studied OPC 
in EXP and ELBW and VLBW infants; this study included all preterm infants’ categories and 
other sick infants requiring NIC. 
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Some studies have investigated gut hormones in preterm infants and their relationship to 
trophic and enteral feedings during the neonatal period (580, 592, 621), these studies did not 
assess the effect of providing mother’s colostrum by the oropharyngeal route on gut 
hormones.  
The Cochrane review (Chapter 2) and the case-control study (Chapter 4), as well as previous 
studies (353, 417), suggested that OPC administration can shorten the time to reach full 
enteral feeds. However, the mechanism through which colostrum administered by the 
oropharyngeal route enables the GIT to adapt to its postnatal function is currently unclear. 
The present study, therefore, evaluated some GutHs in the early postnatal period to assess 
the influence of OPC administration on gut hormone concentrations in preterm and sick 
infants. Changes in plasma concentrations of five different gut hormones were evaluated 
over the first two weeks of life using multiplex technology. Table 5.1 summaries the rationale 
for the gut hormones which were measured in this study.   
Table 5.1  Rationale for the gut hormones studied 
Gut hormone Rationale 
Peptide tyrosine 
tyrosine (PYY) 
Potential biomarker for predicting feeding intolerance (FI) in 
preterm infants. May reflect energy/weight balance (585) and it may 
predict impaired neuroendocrine responses and intestinal growth in 
infants at risk for FI (582).   
Gastric inhibitory 
polypeptide (GIP) 
Potential biomarker in predicting FI. May predict impaired 
neuroendocrine responses, and intestinal growth in infants at risk of 
FI (582, 593). Biomarker for entroinsular axis (587). 
Glucagon-like peptide 
(GLP-1) 
A regulatory signal between enteral feeding and GIT adaptation 
and potential biomarker in predicting FI (582). 
Ghrelin Reflects energy balance and postnatal catch-up growth (601).  
Insulin  Reflects the metabolic state and an important growth regulator 
(622). A potential predictor of long-term insulin resistance (607).   
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5.2.5 Hypothesis and aims 
I hypothesised that oropharyngeal administration of the mother’s own colostrum to infants 
requiring neonatal intensive care is associated with changes in plasma concentrations of gut 
hormones which are known to promote the development of GIT and tolerance to enteral 
feeds. I also hypothesised that postnatal changes in different gut hormones are associated 
with growth rates in the infants.  
5.2.5.1 Aim of the study  
The purpose of this study was to evaluate the impact of OPC administration on gut hormone 
concentrations during the neonatal period. It was a pilot study to provide data that might 
inform appropriate sample size calculations for future studies with the power to assess the 
secondary clinical outcomes.  
5.2.5.1.1 Primary objective 
To evaluate whether early administration of OPC to preterm and unwell infants requiring NIC 
results in beneficial (increase/decrease or both) changes in plasma gut hormone 
concentrations during the first few postnatal weeks.  
5.2.5.1.2 Secondary objectives 
To investigate if there are relationships between changes in the plasma gut hormone 
concentrations and: 
- the growth trajectory of the infants  
-  the clinical outcomes of these infants during the stay in neonatal units.  
5.3 Methods  
This study received a favourable opinion from the East Midlands - Leicester South Research 
Ethics Committee (REC) (Appendix 12) and Human Research Authority (HRA) approval 
(reference number: 17/EM/0323) (Appendix 13). The study protocol was published on the 
HRA website (623).  As a participating National Health Services (NHS) organisation, the 
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Nottingham University Hospitals (NUH-NHS) trust confirmed the Capacity and Capability for 
conducting the study on the Nottingham neonatal units.  
5.3.1 Study design  
It was an observational, non-randomised study; compared infants who received own mother 
colostrum by the oropharyngeal route (OPC group) during the early neonatal period with 
those infants who did not receive OPC (No-OPC group). The neonatal units of the Queen’s 
Medical Centre (QMC) and the City Hospital (CH) at the NUH-NHS trust were the study site. 
5.3.2 Participants 
5.3.2.1 Eligibility criteria 
Infants were eligible for inclusion if they required NIC and were not able to receive enteral 
feeding.  
While all mothers were encouraged to express colostrum for their infant, this was not always 
available for administration in the 96 hours of life. Based on the standard care of the neonatal 
unit, infants who received OPC were assigned to the ‘OPC’ group, and those who did not 
receive OPC were assigned to the ‘No-OPC’ group. As the clinical conditions of, and NEC 
risks for, preterm and near-term/term infants differ, infants who had been recruited into the 
study were stratified for analysis into gestational age groups (<34 weeks (preterm) and >34 
weeks of gestation (near-term/term).  
5.3.2.2 Inclusion criteria 
Infants were considered for inclusion in this study if they have been: 
- admitted to one of the Nottingham’s two neonatal units, and  
- their developmental maturity or clinical condition or both requires that they do not 
receive enteral feeding, and 
- they are eligible to receive OPC according to the guideline of the neonatal units 
(Appendix 7), and 
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- their parents gave informed written consent. 
5.3.2.3 Exclusion criteria  
Infants were not eligible for inclusion in the study if: 
- they had major congenital anomalies, except those affecting the GIT, or 
- death was considered likely within the first 72 hours, or 
- there were contraindications for the infant to receive their mother’s milk as per the 
unit guideline (such as HIV infection), or  
- they were already receiving oral feeds, or 
- there was no informed parental consent to participate in the study. 
5.3.2.4 Involvement of the participants 
The participants were enrolled in the study after written informed consent was obtained from 
the parents and continued until the infant was discharged from the neonatal unit. 
5.3.3 Recruitment 
The researcher identified participants who were eligible for inclusion in the study from the 
ward list and the clinical database (Badger Neonatal) of the participating units. The 
participant’s clinical team who were nominated by the Chief Investigator (CI), appropriately 
trained in keeping with the principles of Good Clinical Practice (GCP) and entered onto the 
delegation log, approached the parents of eligible infants in the neonatal units and the 
postnatal ward at the QMC and CH Campuses of the Nottingham University Hospital NHS 
Trust. Detailed instructions and a study flow chart were provided to the clinical team and 
were available in the Investigator Site Folder (ISF), which included copies of all the study 
documents, at each participating unit. When it was reasonable after delivery, the clinical 
team approached the mothers, explained the study in detail and answered any question 
provided by the parents.  
Parents were offered Parent Information Sheets (PIS) (Appendix 14) approved by the ethics 
committee. The PIS described the objectives of the study, including the study process, how 
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the infant would be involved and the benefits and risks of taking part in the study. The PIS 
also described the infants’ rights, including the confidentiality of their information, voluntary 
participation and withdrawal from the study. Contact details of the research team were also 
provided. The PIS was only available in the English language in paper format in the neonatal 
units. When it was needed, an interpreter assisted with a discussion of the study. All parents 
were given sufficient time to read the PIS and to decide whether to participate in the study. 
The clinical team then introduced those who were interested in the study to the researcher.  
5.3.4 Informed consent  
To keep with the principles of GCP (624)  and protect the participants’ rights, informed 
written consent was obtained from parents of all the participants before the enrolment of their 
infants in the study. The process for obtaining parental informed consent was according to 
the REC guidance, and GCP  and the regulations of the University of Nottingham (UoN) 
(372). 
As mothers automatically have parental responsibility for their babies, written informed 
consent was gained from the infant’s mother. However, an agreement to participate is ideally 
sought from both parents of an eligible infant. Babies admitted to the neonatal unit within the 
first week of age, have very rarely received Birth Registration under UK law 
(https://www.gov.uk/parental-rights). Although the infant’s father to whom the infant’s mother 
is married/civil partnered at the time of the infant’s birth is legally permitted to give consent to 
studies involving his baby, as this study included information on the mother and her 
pregnancy, consent was considered valid when the mother gave consent. 
The consent form included data collection from the medical records, collection and storage of 
blood samples and the parent’s and infant participant’s rights (Appendix 15).  
Consent was received by an appropriate person in keeping with the principles of GCP and 
listed on the delegation log of the research. The consent form was completed and signed by 
the infant’s mother then signed and dated by the person who received the consent. 
According to the regulations of the UoN, the consent form was prepared in three copies; one 
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copy was given to the infant’s parent to keep, one was kept securely by the investigator, and 
a third was retained in the patient’s hospital records.  The decision regarding participation in 
the study was entirely voluntary. It was emphasised to the parents that consent regarding 
study participation could be withdrawn at any time without consequences on the quality or 
quantity of their babies’ medical care.  
5.3.5 Intervention 
Administration of OPC is part of the clinical care of infants on the neonatal units, according to 
the Nottingham Neonatal Service Guideline on the use of OPC (Appendix 7). Small volumes 
(0.2ml) of own mother’s colostrum were given by the oropharyngeal route every four hours 
for three days. OPC was started as early as possible within the first 96 hours of birth with the 
timing was dependent on the availability of the mother’s colostrum. All aspects of care and 
OPC use were at the discretion of and were the responsibility of, the clinical team treating the 
infant. 
5.3.6 Study regimen  
Once the signed written informed consent form was obtained, each participant was allocated 
a study identity code number (SID) to be used on the data collection forms and electronic 
data. A separate confidential record of the participant’s name, date of birth, local hospital 
number Badger unique number, and the SID was made to permit identification of all 
participants enrolled in the study, in case additional follow-up was required. 
The master file linking the study ID with the infants’ identifiable information was kept securely 
and separately at the Division of Child Health, Obstetrics & Gynaecology (COG) of the UoN. 
The study ID was used to label blood sample containers and all participant data records. 
5.3.6.1 Data collection  
With informed written consent, the researcher (AN) collected the study data from routinely 
recorded clinical items obtained from the clinical records. The data were recorded in the data 
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collection forms (DCFs) by hand using a black ballpoint pen. Next, the data were entered into 
encrypted anonymised electronic records.  
The completed DCFs were treated as confidential documents and to protect the rights of the 
study’s participants to privacy, the researchers adhered to the Data Protection Act, 1998. 
The study protocol, PIS and the consent form were updated to ensure compliance with the 
UK new General Data Protection Regulation (GDPR) (406) and Data Protection Act 2018 
(407). A supplementary information sheet was provided to the parents who participated in the 
study before the new law commenced. Only the necessary required information for the study 
was collected on the DCF, and all the DCFs were held securely, in a locked room and locked 
cupboard in the Division of COG at the UoN. Access to the information was limited to the 
researchers and any relevant regulatory authorities. All data were stored on a computer Z 
drive; a dedicated web server for the UON, which was securely password protected.  
5.3.6.1.1 Source of data  
The data were collected from the infants’ medical records including, the medical notes and 
the Badger neonatal database and Trust’s Digital Health Record (DHR) when it was 
necessary. Where an infant admitted to the Nottingham NICU was transferred to a local 
neonatal unit at another hospital Trust for ongoing care, data on outcomes to discharge from 
hospital were collected using the Badger database of that unit and the DHR system with the 
agreement of the local neonatal unit. 
5.3.6.1.2 Type of data  
The collected data included the following:  
 infants’ demographic information; date of birth, date & time of admission to the 
neonatal unit, gestational age, sex, birth weight and date of discharge from 
the neonatal unit  
 clinical characteristics of the infants such as mode of delivery, multiple 
gestations, delivery room resuscitation, 1 and 5-min Apgar score, non-
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invasive ventilation, endotracheal intubation & mechanical ventilation, central 
line placement, nasogastric tube, use of parenteral nutrition and medications 
 infant’s feeding history including, type of milk, mode of feeding, date of start, 
volume received during the intervention, date of attainment of full enteral 
feeding and type of milk received during admission and at discharge to home. 
 any morbidities during a hospital stay, such as NEC, sepsis, pneumonia, any 
other serious complications and death 
 results of the infant’s routine blood glucose testing (if undertaken) 
 infant’s growth parameters, weight, head circumference, at admission, 
throughout the infant’s care in the neonatal unit and before discharge as is 
standard care. It was also planned to include the length of the infants, 
however, measuring the length was not routinely recorded clinical items in the 
Nottingham neonatal units 
 OPC administration including, date of starting, frequency, number of doses 
received, total volume of colostrum received by the infant, duration of OPC, 
parent’s participation in administration, concomitant feeding regimen and any 
reported adverse effects 
 maternal and pregnancy medical history such as, medical and pregnancy-
related illness including diabetes, pre-eclampsia, infection, premature and/or 
prolonged rupture of membranes, antibiotic therapy, antenatal steroid use. 
Maternal data were also collected from the infant’s medical records. As part of 
standard care for infants on the NICU, these maternal data are routinely 
transferred into the infant records.  
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5.3.7 Outcome measures 
5.3.7.1 Primary outcome 
 Postnatal changes in plasma concentrations of gut hormones during the first two 
postnatal weeks. These will be evaluated by measuring plasma concentrations of 
PYY, GIP, GLP-1, ghrelin and insulin at baseline (before or within 24 hours of first 
receiving OPC) and at around 7 and 14 days from baseline. 
5.3.7.2 Secondary outcomes 
The following outcomes were assessed from birth till discharge from the neonatal unit: 
- Infant’s growth during a stay in the neonatal unit. Weight Z scores were calculated 
using clinical actual age percentile and Z-score calculator (544). Head circumference 
(HC) Z scores were not calculated as HC was not measured at birth. Length Z score 
was also not calculated as no data were available for the infant’s length in the 
medical records because the length is not routinely measured during stay in the 
neonatal unit. The difference between birth weight Z-score and weight Z-score at 
discharge from the neonatal units were used to assess the growth trajectory of the 
infants 
- days to reach full enteral (milk) feeds (defined as enteral milk at 150ml/kg/day or 
more sustained for 72 consecutive hours) 
- days of parenteral nutrition (PN)  
- days to first enteral feed 
- days of mechanical ventilation 
- length of stay in NICU, high dependency and low dependency units 
- death before discharge home 
- days of antibiotic use 
- the rate of breastfeeding and the type of milk at discharge 
 206 
 
- feeding intolerance (defined as delayed commencement or/and delayed 
advancement of enteral feeding) 
- incidence of NEC (defined as Bell’s stage ≥ II) 
- incidence of clinically suspected or microbiologically-confirmed late-onset sepsis. 
5.3.8 Measurement of Gut hormones  
5.3.8.1 Blood sampling  
Blood samples for analysis of gut hormones were collected after written informed consent. 
Samples were withdrawn by the clinical team caring for the infant in line with routine blood 
sampling of the infant according to the clinical indications to prevent any additional 
discomfort or disturbance to the infant. Three samples were collected from each infant 
participant: at baseline (GH1) before administration of OPC (or a maximum of 24 hours after 
first OPC administration), around 7 and 14 days (GH7 & GH14). Each sample was a small 
volume of blood (around 250-500µl), in addition to that required for routine laboratory testing 
in the clinical care of the infant. The blood samples were collected in standard, manufactured 
tubes containing ethylene diamine tetra-acetate (EDTA) as an anticoagulant as used in 
clinical practice. A sample collection instruction sheet (Appendix 16) was prepared, and 
copies were kept in the ISF at the two study centres. The researcher (AN) collected and 
transported the blood sampling tubes on Ice from the neonatal units to the laboratory at the 
Division of COG at the UoN. Whilst waiting for collection the blood sample tube was 
immediately stored in a universal container within Ice bag in the refrigerator at the neonatal 
unit. A member of the laboratory team processed the blood samples immediately according 
to the manufacturer’s instructions. Samples were labelled using a combination of study ID, 
and two unique study identifiers (e.g. GH0-245) to permit accurate linkage to study data and 
the consent form. All samples were registered and stored according to the Human Tissue 
Authority’s Code of Practice (HTA) for Research, at the Division of COG (QMC and CH), 
UoN (625).  
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5.3.8.2 Sample preparation   
The blood samples were collected in tubes containing EDTA as an anticoagulant. To 
counterbalance the normal degradation of GIP and GLP-1 by dipeptidyl peptidase IV (DPP-
IV) enzyme (626), 10 µl protease inhibitors (Catalogue number: DPP4-010, Millipore) and 10 
µl of serine protease (Catalogue number: 565000-1VL, Millipore), which stabilises ghrelin 
(627), were immediately added to every 100 µl of blood in the EDTA tube. DPP-IV is a 
protease enzyme present mainly in the endothelial cells, and it also exists in the circulation. 
DPP-IV rapidly inactivates bioactive peptides such as the incretin hormones (628). 
Therefore, inhibition of the DPP-IV prolongs the half-life of the GIP and GLP-1 in the plasma; 
this effect allows better detection of these hormones. The blood samples were then 
centrifuged for 10 minutes at 2,000 g at 4°C. The plasma fractions of the samples were 
divided into aliquots and stored at -80°C until assayed. The cellular fractions were disposed 
of according to the HTA guidelines (625).  Processing of the blood samples was carried out 
by members of the COG laboratory team (Dr Lesia Kurlak, Dr Hiten Mistry, Dr Ian Bloor, Mr 
Mark Pope) or a laboratory research student (Mrs Layla Albustanji). 
5.3.8.3 Quantification of plasma gut hormones 
Plasma concentrations of the study target hormones were measured using microsphere-
based immunoassay such as MILLIPEX MAP assay.  
5.3.8.3.1 Magnetic beads-based immunoassay 
Magnetic beads (MBs) are small sized microspheres having a diameter ranges from 1 to 5 
micron (629).  They consist of an iron core surrounded by solid spherical particles and a 
mixture of two coloured dyes that adjusted to provide multiple distinct colours to enable 
simultaneous measurement of multiple biomolecules in a single microplate well (630). MBs 
immobilise molecules such as proteins, enzymes, peptide and nucleic acids to separate them 
from a sample and act as a sold surface where the assay reaction takes place (631).  
 208 
 
Microbeads classified into two basic categories, nonmagnetic and magnetic. Magnetic beads 
have fluorescent and magnetic features and are compatible with all currently available 
Luminex-based equipment, which is commonly used as a platform in the commercial assay 
(632) 
5.3.8.3.1.1 Principle of MBs immunoassay  
The principle of the assay is analogous to a sandwich ELISA. Sandwich immunoassay is a 
technique using a pair of antibodies specific for the target molecule (e.g. peptide, protein, 
and antigen); one is attached to a solid surface to capture the target, it is referred as a 
capture antibody. The second antibody (detection antibody) binds to the target at a different 
site; thus, the target molecule is grasped between the two antibodies (633).  
In microbeads multiplex assay, sets of microbeads uniquely coded with a two fluorescent 
dye. The captivating antibodies directed against the target biomolecule are covalently 
combined with the beads. Coupled beads react with the sample containing the molecule of 
interest, and a sandwich compound is formed after adding biotinylated (conjugated with 
biotin) detection antibodies specific for the target molecule. Finally, the biotinylated detection 
antibodies bind with Phycoerythrin-Streptavidin conjugate, a reporter dye, which acts as the 
fluorescent indicator (Figure 5.1). The intensity of emitted light quantifies the relative amount 
of the molecule bound to the bead, and the quantity of the molecule found is directly 
proportional to the fluorescent signal (634).   
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Figure 5.1  Magnetic-bead immunoassay general principle 
Schematic diagram presents the sandwich magnetic-bead immunoassay. Magnetic bead: 
internally coloured with fluorescent dyes (red and infrared). Capture and Detection antibody: 
specific for a target molecule. Fluorescence reporter: Streptavidin-Phycoerythrin conjugate 
for detection of molecule via light emission that is directly proportional to the concentration of 
the bound molecule. Diagram adapted from Vignali 2000 (635).  
 
5.3.8.3.1.2 Advantages of magnetic-bead based assay (610) 
MBs immunoassay have many advantages include:  
- MBs have an optimum binding capacity even in small volume due to their small size 
and large surface area that allow the entire particle to react rapidly to stimuli with a 
high reaction rate. Therefore, may generate higher signals than if the same reaction 
is conducted in solutions (636) 
- Microbeads shorten the analysis time due to their low viscosity and high mobility that 
makes them more effective in the transport and delivery of the molecules to the 
reactive surface 
- MBs enhance the sensitivity of the assay because of their central iron core which, 
prevents trapping of the antibodies 
- MBs minimise sample loss, as centrifugation is not needed, which may lead to loss of 
immune complexes or breaking weak antibody-antigen bonds. Therefore, accuracy 
and reproducibility of the results will be ensured 
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- small sample volume is required for simultaneous analysis of multiple molecules that 
make the analysis more cost-effective (632).  
The multiplex assay has some limitations, such as non-specific binding of antibodies that 
present in some samples may confound the measurement. However, many methods are 
available to remove these antibodies and preserve the integrity of the analysis (637). 
Sensitivity in the very low concentrations of some biomolecules and reference values for 
newborn infants remain a challenge for the researchers. Additionally, the multiplex assay 
requires specialised equipment, which creates high costs for initial installation (638).  
5.3.8.4 Gut hormone multiplex assay  
The target GutHs (Table 5.1) were measured using a Human Metabolic Hormone Magnetic 
Bead Panel (MILLIPLEXR Map # HMHEMAG-34K, 2013 EMD Millipore Corporation, 
Billerica, MA, USA.). The kit was obtained from a commercial company (Merck Millipore, 
U.K.) (https://www.merckgroup.com/uk).   
Bio-Plex® 200 (BIO-RAD) system consisting of an analyser, a computer station and a Bio-
Plex Manager software, was used as a platform for the analysis. BIO-RAD is a life science 
commercial company, providing a range of technological products for different areas such as 
life science research, clinical diagnostic, food science, quality control and spectroscopy 
(639)). Bio-Plex 200 is a flow cytometry-based detection system capable of conducting a 
qualitative and quantitative analysis of proteins and nucleic acids in a range of matrices. This 
flow cytometry platform has high sensitivity and allows simultaneous measurement of up to 
100 target molecules in a single well of 96-well plate. It is compatible with magnetic beads, 
used to analyse various biomolecules such as cytokines, hormones, and nucleic acids (640). 
However, Bio-Plex 200 is a costly system which could not be equipped into a total analysis 
system (610). 
Bio-Plex Manager version 6.1 software (BIO-RAD) was used for the quantitative analysis and 
data visualisation (641). The Bio-Plex Manager presents the data as median fluorescence 
intensity and the concentrations of the targeted hormones (pg/mL), which are proportional to 
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the fluorescence intensity. This software generates statistical reports for multiplex data that 
were exported in formats compatible with statistical software such as Microsoft Excel, 
facilitating and accelerating data analysis (641).  
5.3.8.4.1 Procedure of the assay  
The procedure of the Multiplex assay was carried out by Dr Ian Bloor and Mr Mark Pope at 
the Life Sceince Department (Biology Building, University Park Campus), UoN. All steps 
were performed according to the manufacturer’s instructions (Appendix 17). Figure 5.2 
demonstrates the basic steps of the bead-based immunoassay reactions.  
 
 
Figure 5.2  Summary of the procedure of beads-based immunoassay 
Schematic diagram summarises the basic steps of beads multiplex immunoassay (634) 
A: Microbeads are coloured internally with fluorescent dyes and coated with a specific 
capture antibody.  
B: Multiple sets of beads, is made, each bead set is coated with a distinct capture antibody to 
a target molecule  
C:  Addition of the sample and a mix of all desired bead sets are combined and incubated. 
D: Addition of a mixture of detection antibodies specific for the target molecules conjugated 
to a reporter dye, which is also specific for the same target molecules. 
E: The bead-analyte-reporter mixture is analysed through a flow chamber supporting 
individual bead separation.  
F: Each bead has the potential to have analyte bound to capture antibody, and a specific 
detection antibody bound to a reporter-dye, which depends on the analyte in the sample.  
G: A red laser light stimulates the red and infrared dyes within the microbeads, which 
identifies and categorises the beads. A green laser stimulates the detection antibody–
reporter dye complex that bound to the beads; the intensity of the signal quantifies the 
relative amount of the target molecule bound to the microbeads. 
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Each sample was analysed in triplicate with seven standards and two controls, which were 
included in the kit, to verify the efficiency of the experiment. A blank (Serum Matrix: LHGT-
SM, Millipore) that was provided with the kit was included for comparison. Two samples were 
only analysed in duplicates because there was insufficient plasma volume, which was 
expected in newborn infants with high haematocrit. For each gut hormone, a standard curve 
was generated by the Bio-Plex Manager software to determine the hormone concentrations 
of the samples relating to the mean fluorescence intensity (Appendix 18).  
The assay showed good precision (0 to 10.6% intra-assay coefficients of variation (CV)) 
except for two samples that had %CV of 11.5 and 13.9%. Each participant’s set of plasma 
samples was analysed at the same time to prevent potential errors due to inter-assay 
variations. The range of the standard recoveries was 83-110 %, except for PYY (S6; 41%). 
The standards recoveries were determined by back-calculation ((observed 
concentration/expected concentration) x 100), to assess the accuracy of the assay 
(acceptable range: 70-130%). The assay sensitivities (minimum detectable concentration) for 
the measured hormones were as follow:  PYY: 28; GIP: 0.6; GLP-1: 1.2; Ghrelin: 13; Insulin: 
87 pg/mL. Most of the observed concentration values of the measured hormones fall within 
the range of the standard curves except for GLP-1 and ghrelin. For GLP only 4/22 (18%) 
samples were below the range. Fifty per cent of the observed values of ghrelin fall outside of 
the range; this could be due to that the sample contains no hormone or its concentration 
below the detectable levels. Out of range values were also could be attributed to small 
sample volumes or a technical error.   
However, these ghrelin values were expected as ghrelin concentrations are very low or 
undetectable at birth and during the early neonatal period (581, 590). However, the data is 
still valuable by showing very low concentrations.   
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5.3.9 Statistics   
5.3.9.1 Sample size 
The study sample size was calculated using nQuery Advisor + nTrim version 7.0 software 
(642). Using data from a previous study that investigated gut hormones in preterm infants 
(590) this study reported an increase in the mean (SD) plasma PYY concentrations from 
353.0 ± 457.73 pg/ml to 634.3 ± 580.03 pg/ml after one week of enteral feeding, for an alpha 
of 0.05, a sample size of 9 per group would give 80% power to detect a difference.  
The aim was to recruit 40 infants, 20 infants born at <34 weeks of gestation and 20 infants 
born at > 34 weeks of gestation (10 per group). 
This research was a novel study which has been based on feasibility of completion with the 
recognition that this study was only powered to demonstrate likely changes in the primary 
outcome (postnatal changes in plasma gut hormone concentrations).  
5.3.9.2 Statistical analysis 
The Statistical Package for Social Sciences (SPSS) for Windows (Version 23, Armonk, NY: 
IBM Cop) (549), and GraphPad (GraphPad Software Inc., La Jolla, CA, USA) (643) were 
used for performing the statistical tests. A p-value of 0.05 was considered statistically 
significant.  
Participants’ demographic and clinical data were summarised using descriptive analysis for 
categorical variables (frequencies and percentages). Continuous variables were presented 
according to the data distribution as a mean ± standard error of the mean (SEM) for normal 
distribution and median and range/interquartile range (IQR) for skewed data. Normality of 
data was assessed using a histogram plot and Shapiro-Wilks test of normality. A 
transformation was performed for continuous data that did not demonstrate a normal 
distribution.  
Repeated Measure One-way Analysis of Variance (RM-ANOVA) was used to measure 
changes in the gut hormone concentrations over time. Correlations of changes in plasma gut 
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hormones concentrations with feeding volumes and gestational age and birth weight of 
infants were assessed using Pearson’s Correlation Coefficients for parametric data or 
Spearman’s for non-parametric.  
Comparisons between the study groups, for continuous data, independent t-test for 
parametric data, and Mann Whitney U tests for non-parametric data and Fishers’ exact test 
for categorical data are the planned analysis when the study complete.  
Survival analysis using the Kaplan-Meier method is also planned to analyse time to reach 
event outcomes such as full enteral feeding, duration of parenteral nutrition and stay in the 
neonatal unit. Kaplan-Meier curves will be used to present the difference between the study 
groups in outcomes of interest. The Kaplan-Meier analysis is a non-parametric estimate; 
computing the probability of events that occur at a given point of time (644).  
Appropriate, multivariate analysis is planned to adjust for potential confounders such as 
gestational age and birth weights.  
5.3.9.3 Dealing with missing data 
Several methods have been established to deal with partially missed data such as complete-
case analysis and available-case analysis and single imputation. However, such approaches 
have many limitations; therefore, they are generally not recommended when an 
unacceptable percentage of data is missed (> 10%) (552). In this study, the data were 
analysed by the total case basis; for each variable; only those infants with complete data are 
included in the final analysis.   
5.4 Results 
From May 1st 2018 to July 19th 2018, 344 babies were admitted to Nottingham neonatal 
units at the Nottingham University Hospitals NHS Trust; QMC and CH, UK: 70 infants were 
born before a gestational age of <34 weeks and 274 infants were born >34 weeks of 
gestation. Parents of 20 eligible infants who were <34 weeks of gestation had been 
approached to participate in the study. Informed written consents have been obtained from 
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parents of four infants, however, one of these four infants was excluded because he was 
transferred to other hospital before collecting the second and third blood samples. Parents of 
7 eligible infants who were >34 weeks of gestation were approached, parents of 4 infants 
consented to enrol their infants in the study (Figure 5.3). 
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Figure 5.3 Study flow chart 
Flow of the enrolled infants in the study and final analysis.  
n: number of infants 
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5.4.1 Characteristics of the included infants  
Seven infants were included in the analysis, comprising a heterogeneous group. Most of the 
infants were male (85%). The mean ± SEM of the gestational age was 32.8 ± 1.5 weeks, and 
the mean birth weight was 1970 ± 302.20 grams. Six infants received OPC; mean ± SEM, 
age for starting OPC was 2.2 ± 0.4 (95% CI, 1.14 to 3.19) days; number of doses were 
received: 11.5 ± 1.4 (95% CI, 8 to 15) doses; colostrum volume was received: 2.3 ± 0.25 
(95% CI, 1.7 to 3) ml. OPC was provided for 3 ± 0.25 (95% CI, 2.34 to 3.66) days. Most of 
the infants did not receive trophic or enteral feeding throughout when OPC has been given 
except one infant (infant 4) who had started trophic feeding during the second day of OPC 
administration. Table 5.2 presents the characteristics of the seven infants that participated in 
the study. 
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Table 5.2  Characteristics of the participant infants 
Criteria  Infant 1 Infant 2 Infant 3 Infant 4 Infant 5 Infant 6 Infant 7 
Study group OPC OPC OPC OPC No-OPC OPC OPC 
Gender   F M M M M M M 
GA (weeks+ day) 37+1 31+3 35+4 35 36+1 28+2 27+1 
Birth weight (g) 2230 1630 2120 1910 3520 1250 1130 
Birth weight/GA SGA AGA AGA SGA LGA AGA AGA 
Mode of delivery NVD CS CS CS CS NVD NVD 
Apgar score 
1 minute 
5 minute 
 
3 
10 
 
6 
6 
 
1 
4 
 
10 
10 
 
1 
7 
 
3 
8 
 
7 
10 
Inotropes 
administration   
No Yes Yes No No Yes No 
Maternal 
Antenatal steroid  
No No Yes No No Yes Yes 
Underlying 
diagnosis 
Duodenal 
/choanal 
atresia 
Preterm Gastroschisis OA/TOF HIE Preterm Preterm 
Start feeding 
(postnatal day) 
5 3 6 3 4 4 4 
Type of milk  EBM Formula EBM EBM EBM EBM EBM 
Feed volume 
(ml/kg/day) 
       
GH1 NBM NBM NBM 1* NBM NBM NBM 
GH7 110 160 15 150 160 100 145 
GH14 32 145 16 145 165 125 160 
OPC: oropharyngeal colostrum; GA: gestational age; SGA: small for GA; LGA: large for GA; AGA: 
appropriate for GA; NVD; normal vaginal delivery; CS: caesarean section; TOF: tracheoesophageal 
fistula; HIE: hypoxic-ischemic encephalopathy; OA: Oesophageal atresia; GH: gut hormone, 1: first 
sample; 7, 14: days from first sample; NBM: nil by mouth; EBM: expressed breast milk; *: ml/kg/hour. 
 
5.4.2 Gut hormone concentrations over two postnatal weeks  
The mean ± SEM postnatal age of the infants was 2.9 ± 2.4 (95% CI, 1.86 to 3.84) days, and 
almost all of the infants were fasting (6/7 (86%) infants) when the basal blood samples for 
gut hormone assay were taken.  
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5.4.2.1 Peptide tyrosine tyrosine (PYY) 
Five of seven infants showed a significant increase in plasma PYY concentrations during the 
first week. By postnatal day 14, plasma PYY did not show a further increase in its 
concentrations (Figure 5.4). Overall, there were statistically significant changes in plasma 
PYY concentrations over time (p = 0.02). Bonferroni pairwise comparisons demonstrated that 
PYY plasma concentrations increased significantly at D7 compared to the basal value 
(adjusted p = 0.04 (Figure 5.5). 
 
Figure 5.4  Plasma PYY concentrations for individual infant 
Postnatal changes in plasma PPY concentrations (n = 7) over a two weeks period. Each line: 
represents the trend of PYY concentrations for an individual infant. Infants 2, 6 and 7 <34 
weeks gestation; infants 1, 3, 4 and 5 > 34 weeks (All infants received OPC except infant 5); 
Symbols: time point (the day when samples were taken: D1 (baseline), around D7 and D14); 
PYY: peptide tyrosine tyrosine.  
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Figure 5.5  Plasma PYY concentration over time 
Postnatal changes in plasma PYY over a two weeks period (n = 7). Bar: represents PYY 
plasma concentrations. Blood samples were taken for analysing PYY, Brown: baseline 
(around postnatal day 1 of life); Green: around day 7 from baseline; Blue: around day 14; 
Values are mean ± SEM. Comparisons: repeated measure ANOVA and Bonferroni post hoc 
test; **: p = 0.02; * p= 0.04; PYY: peptide tyrosine tyrosine. 
 
5.4.2.2 Gastric inhibitory polypeptide (GIP) 
The majority of the infants showed a significant increase in plasma GIP concentrations at D7. 
By D14, plasma GIP concentrations had a decreasing trend (Figure 5.6). Overall, there was 
a statistically significant increase in the plasma GIP over two postnatal weeks (p = 0.007). 
Adjustment for multiple comparisons (Bonferroni) demonstrated that the increase of GIP 
concentrations from the basal value and D7 (adjusted p = 0.02) and D14 (adjusted p = 0.04) 
remained statistically significant (Figure 5.7).  
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Figure 5.6  GIP plasma concentration for individual infant 
Postnatal changes in plasma GIP concentrations over a two weeks period (n = 7). Each line: 
represents trend of GIP concentrations for individual infant; Infants 2, 6 and 7 <34 weeks 
gestation; Infants 1, 3, 4 and 5 > 34 weeks (All infants received OPC except infant 5). 
Symbols: time point (day when samples were taken): D1 (baseline), around D7 and D14); 
GIP: gastric inhibitory polypeptide 
 
 
Figure 5.7  Plasma GIP concentrations over time 
Postnatal changes in plasma GIP over a two weeks period (n = 7). Bar: represents GIP 
plasma concentrations. Blood samples were taken for analysing GIP, Brown: baseline 
(around first postnatal day of life); Green: around day 7 from baseline; Blue: around day 14; 
Values are mean ± SEM. Comparisons: repeated measure ANOVA (***: p = 0.007) and 
Bonferroni post hoc test (*: p = 0.02; **: p = 0.04); GIP: gastric inhibitory peptide. 
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5.4.2.3 Glucagon-like peptide (GLP-1) 
Four (4/7) infants were included in this analysis because for three infants (one from the <34 
weeks’ group, and two from the >34 weeks group), only two values for plasma GLP-1 
concentrations were detected (other values were below the limit of sensitivity of the assay). 
The four infants showed a substantial increase in plasma GLP-1 at D7, yet, by D14 there 
were reductions in the GLP-1 concentrations (Figure 5.8). Overall, there was a statistically 
significant increase in GLP-1 plasma concentrations over two postnatal weeks (p = 0.02). 
Bonferroni post hoc pairwise comparisons showed a statistically significant increase in 
plasma GLP-1 concentrations at D7 (adjusted p = 0.03) (Figure 5.9).  
 
Figure 5.8  Plasma GLP-1 concentrations for individual infant 
Postnatal changes in plasma GLP-1 concentrations (n = 4) over a two weeks period. Each 
line: represents a trend in GLP-1 concentrations for an individual infant; Infant 2 and 6 <34 
weeks gestation; Infant 4 and 5 >34 weeks (All infants received OPC except infant 5).  
Symbols: time point (day when the sample was taken: D1 (baseline), around D7 and D14); 
GLP-1: glucagon-like peptide 
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Figure 5.9  Plasma GLP-1 concentration over time 
Postnatal changes in plasma GLP-1 (n = 4) over a two weeks period. Bar: represents GLP-1 
plasma concentrations. Blood samples were taken for analysing GLP-1, Brown: baseline 
(around postnatal day 1 of life); Green: around day 7 from baseline; Blue: around day 14; 
Values are mean ± SEM. Comparisons: one-way ANOVA (**p = 0.02) and Bonferroni post 
hoc test (* p= 0.03); GLP-1: glucagon-like peptide 
 
 
5.4.2.4 Ghrelin 
Baseline Ghrelin plasma concentrations (D1) were below the limit of detection of the assay 
for five infants (5/7: 71%); therefore, Ghrelin D1 were not included in the analysis. Around 
postnatal D7 and D14 Ghrelin concentrations were detected in five infants. There were no 
significant changes in Ghrelin concentrations between D7 and D14 (p = 0.23) (Figure 5.10). 
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Figure 5.10  Changes in plasma Ghrelin concentrations 
Postnatal age (days) when (n = 5). Bar: represents ghrelin plasma concentrations; Blood 
samples were taken for analysing ghrelin, Green: around day 7 from baseline; Blue: around 
day 14; Values are mean ± SEM. Comparisons: repeated measures one-way ANOVA 
 
5.4.2.5 Insulin  
There were no statistically significant changes in plasma insulin concentrations during the 
first postnatal weeks (D1: 680.58 ± 153.29 (95% CI, 305 to 1056); D7: 401.67 ± 45 (95% CI, 
292 to 512); D14: 439.67 ± 286.02.59 (95% CI, 229 to 650); p = 0.19).  
5.4.3 Correlation of plasma gut hormone concentrations with 
gestational age and birth weight 
5.4.3.1 Plasma gut hormone concentrations and infant’s gestational age  
There were no statistically significant relationships between gestational age and the basal 
plasma concentrations of the gut hormones investigated in this study except for Ghrelin 
(Table 5.3). Ghrelin basal concentrations (D1 samples) for five infants were below the range 
of the detection of the assay; therefore, basal ghrelin was not included in the analysis. 
However, around postnatal D7 and D14 Ghrelin concentrations were detected in five infants; 
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there was a significant negative correlation between the mean plasma ghrelin concentrations 
(D7 and D14 samples) and the infant’s gestational age (r = -0.7). 
 
Table 5.3  Relationships between basal plasma gut hormone concentrations and 
infant’s gestational age 
Hormone  
(baseline) 
Correlation coefficient r 95% confidence interval P value 
PYY (n = 7) -0.28 -0.85 to 0.60 0.55 
GIP (n = 7) -0.48 -0.91 to 0.43 0.23 
GLP-1 (n = 4) -0.62* 0.99 to 0.63 0.16* 
Insulin (n = 7) 0.02 -0.76 to 0.74 0.96 
PYY: peptide tyrosine tyrosine; GIP: gastric inhibitory peptide; GLP: glucagon-like peptide; 
r: Pearson’s correlation; * Spearman correlation; statistical significant: p<0.05 
 
5.4.3.2 Basal gut hormone concentrations and infant’s birth weight  
There were no statistically significant relationships between basal values of the investigated 
gut hormones and birth weights and birth weight Z score of the infants except for ghrelin as 
demonstrated in Table 5.4. Ghrelin basal concentrations were below the range of the 
detection of the assay; therefore, basal ghrelin was not included in the analysis. As values for 
ghrelin concentrations were detected around D7 and D14 for five infants; the mean plasma 
ghrelin concentrations (D7 and D14 samples) was correlated with the infant’s birth weight (r = 
-0.8). 
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Table 5.4  Relationships between basal gut hormone concentrations and infants’ birth 
weights and birth weight Z scores 
Hormone 
(baseline) 
Birth weight Birth WZS 
Coefficient r (95%CI)  P value Coefficient r (95%CI) P value 
PYY (n = 7) -0.25 (-0.84 to 0.62)  0.58 0.06 (-0.72 to 0.78) 0.89 
GIP (n = 7) -0.28 (-0.86 to 0.59) 0.53 0.32 (-0.57 to 0.87) 0.48 
GLP-1 (n = 4) -0.80 (-0.95 to 0.68)* 0.30 -0.40 (-0.97 to 0.95) 0.75* 
Insulin (n = 7) 0.02 (-0.72 to 0.78) 0.98 -0.02 (-0.76 to 0.75) 0.96 
WZS: weight Z score; CI: confidence interval; PYY: peptide tyrosine tyrosine; GIP: gastric 
inhibitory peptide; GLP: glucagon-like peptide; r: Pearson’s correlation;  * Spearman 
correlation; statistical significant: p<0.05  
 
5.4.4 Correlation of plasma gut hormone concentrations with 
enteral feeds 
Spearman’s correlation was carried out to evaluate the relationships between gut hormone 
levels and milk volumes received by the infants when the blood samples were taken. There 
were positive correlations between plasma concentrations of the investigated gut hormones 
and the milk volumes received by the infants except for ghrelin and insulin as illustrated in 
Table 5.5. 
Table 5.5  Relationships between gut hormone concentrations and mean milk volumes 
received by the infants  
Hormone  Correlation coefficient (r) 95% confidence interval P value 
PYY (n = 7) 0.57 0.17 to 0.80 0.007 
GIP (n = 7) 0.65 0.29 to 0.85 0.002 
GLP-1 (n = 4) 0.55 0.03 to 0.80 0.03 
Ghrelin (n = 4) -0.28 -0.74 to 0.36 0.36 
Insulin (n = 7) -0.41 -0.72 to -0.05 .07 
PYY: peptide tyrosine tyrosine; GIP: gastric inhibitory peptide; GLP: glucagon-like 
peptide; r: Spearman’s correlation; n= number of infants; statistical significant: p<0.05 
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5.4.5 Changes in gut hormone concentrations by gestational age 
group 
No statistically significant differences were observed in the changes of gut hormone plasma 
concentrations among the groups at baseline, D7 and D14 in either gestational age (<34 
weeks and >34 weeks of gestation) expect for plasma GLP-1 (p = 0.01) (Figure 5.11).  
As most of the included infants (6/7 (86%) had received OPC during the first week of life; 
therefore, comparison of infants who received OPC with those who did not receive was not 
possible (lack of a control group). 
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Figure 5.11  Changes in gut hormone concentrations by gestational age group 
Comparisons of changes in plasma gut hormone concentrations among the study groups; 
>34 weeks of gestation (n = 4); <34 weeks of gestation (n = 3). Brown: basal sample (D1); 
Green: second sample (D7: around 7 days from D1); Blue: third sample (D14 around 14 from 
D1). Values: mean ± SEM; **: p = 0.01 (two-way repeated measures ANOVA). PYY: peptide 
tyrosine tyrosine; GIP: gastric inhibitory peptide; GLP: glucagon-like peptide. 
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5.5 Discussion 
5.5.1 Key findings  
These preliminary data showed that there was a trend for an increase in the plasma 
concentrations of different gut hormones during the first postnatal week in preterm and term 
infants. Each hormone had a specific pattern of plasma concentrations soon after birth and 
over the early postnatal weeks. The changes in gut hormone concentrations are likely to be 
related to the infant’s feeds rather than the gestational age or birth weight. 
5.5.2 Gut hormone concentrations during early postnatal weeks  
Gut peptides, which were measured in the current study, showed a significant increase in 
their plasma concentrations during the first postnatal week except for ghrelin and insulin. The 
mean plasma PYY, GIP and GLP-1 concentrations rapidly increased during the first week 
and sustained high in the second week when compared with the baseline fasting 
concentrations. This selective rising of these three hormones may suggest that their actions 
may be what is required for this period of life. A significant rise in the levels of plasma PYY, 
GIP and GLP-1 between birth, and postnatal day 7 were observed by a study that 
investigated the relationship between enteral feeds and gut hormones among preterm infants 
<33 weeks gestation (581). However, participants were retrospectively selected, and the 
serum samples were not primarily collected for the study. Another study also reported a peak 
in serum PYY concentration at day 12 postnatal in preterm infants and day 18 in full-term 
infants (584). The fasting levels of PYY, GIP and GLP-1 were higher than adult fasting levels, 
this finding was built on previous studies, which have found in preterm and term infants 
higher levels of these hormones compared with older children and adults (584, 598, 645). 
The postnatal surge of plasma PYY, GIP and GLP-1 concentrations were linked to postnatal 
adaptation to prepare the GIT for enteral feeding.  High plasma PYY and GIP concentrations 
during the first week of life have been associated with quicker attainment of full enteral feeds 
in preterm infants (< 33 weeks) adjusted for potential confounders (581); this may indicate 
functioning enterocytes that may reflect intact gut hormone axes (581, 590, 593). Therefore, 
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their plasma concentrations may be possible indicators that could identify high-risk infants for 
feeding intolerance (581).  
In the current study, the median fasting plasma PYY, GIP and GLP-1 concentrations were 
higher compared to a previous study (581) that investigated gut hormone concentrations 
during the first postnatal week among preterm infants (PYY: 356.08 versus 14.0; GIP: 
21.8700 versus 9.0; GLP-1: 6.94 versus 0.6 pg/mL). Although the previous study used the 
same immunoassay methods (Milliplex Map Human Gut Hormone Panel, Millipore, Billerica, 
MA); however, it included a lower gestational age. Notably, the higher level of plasma GLP-1 
could be related to the use of DPP-IV inhibitor to counteract the physiological degradation of 
GLP-1 by the enzyme DDP-IV (628) while the previous study did not state if DPP-IV inhibitor 
has been added to the blood samples. In the present study, plasma PYY, GIP and GLP-1 
concentrations were also higher compared to another previous study, which found high PYY, 
GIP and GLP-1 at birth associated with a significant postnatal increase among preterm 
infants (< 37 weeks gestation) (590). This previous study also used the same multiplex 
immunoassay, and DDP-IV inhibitor was added to the blood samples (590). The observed 
higher plasma PYY, GIP and GLP-1 concentrations in the current study might be suggested 
to the use of OPC in the study cohort (86% of the infants received OPC during fasting status 
and when the basal samples were collected). Colostral growth factors such as epidermal 
growth factor and insulin-like growth factors (234, 236) may travel to the gut if not absorbed 
by the buccal mucosa, and stimulate gut maturation. Moreover, gastrointestinal peptides 
such as GIP has been found in human colostrum and milk during the first postnatal weeks 
may also be important factors for using OPC (646, 647). However, the sample size was not 
sufficient to detect this relationship, lacked a control group, and the potential confounders 
might have influenced the results. Additionally, using different methodology and sitting might 
limit comparison with previous studies.  
In this study as well as other studies (581, 590), fasting plasma Ghrelin concentrations were 
very low or undetectable and, plasma ghrelin did not show significant changes during the 
study period. Plasma ghrelin concentrations had been reported to increase by 2 to 3 weeks 
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after birth and peak after four weeks continuing up to 24 months (597, 598). Nevertheless, 
measurements of ghrelin taken during the first two weeks, with further serial measurements 
of plasma ghrelin may provide more data on the changes of plasma ghrelin. Delayed 
postnatal increase in ghrelin levels compared to other gut hormones may be related to the 
period of maturation of the stomach, which is the main site for ghrelin secretion (594), by 
other gut peptides that increased earlier such as PYY and GIP. Ghrelin stimulates growth 
hormone secretion and appetite, reduces utilisation of fat and maintains blood glucose levels 
(648, 649). Consequently, it may reflect a physiological requirement, at this stage of life, 
when growth hormone commences to exert its effects, and changes in feeding occur.  
Postnatal plasma insulin concentrations also did not show a significant increase; this might 
be related to the physiological fall in the blood glucose concentrations after birth, that 
suppresses insulin secretion as a part of the regulatory mechanisms for postnatal glucose 
homeostasis (91). Plasma insulin levels also did not show a consistent trend over two weeks; 
this could be attributed to variability in the supplemental parenteral nutrition had been 
received by the infant while insulin blood samples were being taken. Moreover, differences in 
the clinical conditions of the participant infants may have a role in determining circulating 
insulin concentration. For instance, there was one participant who had hypoglycaemia during 
the first postnatal day, and he received intravenous bolus glucose. This infant had a higher 
basal plasma insulin level compared to the other infants. Rapid correction of hypoglycaemia 
is a probable reason for the high insulin in this infant. Another infant (27 weeks gestation) 
was receiving total parenteral nutrition and intravenous insulin during the period of sample 
collection.  
The trend of plasma insulin was variable after birth. Whilst one study found no significant 
changes in insulin concentrations during the early postnatal weeks (590), another study 
reported a significant increase in plasma insulin concentrations during the first week of life 
(581) in preterm term infants <33 weeks with a mean gestational age of 28.1 ± 1.3 weeks, 
and most of the infants were receiving parenteral nutrition. However, variable insulin 
response to blood glucose concentrations has been demonstrated during the neonatal 
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period, particularly for extremely preterm infants (605).  Early postnatal hypoglycaemia 
resulting in the reduction of insulin levels was thought to be an essential part of adaptation to 
extra-uterine life (650). Because blood samples were only obtained at times when blood 
sampling was required for clinical reasons, exact blood sugar values were not available, 
especially when the second and third samples for gut hormones were taken. Therefore, the 
correlation of insulin concentrations with the corresponding blood sugar was not achievable.   
5.5.3 Correlation of plasma gut hormones with gestational age 
and birth weight 
There were no correlations between the basal (fasting) concentrations of the different gut 
hormones investigated in the present study and the infant’s gestational age or birth weight. 
Previous studies were conflicting for correlation of circulating PYY and GIP with gestational 
age. Whilst some studies found that PYY concentrations negatively correlated to gestational 
age (585, 598, 645) others found no relationships between the levels of circulating PYY and 
gestational age (581, 584); this conflict could be attributed to differences in the methodology 
between the studies. The basal GLP-1 levels were negatively correlated (r = -0.84) to the 
gestational age but this did not reach statistical significance that might be related to the 
sample size for baseline GLP-1 (n = 4) because three infants had low values that were below 
the sensitivity of the assay. Likewise, some studies showed no relationship between GLP-1 
and gestational age (592, 593, 616) and a negative correlation was reported by others (590). 
Some studies reported higher concentrations in preterm infants compared to full term, (585, 
597, 598); this difference was explained to be due to increased synthesis and decreased 
hepatic and renal clearance as a consequence of prematurity (648). 
There was a significant negative correlation between the mean plasma ghrelin concentration 
and the infant’s birth weight (r = -0.8); this finding was consistent with previous studies 
investigating ghrelin during the early life (585, 598, 651). High ghrelin levels have been 
reported in the umbilical cord blood and at one week of life in SGA infants (651). In preterm 
infants, at birth, high plasma ghrelin reflects the nutritional status and represents a negative 
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energy balance (585). Increased plasma ghrelin concentrations have also been associated 
with statuses of negative energy-weight balance such as anorexia nervosa and malignancy 
cachexia as a compensatory mechanism through its orexigenic and adipogenic effects (652). 
Therefore, Ghrelin has been suggested to be related to postnatal growth and its plasma 
concentrations could be considered as a predictor for postnatal catch-up growth, particularly 
in preterm infants (585, 597).  
5.5.4 Correlations of plasma gut hormones with enteral feeds 
The observed postnatal increase in plasma concentrations of gut hormones was likely 
related to the initiation of enteral feeding. Plasma concentrations of PYY, GIP and GLP-1 
during the early postnatal weeks were in direct relationship with the milk volumes received by 
the infants. The rapid increase in plasma gut hormones with trophic and enteral feeding has 
been previously reported (580, 590). This relationship depends on the milk increment and the 
cumulative milk taken by the infants (580) and what time the blood sample was obtained 
around the feed (before or after). In the current study, although 86% of the participant infants 
received OPC during the first week of life, a control group was not available for comparison. 
Relating the timing of sample collection to the timing of the feeds was also not feasible 
because the blood samples were only obtained when clinically indicated blood sampling; this 
limitation is less likely relevant especially in preterm infants who are often fed more 
frequently and over longer periods in comparison to older infants and children (579). 
Furthermore, potential factors, such as receiving a blood transfusion, which is expected 
especially in an infant requiring NIC, may have confounded the results. 
Though, the data suggested a significant rise in gut hormones in response to enteral feeding, 
but the small sample size and the heterogeneous cohort could have affected the findings. As 
enteral feeding in newborn infants is influenced by many factors such as gestational age and 
the infant’s clinical status, it may be difficult to elucidate the relationship of enteral feeds to 
the plasma gut hormones in a small cohort during a short postnatal period. Additionally, the 
type of milk and the pattern of enteral feeding play a role in the pathway of gut hormone 
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secretions and maturation of the gut (581, 653). Nutritional compositions of the milk, such as 
protein, fat and carbohydrates, and their proportions that were received by the infants, 
influence the release of certain gut peptides (581). For example, GIP is secreted mainly in 
response to carbohydrates in the intestinal lumen to stimulate insulin secretion (654), while, 
PYY release has been related to the enteral intake of protein, fat and also carbohydrates 
(581). Higher GIP concentrations (induce insulin secretion and fat deposition) were reported 
in formula-fed infants compared to breastfed infants at 1, 3 and 6 months of age (655); this 
might in part explain the protective role of breastfeeding against obesity.  
Notably, plasma ghrelin concentrations did not correlate to enteral feeds in this study, as well 
as in previous studies (590, 597). This finding supports the requirement of ghrelin in a later 
postnatal life as discussed previously. However, as feeding preterm infants is not determined 
by appetite and the milk volume is influenced by the infants’ clinical conditions, evaluating the 
effects and relationship of ghrelin with enteral feeds in preterm infants might be a complex 
issue during the early postnatal period.    
Although gut hormones have been studied since the1970s (653, 656), most studies 
investigating different gut hormones during the neonatal period were observational, with 
small sample size and some were retrospective. Many studies were conducted in animal 
models, which may not have represented the conditions of preterm infants (657-659). 
Furthermore, experimental data have to be translated into the clinical setting. Evidence 
underpinning the pattern of gut hormone responses and their potential implications in clinical 
practices during early life appears to be insufficient.  
5.5.5 Strengths and limitations 
This is the first study that highlighted the potential effects of OPC administration on gut 
hormone release in preterm and sick infants, to the best of my knowledge. Moreover, most of 
the previous research studied OPC in EXP and ELBW and VLBW infants; this study included 
all preterm infants’ categories and other sick infants requiring NIC. The study followed open 
access published protocol (623). In advance publication of the protocol can enhance 
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transparency of the research, provides detailed information and more opportunities for peer 
reviews of the methods and collaboration (571). It also minimises potential reporting bias 
(463).   
I have also used multiplex immunoassay an advanced technique that involves small sample 
volumes. Preterm and sick infants have high haematocrits (61% ± 7.4% (660)) during the first 
few postnatal days. The haematocrit is the percentage of red blood cells in the blood. When 
the haematocrit is high; there is a less plasma or serum obtainable from a blood sample. 
Therefore, using a technique, which requires a small plasma volume was very helpful. This 
technique also saves time and was cost-effective as multiple hormones could be analysed 
simultaneously in one sample.  
This current study faced many limitations; it was not completed because of the Chief 
Investigator left the university necessitating a new ethical approval that took time more than 
expected. 
The small sample size and heterogeneity of the participant infants created an important 
limitation for the study. Recruitment of participants was limited by the busy NICUs where 
clinical needs take priority over activities that are entirely research orientated; this was 
compounded by the lack of a clinical staff member who had GCP training; therefore, some 
eligible infants could not be recruited. Additionally, another a clinical trial was ongoing during 
this study period had some influence on the recruitment. For instance, the Study of Preterm 
Infant and Neurodevelopment Genes (SPRING) (661), a prospective cohort study that 
investigating the relationship between neuropsychiatric disorders, genetic risks and preterm 
birth (delivery < 32 weeks gestation), was also collecting blood sample (1ml) from each 
participant and parents were concerned about this.  
Some infants were transferred to another hospital before enrolment in the study although 
their parent agreed. This issue created a threat to the progress of the study particularly when 
infants were transferred after enrolment, and the basal blood samples had been taken. 
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However, this is a challenge for any research recruiting neonates, whose clinical care often 
necessitates transfer to other hospitals.  
Blood samples were obtained only when routine blood sampling of the infant was needed for 
clinical indications; therefore, it was difficult, taking the blood samples at the exact scheduled 
time; however, generally, most of the samples were taken around the planned days. The 
different techniques of sample collection, such as heel prick or using an indwelling central 
catheter, may have affected the quality of the samples for immunoassay of the hormones. 
Moreover, some values were below the range of the range of the standard curves; however, 
using higher sample volumes and saturation of the standard curves at lower ends may 
broaden the detection especially for hormone such as ghrelin, which is expected to be low at 
this stage of life (581, 590). 
5.5.6 Conclusion 
Preliminary data from this pilot study demonstrated that there was a trend for postnatal 
increase in plasma gut hormone concentrations, which may be due to enteral feeding, a 
physiological trend or another explanation. Despite, the heterogeneity of the study cohort, 
and variability in the feeding of the participants, most of the gut hormones of interest in this 
study showed a similar postnatal trend. Alhough most of the participant infants received early 
OPC, the small sample and lack of comparison group limited demonstrating a potential effect 
of OPC administration on plasma gut hormone concentrations. However, the study did not 
complete and recruiting further participants are needed to report a final conclusion.  Further 
research is needed to establish whether early OPC administration could stimulate gut 
hormone secretions and promote maturation of the gut. 
5.5.6.1 Implications for future research  
Given the current lack of studies investigating the effects of OPC administration on the 
response of gut hormones in preterm and sick neonates, there is scope for the development 
of further research. Some likely areas for future research are suggested below: 
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- Large, well-designed RCTs that attempt to control for potential confounders, such as 
gestational age, birth weight and clinical status of the infants. 
- Future research may consider the effect of different feeding strategies on the different 
gut hormones (e.g. continuous versus bolus feeding). 
- Gut hormone concentrations might be assessed more precisely if the collection of 
blood samples are obtained more frequently during the first few postnatal weeks. The 
samples could be best taken at a fixed time to feeds (before and after) as secretion of 
the gut peptides is related to food intake (579, 593). The type of milk feeds should 
also be taken into consideration to minimise potential variability and may produce 
better results. 
- Comparing sick newborn infants requiring NIC with healthy infants could be an option 
for future research. This comparison may identify a possible physiological pattern of 
hormonal change from that influenced by the OPC.  
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Chapter 6. Conclusion 
This thesis was undertaken to determine whether early (within the first seven days of life) 
oropharyngeal administration of mother’s colostrum (OPC) to preterm and sick infants 
prevents prematurity-related complications and improves health outcomes for the infants.    
This chapter summarises the main findings and limitations of this thesis and overviews the 
implications for clinical practice and research.  
6.1 Summary of findings 
6.1.1 Oropharyngeal administration of mother’s own colostrum 
to preterm infants: a survey of practice 
This study aimed to gain an overview of the current use and practice of OPC in the UK. This 
aim was achieved by surveying neonatal professionals across UK neonatal units to 
determine the practice of OPC administration, and their knowledge and perceptions toward 
OPC application in the care of preterm infants, using an online questionnaire. Surveys are 
well-recognised in healthcare research as a method for gathering data on healthcare 
practices, knowledge and attitudes among professionals and providers (380). This survey 
showed that OPC use had been introduced into UK neonatal practice despite a lack of 
evidence concerning its use. This survey also revealed an inconsistency in the practices of 
OPC administration amongst UK neonatal units. Whilst OPC appears to be an easy and 
feasible procedure that is well tolerated by preterm infants; it was often provided without 
written guidelines or policy indicating the need for evidence-based clinical guidelines and 
policies to practice OPC.  
6.1.2 Oropharyngeal colostrum in preventing mortality and 
morbidity in preterm infants: Cochrane systematic review 
This Cochrane systematic review was conducted to appraise the available randomised 
controlled trials (RCTs) to assess the use of OPC in reducing mortality and morbidities for 
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preterm infants. OPC administration shortens the time to achieve full enteral feeds. The 
available evidence was insufficient and of low to very low quality to establish if early OPC 
can reduce the duration of hospital stay, the risk of necrotising enterocolitis (NEC), late-onset 
infection (LOI), or death in preterm infants. Adequately powered RCTs that also evaluate 
potential harm would be needed for a more precise assessment of OPC effects on health 
outcomes of preterm infants.  
6.1.3 The impact of oropharyngeal administration of mother’s 
colostrum on the clinical outcomes of preterm infants: a 
case-control study 
Although OPC has been increasingly adopted by the UK neonatal units, to the best of my 
knowledge, there is no published study investigating the use and effects of OPC in preterm 
infants in the UK. This study aimed to evaluate the effects of OPC on the clinical outcomes 
for preterm infants in the UK. This aim was achieved by conducting a matched case-control 
study that compared clinical outcomes during the hospital stay of preterm (≤ 32 weeks) 
infants who were admitted to the Nottingham neonatal units after the implementation of OPC 
in the care of preterm infants, with those who were admitted before the use of OPC in the 
units. Preterm infants who received OPC started feeding and attained full enteral feeds 
(150ml/Kg/day for consecutive 72 hours) earlier than those infants who did not receive OPC. 
They also received more breast milk at discharge home. However, the two groups had a 
similar length of hospital stay, weight Z-score at hospital discharge, and incidence of NEC, 
LOI and death.     
6.1.4 Gut hormones response to oropharyngeal administration 
of mother’s colostrum to infants in neonatal intensive care 
The Cochrane review (Chapter 3) and the case-control study (Chapter 4), as well as previous 
studies (353, 417), showed that infants who received OPC reached full enteral feeds faster 
than controls. Gut hormones are peptides secreted by the gastrointestinal tract (GIT) in 
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response to nutrients intake (306). Enteral feeds are vital for the growth and development of 
the GIT to adapt to extra-uterine life (579).  After birth, there is substantial secretion of 
different gut hormones in response to the introduction of trophic and enteral feedings (580). 
The postnatal rise in gut hormones is absent in those infants who do not receive enteral 
feeds (306, 574). This study was, therefore, conducted to investigate the effect of colostrum 
administered by the oropharyngeal route on the secretion of gut hormones to gain insight into 
the possible mechanisms responsible for quicker attainment of full enteral feeding in 
response to OPC use observed in this thesis and previous studies. To achieve this, I 
commenced a non-randomised observational study in the Nottingham neonatal intensive 
care units to evaluate the impact of OPC administration on postnatal changes in a set of gut 
hormones in preterm and ill infants requiring neonatal intensive care (NIC).  
To the best of my knowledge, no published study has investigated gut hormone secretion in 
response to OPC administration. Moreover, most of the previous research has studied OPC 
in extremely preterm, extremely low birth weight and very low birth weight infants; this study 
included all categories of preterm infants and other sick infants requiring NIC. This study did 
not complete due to unforeseen obstacles. However, preliminary data showed that there 
were significant changes in the plasma gut hormone concentrations over two weeks in 
preterm and term infants who received OPC. Each hormone had a specific pattern of plasma 
concentrations soon after birth and over the early postnatal weeks. The changes in gut 
hormone concentrations are likely to be related to the infant’s feeds rather than the 
gestational age or birth weight. Recruitment of more participants may confirm or amend 
these findings. Further research is needed to establish whether and if so, how early OPC 
administration stimulates gut hormone secretion and promotes maturation of the gut. 
6.2 Strengths and Limitations 
This thesis has provided more insight into the use of OPC in the care of preterm infants.  
This work contributes to the existing knowledge about the oropharyngeal administration of 
the mother’s colostrum to preterm infants during the early neonatal period by presenting data 
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from the UK. Additionally, I believe this is the first research investigating the secretion of gut 
hormones in response to OPC in preterm and ill full-term infants. Although a relatively limited 
sample with ongoing recruitment, this project will add to the growing body of research that 
indicates the potential benefits of administering OPC in the care of preterm infants. This was 
achieved using a range of different research methodologies. 
The survey of neonatal professionals found that OPC use was adopted by the UK neonatal 
units and highlighted that its current practice of OPC administration was not evidence-based. 
The documentation of uncertainty in this area of care and a gap in the available evidence 
may result in the development of high-quality RCTs and evidence-based guidelines.  
The Cochrane systematic review appraised the currently available evidence to evaluate the 
effects of OPC in preventing mortalities and morbidities of preterm infants. This review 
reported the lack of high-quality evidence, to support the proposed effects of OPC on 
preterm infants, and concluded that large well-designed RCTs are needed. This review was 
the first Cochrane review focusing on the effects of OPC (Cochrane database for systematic 
reviews of intervention (429)). 
This thesis also underlined the variability of OPC use and its practice nationally (as 
presented in the survey study) and internationally (as demonstrated in the Cochrane review). 
These findings indicate the requirement of a standardised protocol for using OPC that may 
enable more infants to benefit from this intervention, and may also facilitate and enable more 
precise comparisons in future research. Standardisation of clinical feeding protocols for 
preterm term infants have been linked with a reduction in practice variation (662, 663); for 
example, differences in clinical practice were proposed as one of the iatrogenic factors for 
NEC, and standardised feeding protocols have been reported as one of the modifiable 
factors that might reduce and prevent NEC in preterm infants (151, 662).  
The case-control study (Chapter 4) found that although a guideline supported the practice of 
OPC administration, compliance with the unit’s guideline for OPC administration was low. 
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This finding highlighted the need for regular reviewing of clinical guidelines and more 
education, especially for newly adopted guidelines, for effective practice changes (663). 
This thesis faced some limitations as expected in any research. For instance, the survey of 
the UK neonatal professionals may reflect the performance of those who responded and may 
not reflect the actual practice that could limit generalisability to all UK neonatal units. 
However, this study surveyed both doctors and nurses and included all levels of neonatal 
units which may minimise this limitation.  
Due to the relatively small number of studies identified, the Cochrane review could be 
affected by publication bias, however, to minimise this bias, additional search sources such 
as the reference lists of included trials and abstracts and proceedings of major perinatal 
conferences were screened. Despite much effort to ensure that the search was 
comprehensive, some relevant studies have been missed should also be considered. 
Another potential bias was incomplete reporting, to minimise this bias, study authors were 
contacted as needed. Additional information that was provided by study authors were 
included in the analysis. However, most data entered in the analyses were obtained from the 
study reports. Inclusion of very or extremely low birth weight infants may limit the applicability 
of the review findings to these sub-groups of preterm infants.   
The case-controlled study (Chapter 4) was susceptible to information bias due to the use of 
secondary data that was collected from the participants’ medical records. These data were 
routinely collected health records, collected without predefined specific research questions 
as they were not documented intentionally for research purpose. However, to minimise this 
limitation, the Badger neonatal database was used for data collection. Badger neonatal is 
regularly assessed by the National Neonatal Audit Programme (414) and also monitored by 
the performing and publications of research that evaluate the accuracy, validity, and quality 
of these data. Furthermore, additional sources such as the local NHS Trust’s Digital Health 
Records were also used as needed. Using a historical cohort before and after the 
introduction of OPC might also bias the results (442, 520); however, this potential bias was 
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minimised by using a matched case-control design. Cases were matched with controls using 
sex, gestational age and birth weight, which are well-known potential confounders that 
influence the outcomes of preterm infants. Another possible limitation for this study is that 
other interventions may have been occurring in the Nottingham neonatal units during the 
same period as the new OPC guideline was being introduced, which may have influenced 
the results. However, efforts were taken to identify whether any other intervention were 
implemented during OPC adoption. In particular, guidelines for feeding preterm infants and 
breastfeeding support did not change throughout the study period. Data included in the 
analysis were only from the Nottingham neonatal units; therefore, the generalisability of the 
findings might be limited.  
My thesis also faced unforeseen limitation as the study that was investigating gut hormones 
response to OPC in preterm infants did not complete. The study has been paused due to the 
move of the Chief Investigator to a different institution outside the UK; this necessitated 
getting another ethical approval, which took a drastically longer time than expected. 
Therefore, I could not complete data collection for this study while being constrained with my 
PhD timeframe. However, preliminary analysis of the available data may help in generating 
hypothesis and calculating sample size for future studies. The study is ongoing, and 
completing recruitment of the planned sample may confirm or alter the findings. 
6.3 Implications for practice 
Rates of preterm birth are rising (2, 58) and surviving preterm infants are at high risk of short 
and long-term morbidities (12) such as NEC and LOI which are the main causes of deaths 
among preterm infants (59). Consequently, preterm infants represent a major challenge to 
public health worldwide; therefore, preventive interventions are highly needed. Currently, 
there is a progressive use of OPC among neonatal units to prevent sepsis and NEC. OPC 
appears to be a beneficial intervention, its effectiveness remains uncertain. Although it did, 
however, appear safe in the short-term so the current adoption into practice across the UK 
may be warranted research to confirm or refute this would be helpful to clinical practice. 
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However, available evidence does not allow firm recommendations for or against the use of 
OPC to be made. An ongoing RCT (359) aims to recruit 498 extremely preterm infants with 
birth weight < 1250 grams, within the first 96 hours of life; the results of this trial may support 
or against the use of OPC in the care of preterm infants.  
Through the survey study (Chapter 2), lack of knowledge was the main reason for those units 
that did not use OPC; though, many responders were enthusiastic for the introduction of 
OPC practice in their units. OPC was also often not in keeping with the unit’s guideline for 
OPC administration, as demonstrated in the case-control study (Chapter 4). Therefore, more 
education and regular audit of practice may be valuable for the implementations of new 
practice and guidelines such as OPC. Moreover, the ideal dosage and frequency and the 
best timing of initiation and duration of OPC administration need to be optimised. Further 
RCTs should provide more definitive evidence. Ongoing RCTs evaluating the use of OPC in 
preterm infants (359, 503, 619, 620) may present more data to inform the future development 
of evidence-based clinical guidelines on OPC use.  
6.4 Implications for future research 
Prematurity-related complications and the continued increase in preterm births necessitate 
more interventions that may improve outcomes for preterm infants. Therefore, the well-
known advantages of breast milk (185, 186, 664) and the proposed benefits and cost-
effectiveness of OPC (351-353) warranted research in this thesis and other studies. The 
increase of OPC use in the care of preterm infants despite the lack of high-quality studies 
indicates a definite need for further research to evaluate whether OPC administration to 
preterm and sick infants during the early neonatal period is safe and could have a positive 
impact on this specific population. The future studies should be high-quality research 
including, adequately powered RCTs, systematic reviews such as follow up of the published 
Cochrane review (Chapter 3). 
Several suggestions have emerged as a consequence of this work as potential themes for 
future research: 
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- As described in this thesis there is variation in OPC procedures between different settings 
(Chapter 2) and among neonatal units within the UK (Chapter 3). Therefore, further 
research to optimise the practice of using OPC, regarding the dose, frequency, duration 
and procedure for administration of OPC is needed.  
- Validation of clinically relevant outcome measures is needed for more reliable and precise 
research.  
- This thesis has shown that the safety and adverse effects of OPC administration were not 
adequately addressed in currently available studies. Therefore, well-designed longitudinal 
studies that focus on safety is worthy.   
- A further study to assess long-term outcomes is also needed. 
- In neonatal practice, providing feeds to preterm infants and oral care including OPC 
procedure are primarily a nurse prerogative. Thus nurses may have a unique role in 
contributing to new knowledge regarding this intervention. Involving nurses in the design 
of clinical guidelines and further research might be helpful.  
- Parent-related outcomes such as parental anxiety and depression may also be of interest. 
Involving the parents might be informative in future research as they may provide 
evidence from their perspective that may improve the quality of the research.  
- Current studies have focused on the administration of colostrum by the oropharyngeal 
route, however, administrating transitional and mature milk by this route might also be of 
benefit particularly to ELBW infants who are tube feed for extended period.   
- Owing to the substantial burden of prematurity on the health care system, families and 
societies, evaluation of the cost-effectiveness of OPC use in the standard care of preterm 
and ill infants could be a practical consideration.  
- It is important to note that most of the previous research has come from high-income 
countries. Therefore,  more focus on low-resource settings, where approximately 60% of 
preterm births and the highest mortality occur (12), could provide important findings.  
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6.4.1 Ongoing studies    
Despite research assessing OPC administration continuing, it appears that ongoing studies 
are still insufficient, they include:  
- “Oropharyngeal administration of mother’s colostrum, health outcomes of premature 
infants: study protocol for a randomized controlled trial” (359) 
A randomised double-blind, placebo-controlled (ClinicalTrials.gov: NCT02116699) 
Target sample: 498 extremely preterm infants from five NICUs within the USA 
Primary outcome:  incidence of late-onset sepsis, necrotising enterocolitis and death 
- “The effect of oropharyngeal colostrum administration in preterm infants” 
Randomised double-blind- placebo-controlled (who.int/trialsearch: JPRN 
UMIN000022923), Okayama University Hospital, Japan 
Target sample: 30 infants (<32 weeks) 
Primary outcome: longitudinal change of reactive oxygen metabolite and biological anti-
oxygen potential of preterm infants with oropharyngeal colostrum administration. 
- “Impact of Oropharyngeal Administration of Mother's Milk Prior to Gavage Feeding on 
Hospital Acquired Neonatal Infection”  
       Randomised single-blind (assessor blinded) (clinicaltial.gov: NCT03513146), Mansoura 
University Children Hospital, Egypt 
   Target sample: 100 infants <32 weeks’ gestation  
      Primary outcome: culture-proven neonatal sepsis acquired during neonatal care admission  
- “Efficacy of oropharyngeal administration of colostrum in reducing morbidity and mortality 
in very preterm infants: A randomized controlled trial –Colostrum” 
Double-blinded, placebo-controlled (who.int/trialsearch: CTRI/2017/11/010396) 
Neonatology department, Paediatrics division, Women and Child Hospital, India  
Target sample: 260 preterm infants 26-31 completed weeks (recruiting) 
Primary outcome: incidence of death, late-onset sepsis or necrotising enterocolitis.  
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6.5 Personal reflections  
Throughout my PhD study, I benefitted from having the opportunity to gain new skills and 
develop competencies that enriched me both as a researcher and as a clinician. The 
approach of my thesis required different methodologies; critical appraising of evidence using 
systematic review, descriptive study, case-control study and non-randomised observational 
study, every study had its challenges to overcome. In particular, the study which seeks to 
deal with patients allowed experiencing writing a study protocol for regulatory approvals and 
to manage biological samples.  Additionally, I also learned that it is imperative to conduct this 
process at an early stage to facilitate as smooth a passage as possible. 
A great lesson I have learned that sometimes we have to take a more flexible attitude and be 
broadminded when looking for alternative ways to meet challenges, however, by patience 
and perseverance these challenges can be overcome. 
Should this research contribute to improving the outcomes and quality of life for any of these 
vulnerable infants, then the difficulties and challenges I faced during my study would be 
worthwhile. 
6.6 Conclusive remarks   
Preterm infants deserve to have a good quality of life and to receive appropriate 
management supported by high-quality evidence. OPC administration is a biologically 
plausible intervention that can reduce the mortality and morbidities of preterm infants. 
However, the evidence base for this intervention is currently inadequate. The work in this 
thesis should in part help to expand the current knowledge about OPC use informing 
guidelines and future clinical decision by providing data needed to efficiently plan further 
high-quality research. 
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Appendix 8 Oropharyngeal administration of colostrum (OPC) data collection form  
Feeding Status  Start/day End/day Volume Remarks 
TPN     
Trophic F     
Enteral    >2 ml/kg/hr of milk 
 
Feeding  Date (DOL) EBM Formula Route  Volume/kg/24   
Full enteral 
(120ml/kg) 
      
Full enteral 
(150ml/kg/day) 
      
Breast feeding:    Yes                     No   
Withholding feeds >4 hours:  
   No                          Yes                                              
Reasons:  
Duration: 
OPC administration 
Received 
OPC 
Yes     No   
Postnatal day:                                                                      
Start:                             Stop: 
Frequency 
(hourly) 
2     3     4       other    specify:  Total doses 
received: 
Duration 24 hours   48 hours   72 hours  
Other           Specify: 
Total volume received:          
ml 
 
Colostrum 
Fresh    Refrigerated     Frozen  Type:  
OPC 
doses/day 
D1:             doses         volume= 
D2:             doses         volume= 
D3:             doses         volume= 
D4:             doses         volume= 
D5:             doses         volume= 
Trophic feeds: Yes    No  
Milk volume:           type: 
Enteral feed: Yes     No  
Milk volume:         type: 
Adverse effects Yes 
Date/ti
me 
Frequency No comments 
HR < 100      
HR > 100      
RR > 80      
Apnoea >20 sec      
SpO2 <80%      
Aspiration/Chocking          
          Milk in mouth 
  X-ray changes 
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